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Abstract 
Catheter-associated urinary tract infections (CAUTIs) make up the largest proportion of 
hospital acquired infections. Uropathogenic Escherichia coli (UPEC) are a major 
causative agent of CAUTI partially due to the bacteria’s ability to form biofilms on the 
catheter surface in addition to their extensive array of virulence factors that facilitate 
infection. Anti- infective coatings for urinary catheters are a promising strategy to 
prevent bacterial attachment and subsequent biofilm formation on the catheter thus 
helping to prevent CAUTI. Concerns have been raised that exposure to biocides may 
select for biocide resistant populations of bacteria in addition to promoting cross-
resistance with third part agents such as antibiotics. This, in addition to further concerns 
over biocide cytotoxicity, has led to the search for alternative anti- infective coating 
agents that exhibit long-term antimicrobial activity and low-level cytotoxicity. Quorum 
sensing inhibitors (QSIs) have emerged as potential candidates to prevent such biofilm 
associated infections, however the long-term effects of QSIs and biocides in 
uropathogens is poorly understood.  
In this investigation, the impact of repeated exposure of eight UPEC strains to four 
biocides (PHMB, triclosan, BAC, silver nitrate) and three QSIs (cinnamaldehyde, 
furanone C30 and F-DPD) were evaluated. Antimicrobial susceptibility in planktonic 
(MIC and MBC) and biofilm (MBEC) states were determined before and after repeated 
exposure to each antimicrobial. Changes in pathogenicity were assessed in a Galleria 
mellonella waxworm model and through the use of cell invasion assays (SMC and 
HUEPC cell lines). Antimicrobial activity and cytotoxicity of antimicrobial 
impregnated polymers was assessed via inhibition assays and through agar overlay tests. 
After the initial assessment, the sol gel coating was determined to have the highest 
biocompatibility, and was assessed for antimicrobial activity in a continuous culture 
drip-flow biofilm reactor. In an attempt to understand the mechanisms that govern 
antimicrobial adaptation in UPEC, strain EC958 was subjected to full genome and 
RNA-sequencing and differential expression gene analysis.  
The results of these experiments show the multiple and varied effects that occur after 
exposure to broad-spectrum antimicrobials must be taken into consideration when 
developing a new antimicrobial coating as these effects have impacts on resistance, 
virulence, biofilm formation, and antibiotic resistance. 
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1.1.0 Introduction 
Urinary catheterisation is a technique for bladder emptying by employing a catheter 
(flexible tube) to drain the bladder or urinary reservoir [1]. Catheterisation is used to 
treat urinary retention resulting from a wide variety of conditions including: spinal cord 
injury, multiple sclerosis, neurological disorders, diabetes, injury to the bladder region 
or bladder cancer [2]. There are many complications associated with catheterisation 
largely due to contamination of the catheter surface during insertion with commensa l 
bacteria leading to infection. Catheterisation may result in urinary tract infection (UTI), 
potentially leading to pyelonephritis (infection of the kidney), and eventual bacteraemia 
(bacteria in the blood) [3]. These complications can lead to septicaemia, which can be 
fatal [3]. Bacterial infections are normally treated with courses of antibiotics, however, 
many uropathogenic bacteria are now developing resistance to multiple antibiotics [4]. 
Further complicating treatment is the formation of bacterial biofilms on the catheter 
surface which poses challenges in terms of recalcitrance and persistence resulting in 
difficult to eradicate infections.  
A bacterial biofilm is a coherent cluster of bacterial cells embedded in a gel- like matrix 
of extracellular polymeric substances (EPS) which includes polysaccharides, proteins 
and DNA [5]. Biofilms have been shown to be recalcitrant to many antimicrobial agents 
in addition to the actions of the host immune system making them far less susceptible to 
antimicrobials compared with their planktonic counterparts [5]. Biofilms show 
decreased susceptibility to antibiotics due to the shielding effect of the EPS, low 
metabolic activity of the cells within the biofilm and due to the actions of membrane-
bound efflux pumps that actively expel antimicrobial compounds from the cell [5]. Also, 
antibiotic-resistance genes are readily transferred between bacteria in a biofilm by 
horizontal gene transfer allowing the dissemination of resistance through a bacterial 
population [6]. Antibiotic treatment of catheter-associated urinary tract infections 
(CAUTIs) is often ineffective due to the antimicrobial recalcitrance of the biofilm and 
the potential for the generation of antibiotic resistance. It is therefore important that 
preventative treatments for these catheter-associated complications are investigated; this 
will reduce the financial burden on the healthcare system in terms of hospital 
admissions and treatment costs, and greatly improve patient health.  
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Biocides are  broad-spectrum antimicrobial chemicals whose purpose is to inhibit the 
growth of or kill microorganisms [7]. Catheters have been developed that have been 
coated with biocides [8] in order to reduce bacterial contamination of the catheter  
surface. However, previous research has suggested that long-term exposure to certain 
biocides can cause certain bacterial species to become more resistant to biocides in 
addition to third party agents such as antibiotics due to the presence of shared target 
sites between the antibiotic and biocide in addition to the activation of broad-range 
defence mechanisms such as increased efflux activity or decreased cell permeability [9]. 
This is termed 'cross-resistance' and is a cause for concern when considering the impact 
of biocide coated catheters on the antimicrobial susceptibility profiles of uropathogens. 
Furthermore, biocides may be associated with cytotoxicity in the host, especially at 
concentrations that would be required to fully eradicate a bacterial biofilm. 
A novel approach in the production of anti- infective catheter coatings is to use quorum 
sensing inhibitors (QSIs). Quorum sensing  (QS) is a process by which bacteria produce 
and detect signalling molecules and thereby coordinate their behaviour in a cell density 
dependent manner [10]. Quorum sensing it is an important contributor to the formation 
of bacterial biofilms in certain bacterial species. QSIs act to disrupt this communication 
between bacteria and provide a potential treatment option to prevent the establishment 
of bacterial biofilms and reduce biofilm formation. By combining quorum sensing 
inhibitors with traditional biocides it may be possible to prevent the formation of mature 
biofilms allowing eradication of the residual contaminating bacteria at lower 
concentrations of biocide than would be required to eradicate an established biofilm. 
The development of an anti- infective catheter coating which offers anti-biofilm and 
antibacterial and activity would therefore improve the outcome of antimicrobial 
treatment and help to prevent the establishment of CAUTIs. 
1.2.0 Catheter-associated UTI 
1.2.1 Financial cost of CAUTI on the NHS 
It is estimated that UTIs affect around 150 million people per year globally [11]. The 
NHS in England spent £434 million in 2013/14 treating 184,000 hospital admissions for 
a UTI [12]; 80% of these infections are associated with indwelling urinary catheters 
[13]. Catheterisation is, therefore, one of the most important risk factors for developing 
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a UTI and as such it has been shown that there is a 5-8% increase in risk of developing 
bacteriuria (bacteria in the urine) for every day that a catheter is inserted and almost all 
catheterised patients will have bacteriuria after four weeks of insertion [14]. It is 
therefore unsurprising that UTI's make up the largest proportion (45%) of hospital 
acquired infections (HAI) posing an impending infection risk to the populace and a 
financial burden on healthcare service providers [15]. It is estimated that approximately 
3% of people over the age of 65 require a catheter and, with an aging population, this 
figure is likely to increase [16]. With the treatment of CAUTI's costing the NHS on 
average £2000 per episode [16] it has become vital to prevent these infections before 
they become serious enough for hospitalisation.  
1.2.2 Other diseases associated with catheterisation 
Not only does insertion of a urinary catheter greatly increase the risk of developing a 
UTI but there are also many other complications associated with damage to the urinary 
tract as a result of catheterisation e.g. pyelonephritis, bacteraemia, carcinoma of the 
bladder, local periurinary tract infections, infection stones, blockage of catheter [1]. 
These complications can be serious and, in vulnerable patients, fatal. Currently 
Escherichia coli (E. coli) is the leading cause of blood stream infection in the UK with 
40,580 cases reported in 2016–17 and a mortality rate of 14.8% [17]. Of these cases, 
21% are linked to the presence of an indwelling urinary catheter [17]. 
Long-term catheterisation is a commonly used management option for elderly patients, 
where alternative treatments for bladder dysfunction are inappropriate or unsuccessful  
[18]. These patients are at an increased risk of developing CAUTI and associated 
secondary infections due to the hormonal, physiological and immunological effects of 
aging [18]. This has a detrimental impact on their quality of life and leads to a 
substantially increased morbidity and mortality rate.  
1.2.3 Antibiotic resistance in uropathogens 
It has become common practice to give catheterised patients prophylactic antibiotics 
however antibiotic resistance among uropathogens has become a substantial cause for 
concern. As such, the National Institute for Health and Care Excellence (NICE) has 
recently recommended that antibiotics should not be used to treat asymptomatic 
bacteriuria in adults with catheters and non-pregnant women, or to be used 
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prophylactically for patients with catheters [19]. Research carried out by Dewar et al. 
[20] has shown that antibiotic resistance has become very prevalent particularly among 
Gram-negative bacteria due to the production of extended-spectrum β-lactamases 
(ESBLs). Examples of antibiotics that Gram-negative bacteria isolated from community 
patients are resistant to include cephalosporins, penicillins, fluoroquinolones and 
trimethoprim [20]. 
1.2.4 Uropathogenic Escherichia coli (UPEC) 
E.coli is the most common causative agent of UTI, accounting for 80-90% of all 
reported uncomplicated UTI cases [21], 50% of nosocomial [22] and 65% of all 
complicated UTI infections (including CAUTI) [23]. UPEC are classified as the O 
(semantic) and K (capsular) serotypes and are distinct from the gastrointestina l 
serotypes as UPEC have extra genes that encode P fimbriae/ pyelonephritis associated 
pili (PAP) [24]. These genes are found in mobile genetic elements known as 
pathogenicity islands [21]. Other key virulence factors in UPEC include: Type 1 pili, 
lipopolysaccharide (LPS), flagella, curli, secreted toxins, secretion systems, and TonB-
dependent iron-uptake receptors [25].  
Type 1 pili terminate at the FimH adhesin which binds to mannosylated glycoproteins 
on human bladder epithelium [26] and other cell surfaces. PAP are homologous to type 
1 pili in that they share evolutionary origin therefore have a similar structure but not 
necessarily function [27]. The adhesin at the end of P fimbriae is called PapG and 
specifically binds to the globoside, galabiose 4 (GBO4), on the uroepithelium of the 
human kidney [28] and other cell surfaces. These unique structures make UPEC highly 
virulent urinary pathogens as they are able to adhere to the uroepithelia against the flow 
of urine facilitating colonisation of the host. PapG adhesins have been found in up to 
100% of strains causing UTI showing the clinical relevance of this virulence factor [29]. 
Other bacterial surface appendages have been associated with UPEC virulence - such as 
curli and flagella [25]. Curli secrete soluble monomers that are alike in characteristics to 
amyloid fibrils, which are associated with many human degenerative disorders such as 
Parkinson's disease [30]. These bacterial amyloids are involved in adhesion to surfaces, 
cell aggregation, host cell adhesion and invasion [31]. It has also been shown that curli 
play an important role in biofilm formation and are potent inducers of the host 
inflammatory response [31]. Flagella are organelles that provide motive force for 
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bacterial cells but they have also been implicated in cell invasion and infection of the 
urinary tract [32]. 
LPS molecules are found on the bacterial cell surface and consist of fatty acids lined to 
an oligosaccharide core, which in turn is bound to a long polysaccharide chain 
commonly called O antigen [25]. Mutations to genes encoding LPS have affected 
UPEC's susceptibility to detergents, and the ability to adhere to and invade urothelial 
cells [33]. When the waaL gene (O-antigen ligase gene) was deleted proinflammatory 
cytokine secretion was enhanced [33] indicating the role of LPS in evoking host 
immune response.  
UPEC are also able to secrete toxins, adhesins and enzymes via membrane vesicles 
which provide a way of delivering these elements to host cells without them being 
degraded by the extracellular environment [34]. Toxins that have been associated with 
UPEC strains are: α-hemolysin, cytotoxic necrotizing factor 1, vacuolating 
autotransporter toxin, and secreted autotransporter toxin [35]. 
Iron is a key nutrient for UPEC as it is required for cell division and pathogenesis [36]. 
As the urinary tract is an iron- limited environment, UPEC have numerous iron transport 
and iron chelating mechanisms such as yersiniabactin, salmochelin, aerobactin, and 
siderophores [25]. Siderophore receptors require the TonB cytoplasmic membrane-
localized complex which has been shown, in gene deletion mutants, to be critical for 
UPEC virulence [37]. 
1.3.0 Bacterial Biofilms in Catheter-associated UTI  
The formation of a bacterial biofilm can be divided into three stages: attachment, 
maturation, and dispersal [38] and can be seen in Figure 1.1. After the formation of a 
conditioning film, the bacterial cells attach to the surface due to the actions of reversible 
attracting forces such as electrostatic interactions and van der Walls forces. Irreversible 
attachment follows due to the binding of cell surface appendages such as bacterial pili to 
the underlying substratum. Following adhesion is the formation of microcolonies, the 
production of extracellular polymeric substance and the maturation of the biofilm. This 
maturation process is governed through the actions of quorum sensing between the 
bacterial cells. Once the biofilm has matured it will enter a phase of dispersal, whereby 
planktonic cells will be shed from the biofilm surface and will travel to a new site to 
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initiate the formation of a new biofilm [39]. It has been shown that biofilm development 
is dependent on environmental cues e.g. the availability of nutrients [39] in addition to 
the actions of quorum sensing molecules [5]. 
 
Figure 1.1 Biofilm formation on a solid surface. Biofilm formation is divided into three 
stages: attachment, maturation, and dispersal [38]. 
1.3.1 Intracellular biofilm communities 
During the first stages of infection and biofilm formation UPEC transition from 
reversible to irreversible binding to cell surface. It is this stage when the bacteria 
undergo genetic change to produce adhesins and pili structures (e.g. PAP and type 1 - 
see above) that allow this binding to cells [40].  
Not only do these structures allow attachment to the substratum of the urinary tract and 
therefore subsequent infection but they also allow the internalisation of UPEC into host 
cells to form intracellular biofilms (or intracellular bacterial communities [IBCs]) which 
can cause infection relapse in the form of recurrent UTI [40]. In the bladder, these 
intracellular biofilms have been shown to become encapsulated in a uroplakin shell that 
would protect the bacteria from antibiotics in the urine and the actions of the host 
inflammatory responses - allowing the bacteria within to proliferate, re- invade 
uroepithelia, and form a persistent reservoir [41]. 
1.3.2 Quorum sensing and bacterial biofilms 
Quorum sensing is density dependent bacterial communication whereby bacterial cells 
sense the concentration of signal molecules and activate QS-controlled genes in 
response [42]. As bacterial density increases the biofilm develops new characteristics 
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that are different to their planktonic bacterial counterparts, specifically the biofilm tends 
to be more virulent and less susceptible to antimicrobial drugs. 
Quorum sensing in UPEC is mediated by acyl-homoserine lactone (AHL) and 
autoinducer-2 (AI-2) (Figure 1.2) [43]. In Gram-negative bacteria, AHLs are the most 
common class of autoinducers [43]. They have a core N-acylated homoserine-lactone 
ring and can freely diffuse across the cell membrane [43]. There are three families of 
AHL synthases: LuxI, HdtS, and LuxM [44]. The LuxI family is the most 
comprehensively studied. This enzyme family uses S-adenosyl-methionine (SAM) and 
acyl-acyl-carrier-protein (acyl-ACP) as substrates to produce AHL and 5'-methyl-
thioadenosine [44]. E.coli cannot produce AHL as it does not have an AHL synthase 
gene [45]. However, it can respond to AHL because the bacteria produce SdiA which is 
a homologue of LuxR an AHL signal receptor [45]. LuxR receptors possess an amino-
terminal AHL-binding domain and a carboxy-terminal DNA-binding domain and are 
transcription factors for a range of QS controlled genes [44]. SdiA detects a broad range 
of AHLs and in the absence of AHLs, the protein is degraded [46].  
AI-2 consists of derivatives of 4,5-dihydroxy-2,3-pentanedione (DPD) [47]. It has been 
shown that AI-2 production is directly correlated to biofilm production in E.coli [48]. 
S-ribosylhomocysteine lyase (LuxS), the AI-2 synthase, is known to be present in more 
than 500 bacterial species [43]. The production of DPD is catalysed by LuxS although 
the enzyme also forms an integral part of the activated methyl cycle (AMC), which is an 
important metabolic pathway that serves to recycle homocysteine. During the second 
product of this reaction DPD undergoes spontaneous cyclization to form a mixture of 
different furanones collectively known as AI-2 [47]. At high cell densities, the AI-2 
molecules are actively transported into the cell by association of receptor LsrB in E.coli  
[49]. The AI-2 is then imported by the LsrABC transport system where it is 
phosphorylated by LsrK and is thought to interact with LsrR, relieving the repression of 
the lsr operon [46]. The resulting downstream reactions activate the transcription of 
target genes to produce a particular QS response [50]. It has been shown that AI-2 
controls 166 to 404 genes, including those for chemotaxis, flagellar synthesis, motility, 
and virulence factors in E. coli [48]. The LuxS/AI-2 system, or homologues of it,  is 
found in both Gram negative and Gram positive bacteria [48]. 
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Figure 1.2 Quorum sensing systems in E.coli. AHL is the most common system in 
Gram negative bacteria, E. coli express SdiA which recognises AHL and initiates 
transcription of QS controlled genes. AI-2 is the system that E. coli mostly uses, LuxS 
synthesises AI-2 and is recognised by LsrB. The phosphorylated AI-2 inhibits LsrR 
repression of QS controlled genes.  
1.3.3 Biofilm resistance 
Bacterial biofilms show tolerance or resistance to antimicrobial agents through a variety 
of mechanisms. The structure of the biofilm itself can cause antimicrobials to become 
less effective due to the shielding effect of the surrounding matrix. Subpopulat ions 
within the bacteria are slow growing or even dormant due to limited nutrients [51] or 
oxygen gradients [52] in the center of the biofilm which results in antibiotics that target 
active biological processes being less effective on these populations [53]. Also 
conditions within the biofilm (i.e. differences in pH and CO2) can affect the action of 
some antimicrobials e.g. the activity of tetracyclines are compromised at low pH [54]. 
Quorum sensing also has a role to play in biofilm antimicrobial tolerance, for example 
eDNA release is regulated by quorum sensing and this is known to be a chelator of 
aminoglycosides [55]. Activity of the bacterial cells, such as actively expelling 
antimicrobials through increased efflux pump activity also promotes the reduced 
susceptibility phenotype of biofilms [5]. In addition, bacteria are in closer proximity to 
each other so there is a higher chance of genetic transfer of resistance genes between 
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bacterial cells in a biofilm promoting the spread of antibiotic resistance throughout the 
biofilm community [6].  Additionally, when a selection pressure is introduced (such as 
antibiotics) the high density of bacterial cells induces increased competition and 
therefore selection for mutator phenotypes which means that there is a higher mutation 
rate within a biofilm compared to planktonic communities [56].  
Another mechanism of biofilm resistance is the propagation of persister cells. Persister 
cells do not undergo a genetic change nor do they grow in the presence of antibiotics 
like resistant cells [57]. However, persister cells are essentially dormant, and therefore 
multidrug resistant, which are able to re-establish biofilm after the treatment has ended 
[58]. In biofilms, persister cells make up around 1% of the population providing a 
reservoir of resistance [57].  
1.3.3 Biofilm associated infections 
Biofilms are associated with chronic infection which persists despite immune 
response/antibiotic therapy [5]. The surface of a catheter provides an optimum surface 
for a biofilm to form and the subsequent dispersion of viable planktonic bacteria from 
the biofilm can lead to bacteria infecting the bladder, kidneys and becoming systemic. 
Not only does the formation of a biofilm produce a reservoir for bacteria to infect the 
patient but the mass of the biofilm may even occlude the catheter lumen and obstruct 
urine outflow which could cause septicemia due to a back-flow of bacterial filled urine 
within the urethra. This is a particular problem in biofilms incorporating urease 
producing bacteria, such as Proteus mirabilis, as this species forms crystalline biofilms 
which occlude the catheter lumen [59].  
1.4.0 Quorum Sensing Inhibitors 
Quorum sensing inhibitors act by targeting the generation, dissemination, or reception 
of the QS signal [60]. There is now an interest in developing pharmaceuticals based on 
disrupting QS to treat or prevent chronic infections. Targeting the enzymes involved in 
synthesising AI-2 is a promising strategy.  Lux-S is an attractive target as it is only 
found in bacteria [10] and several Lux-S inhibitors have been synthesised [61]. 
Inhibiting Lux-S has been shown to limit biofilm formation [62], however it has also 
been shown that inhibition of Lux-S may lead to increased mutation rate plasticity, as 
demonstrated by increased resistance to rifampicin in E.coli [63]. 
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1.4.1 Dihydroxypentanedione 
Blocking the QS signal is primarily achieved by synthetically creating analogues that 
act as competitive inhibitors of the AI-2-binding site [60]. Dihydroxypentanedione 
(DPD) has been used to prevent AI-2 binding to the periplasmic receptor [64]. Isobutyl-
DPD and phenyl-DPD inhibited E. coli and P. aeruginosa biofilm formation and 
resulted in a removal of preformed biofilms in a microfluidics biofilm reactor [65]. 
 
Figure 1.3 Mechanism of action of DPD. The DPD molecule acts as a competitive 
inhibitor of the AI-2 binding site thereby inhibiting quorum sensing. 
1.4.2 Furanone 
A small variety of compounds including furanone, have been shown to inhibit AI-2 
signal transduction. Furanones, are natural compounds produced naturally in the 
environment by the red alga Delisea pulchra [10]. Furanone has been shown to inhibit 
AI-2 QS in Vibrio harveyi by decreasing the DNA binding ability of the response 
regulator LuxR [10]. In addition, the natural furanone covalently modifies and  
inactivates LuxS and accelerates LuxR turnover [66]. E.coli biofilm formation is 
inhibited by furanone as shown in previous studies [67, 68], which is in part due to the 
repression of AI-2 induced genes involved in chemotaxis, flagella, and motility [69]. 
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Figure 1.4 Mechanism of action of furanone. Quorum sensing inhibition is achieved by 
inhibition of LuxS and LuxR binding to target genes. Furanone also increases LuxR 
turnover. 
1.4.3 Cinnamaldehyde 
Cinnamaldehyde is a natural product from the bark of the cinnamon tree, and has been 
observed to inhibit AI-2 based quorum sensing in Vibrio spp. [49]. Cinnamaldehyde 
elucidates its quorum sensing inhibition by blocking the DNA binding ability of 
response regulator LuxR and can disrupt biofilm formation by reducing 
formation/accumulation of EPS [70]. Cinnamaldehyde treatment has been shown to 
affect biofilm formation and to increase biofilm susceptibility towards antibiotic 
treatment in P. aeruginosa [71]. 
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Figure 1.5 Mechanism of action of cinnamaldehyde. Cinnamaldehyde inhibits quorum 
sensing through inhibition of LuxR binding.  
1.5.0 Biocides 
Biocides have been used for many years being incorporated into soaps, cosmetics and 
disinfectants [72]. There are a variety of different types of biocide that are being 
investigated for use in humans, all have a very broad mechanism of action primarily 
focussing on the bacterial cell membrane. Therefore the composition of the bacterial 
cell membrane can have a significant impact on the efficacy of a particular biocide.  A 
representation of a Gram-negative cell membrane is shown in Figure 1.6. 
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Figure 1.6 The Gram-negative cell and Gram-positive cell membranes. The Gram-
negative membrane is composed of the outer phospholipid membrane, periplasmic 
space, and the inner phospholipid membrane. The Gram-positive cell membrane differs 
in the thicker peptidoglycan layer and only one plasma membrane. 
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1.5.1 PHMB 
Cationic biocides, such as polyhexamethylene biguanide (PHMB) and chlorhexidine, 
often rely on an initial attraction between the biocide and anionic bacterial membrane in 
order to exhibit their antimicrobial effect. PHMB, a polymeric biguanide, is a general 
disinfecting agent utilised by the food industry, used to disinfect swimming pools and 
can be found in in contact lens solution. PHMB is a polycationic linear polymer with a 
hydrophobic backbone and multiple cationic groupings separated by hexamethylene 
chains [73]. PHMB largely acts by displacing cations, such as calcium, in the bacterial 
outer membrane because it competes for negatively charged sites on the peptidoglycan 
underneath [74]. This disrupts the outer membrane and allows the PHMB molecules to 
further act on the inner membrane. Here PHMB  bridges with acidic phospholipids in 
the inner membrane causing membrane rigidity and resulting membrane fissures [75], 
this is followed by loss of K+ ions, and possible impairment of the function of 
neighboring proteins. This destroys the membrane integrity which causes leakage of 
intracellular components, affects the function of cell membrane associated proteins and 
causes eventual cell lysis [76]. The bacteria may be able to recover and reform the 
membrane at bacteriostatic concentrations but at lethal concentrations the cytoplasm 
coagulates as nucleic acids react with PHMB, the membrane precipitates and the cell 
undergoes lysis [75].   
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Figure 1.7 Mechanism of action of the cationic biocide, PHMB. PHMB displaces 
cations in the outer membrane and bridges with acidic phospholipids in the inner 
membrane causing membrane rigidity, leakage of intracellular proteins, and cell lysis. 
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1.5.2 Triclosan 
Triclosan (2,4,4′-trichloro-2′-hydroxydiphenyl ether) is a bis-phenol commonly used in 
hand soaps [77]. In studies with E. coli, triclosan at subinhibitory concentrations 
inhibited the uptake of essential nutrients due to its disruptive effects on the bacterial 
cytoplasmic membrane, whilst at higher, bactericidal concentrations resulted in the 
rapid release of cellular components and cell death [78]. Triclosan directly damages the 
cell membrane by solubilising lipids within the membrane which disrupts the membrane 
structure leading to leakage and lysis [79]. At bacteriostatic concentrations, triclosan 
inhibits lipid biosynthesis via targeting ENR (enoyl-acyl carrier protein reductase) 
encoded by gene fabI [80]. Triclosan inhibits this enzyme by interacting with ENR and 
increasing its binding affinity to the cofactor NAD+ [81]. When triclosan, enzyme and 
cofactor are bound together this forms a stable ternary complex that cannot catalyse the 
reaction [79]. When the cell cannot synthesise fatty acids growth is inhibited.  Triclosan 
also acts by disrupting the glycolysis pathway by inhibiting a number of the enzymes 
involved (pyruvate kinase, lactic dehydrogenase, aldolase) and increasing the sensitivity 
of the pathway to acid inhibition [82]. 
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Figure 1.8 Mechanism of action of the biocide, triclosan. Triclosan directly damages 
the cell membrane by solubilising lipids within the membrane, and inhibits lipid 
biosynthesis via targeting ENR (enoyl-acyl carrier protein reductase). 
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1.5.3 Benzalkonium chloride 
Benzalkonium chloride (BAC) is a quaternary ammonium compound (QAC). QACs are 
often monocationic surfactants generally containing one quaternary nitrogen associated 
with at least one major hydrophobic component [73]. The proposed mechanism of 
action of BAC against microorganisms is: (i) adsorption to and penetration of the cell 
wall; (ii) binding of the polar head group to phospholipids within  the cytoplasmic 
membrane (lipid or protein), followed by membrane disorganization due to 
interdigitation of the alkyl tail into the membrane core; (iii) leakage of intracellular 
lower-weight material; (iv) degradation of proteins and nucleic acids; and (v) cell wall 
lysis caused by autolytic enzymes [83]. BAC will disrupt the phospholipid bilayer, 
proteins in the cytoplasmic membrane, and nucleic acids in cytoplasm [84]. BAC can 
also damage the outer membrane of Gram-negative bacteria, thereby promoting its own 
uptake [77]. Self-promoted uptake has been seen in other cationic biocides (such as 
PHMB and chlorhexidine) where the cation interacts with cross-linked cations in the 
outer membrane which causes structural and functional changes to the outer membrane  
and loss of the previously associated cations causing a reduction of electostatic charge. 
This leads an increase in outer membrane permeability to hydrophobic (cationic) 
compounds and a stronger electrostatic interaction between the cationic biocide and the 
anionic cell [85]. 
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Figure 1.9 Mechanism of action of the biocide, BAC. BAC binds to phospholipid head 
groups in the outer cell membrane, leading to membrane disorganisation, leakage of 
intracellular proteins, and cell wall lysis. 
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1.5.4 Silver Nitrate 
Silver has been used for antimicrobial benefits for many years. Silver ions interact with 
thiol (sulfydryl, SH) groups [86] which has been implicated in damaging the 
cytoplasmic membrane, intracellular proteins and DNA [77]. Silver has been found to 
inhibit the respiratory chain in E.coli by interacting with cytochrome a2 [87] and 
inhibiting phosphate uptake and exchange [88]. Silver ions also form complexes with 
DNA bases in preference to phosphate groups [89]. Silver ions inhibit several functions 
in the cell and this leads to the generation of reactive oxygen species, which are 
produced possibly through the inhibition of a respiratory enzyme by silver ions and 
attack the cell itself [90]. Utilising silver in medical applications has seen some success 
such as incorporation into antimicrobial impregnated wounds dressings [91].  
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Figure 1.10 Mechanism of action of the biocide, silver nitrate. Silver interacts with 
thiol (sulfydryl, SH) groups on both extracellular and intracellular proteins, and 
generation of reactive oxygen species causes cell death. 
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1.5.5 Biocide resistance 
As with antibiotics, the indiscriminate use of biocides has caused concern about the 
selection of biocide resistant bacteria [92]. Biocides have a broad spectrum of action 
therefore they act on multiple non-specific targets. With multiple targets, there is a 
lower chance that a single mutation will lead to resistance [93]. Despite this there are 
still multiple documented cases of biocide resistance in bacteria. Furthermore, there is 
concern that the development of resistance to biocides may also confer resistance to 
antibiotics due to the presence of shared target sites or due to phenotypic alterations in 
the bacteria physiology that alter electrostatic charge, decrease cell permeability or 
increase efflux. This has been shown to occur in Pseudomonas aeruginosa by mutation 
in the regulator gene controlling multidrug efflux pumps when exposed to triclosan [94].  
Gilbert et al. found that whilst the concentration exponent for PHMB was significantly 
different between planktonic and biofilm populations of E.coli [76] there was no 
evidence of acquired resistance to PHMB within the bacterial population [75]. However 
there are many changes that have been observed in E.coli when exposed to PHMB, 
these include: Loss of flagella, RbsD downregulation (ribose transporter), cell-cell 
aggregation, and tnaA downregulation (tnaA can signal biofilm formation) [95] 
indicating that biocide adaptation may have multiple consequences on the bacterial cell  
aside from the generation of insusceptability. 
It has been previously documented that significant decreases in BAC susceptibility after 
long-term bacterial exposure have not been detected [96]. However, QAC resistance has 
become an increasing area of concern since the use of these disinfectants have become 
more widespread [97]. As such, QAC resistance genes have been found in E.coli 
recovered from retail meat [98]. Changes in gene expression have been identified in 
BAC adapted E.coli including tolC, an efflux pump, and OmpA, porins [99]. A study by 
McCay et al [100] found that P. aeruginosa exposed to sub- inhibitory concentrations of 
BAC showed increased expression of multidrug efflux genes mexB, mexD, mexF and 
mexY. This increase in expression would decrease susceptibility to antimicrobials due to 
increased efflux. 
Previous investigations corroborate the selection of silver resistance in other Gram 
negative pathogens including E.coli [101], and high levels of silver resistance are 
already being documented in invasive Enterobacteriaceae [102] possibly due to active 
 24 
 
efflux and loss of outer membrane porins [103]. Indeed, silver-resistant E.coli have been 
shown to have acquired mutations in ompR and cusS [103]. These mutations caused the 
loss of ompC/F porins and derepression of the CusCFBA efflux transporter. The 
combined effect of decreased cell wall permeability and increased efflux resulted in 
reduced concentrations of intracellular silver. 
Despite the previously mentioned evidence on the induction of biocide resistance in 
bacteria, understanding the real-world impact of bacterial resistance to biocides may be 
more complicated than previously thought. Forbes et al. [80] induced resistance to 
triclosan in Staphylococcus aureus (S. aureus) and this resulted in an increased 
susceptibility to antibiotics, reduced planktonic and biofilm growth, impaired 
haemolysis, coagulase and DNase activity, decreased competitive fitness and relative 
pathogenicity. The triclosan adapted strain demonstrated impaired cross-wall formation 
partially explaining growth deficits and also showed reduction in multiple cell surface 
adhesins potentially explaining decreased virulence [104]. This shows that biocide 
resistance may be associated with other functional deficits which brings into question 
how biocide adapted bacteria behave during infection. These previous data only 
concerned S. aureus so research into the effects of biocide resistance on other bacterial 
pathogens, such as E.coli, should be investigated. Yu et al. [93] discovered many genes 
were upregulated in triclosan resistant E.coli however they did not investigate whether 
these genes conferred resistance or perhaps had other effects. It is known that 
overexpression of sdiA is known to change cell morphology to rounder and shorter 
forms and can affect the expression of efflux pump proteins, it has also been linked to 
resistance to other drugs.  
Another important consideration is the formulation of biocides used. Most in vitro 
experiments use biocide in aqueous solution however in consumer products the biocide 
would be formulated with surfactants and sequestrants. Experiments to compare 
formulated with unformulated biocides revealed that formulated biocides were more 
potent and induced resistance was less significant compared with unformulated biocides, 
likely due to their multiple-target site mode of action [105]. In vitro studies that used 
unformulated biocides should therefore be viewed critically when discussing biocide 
resistance. 
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1.6.0 Current anti-infective catheter coatings  
Coating a catheter with an antimicrobial has become an increasingly popular area of 
research. Recently a coating was developed with immobilised acylase which was 
reported to reduce P. aeruginosa biofilm formation by 60% [106]. Acylase catalyses the 
degradation of AHL molecules and so inhibits quorum sensing by bacteria that use this 
system [107]. This is one of the first coatings that have been developed to incorporate 
quorum sensing inhibitors. Biocide catheter coatings have shown promising results 
[108] with triclosan being effective against E. coli and P. mirabilis biofilms [109, 110]. 
PLGA coatings containing cinnamaldehyde have been shown to be effective against E. 
coli biofilms [111, 112]. 
There are anti- infective catheter coatings already in clinical use. Silver coated catheters 
were among the first to be developed and two types of coating, silver oxide and silver 
alloy, were used [113]. Now a hydrogel silver alloy-coated latex catheter (CR Bard Inc.) 
is amongst the most popular used in practice, however results into the efficacy of this 
coating have been variable [114]. In certain investigations, silver coated catheters have 
been shown to be no more effective at preventing infections than non-coated catheters 
[113]. Devak et al. reported that the anti-attachment effect apparently seen in silver 
coatings was actually an effect of the hydrogel rather than the silver itself [115]. In a 
trial recruiting 6394 catheterised patients, it was found that there was no evidence to 
suggest that silver coated catheters benefited patients compared to non-coated catheters 
[114]. Considering the large body of evidence on the development of silver resistance in 
bacteria [116] this may be a consequence of adaptation of the bacteria to prolonged 
silver exposure causing a reduction in susceptibility. This would be particularly 
problematic when considering long-term catheterisation.  
Two further antimicrobial catheter coatings have been developed and evaluated in 
clinical studies, these are Nitrofurazone and aminocycline/rifampicin mixture [117]. 
The minocycline/rifampicin coating was not taken past the initial trial stages but 
nitrofurazone- impregnated urethral catheters are currently commercially available 
(Rochester Medical Corp) [114]. Trial data suggest that nitrofurazone coated catheters 
may be effective for the first 3 days after insertion but after that time there was no 
significant difference in incidence of CAUTI compared to non-coated catheters [114] 
highlighting the short-lived activity of certain coating agents. 
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1.6.1 Modified surface coatings 
A 'passive' coating is when the physicochemical properties of a surface is altered so 
bacterial attachment to the surface is prevented [118]. These types of coatings can be 
limited due to the surfaces being modified after implantation, often as a consequence of 
a conditioning layer of host proteins adhering to the device providing sites for bacterial 
adherence. Kingshott et al found that PEG modified stainless steel had no effect on 
bacterial attachment but PEG modified carboxylated poly(ethylene terephthalate) 
(PET−COOH) reduced bacterial attachment [119]. Silicone modified with polyethylene 
oxide (PEO) and polypropylene oxide (PPO) brushes showed limited effectiveness at 
reducing biofilm adherence and high variability between bacterial strains (adhesion, 
growth, and detachment of Staphylococcus species were affected but Pseudomonas 
aeruginosa was not) [120]. 
1.6.2 Active release coatings 
'Active' release coatings incorporate antimicrobials that are released over a period of 
time to reduce bacterial attachment to the surface [118]. Compounds that have been 
incorporated into active release coatings include silver [121], antibiotics [122], nitric 
oxide [123], and antibodies [124]. Schierholz et al found that the hydrophobicity of both 
the compound and the polymer matrix determines the release profile of the 
antimicrobial [125]. For example, hydrophilic molecules incorporated into hydrophobic 
polymers leached via an initial "burst" followed by substantially lower levels of release 
at extended periods. However, when molecule and polymer are both hydrophobic, there 
is a less significant initial release and a more sustained release over longer periods of 
time.    
Antibiotics have been incorporated into a variety of polymers including hydroxyapatite  
[122], polyurathane [126], and biodegradable polymers such as polylactide-co-glycolide 
(PLGA) [127]. Initial coatings with incorporated silver were shown to have limited 
efficacy in vivo [128]. It is thought that the reason for this is that the oxidised, active 
form of the silver ion (Ag+) is not released in metallic surface coatings [118]. Research 
has been done to develop coatings that actively release oxidised silver ions. Silver 
nanoparticles have become an increasing area of interest in this field. Yu et al have 
developed a poly(L-lactic acid) (PLLA) coating containing silver nanoparticles that 
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showed antibacterial activity and favourable biocompatibility [129]. A silver 
nanoparticle poly (lactic-co-glycolic acid) (PLGA) coating was developed for urinary 
catheters and showed enhanced resistance to encrustation compared with non-coated 
catheters, however the coating also contained norfloxacin (an antibiotic) [130] so it is 
unclear if the anti- infective properties of this coating can be solely attributed to the 
silver nanoparticles or are due to this combinatorial effect.  
1.6.3 Coatings with covalently bonded antimicrobials 
For some applications, the antimicrobials are incorporated directly onto the surface of 
medical devices by covalent bonds. Covalent bonds occur between atoms that share a 
pair of electrons and the attractive and repulsive forces between them form a stable 
bond [131]. The benefit of this method is that the antibacterial effect for the implant or 
device would be permanent rather than leaching out over time [132]. However there are 
limited numbers of compounds that can be incorporated in this way because the active 
site of molecules may be masked by the covalent attachment [133]. Furthermore, 
deposition of host proteins on the device surface may shield the effect of the adhered 
antimicrobial. 
Catheters are commonly made from silicone, polyethylene, polyurethane, or latex, all of 
which are hydrophobic and therefore can't bind molecules with much stability. The 
catheter material is 'functionalised' first (introduction of polar, ionic, or radical groups 
on the surface) to allow the binding of the antimicrobial molecules. This is usually done 
with plasma, gamma, or ultraviolet radiation [134].  
Antimicrobial compounds that have been covalently bound to silicon previously include 
quaternary ammonium silane (QAS), which has been incorporated onto silicon discs by 
oxidisation of the silicon with argon plasma, coating with QAS, and drying at 80ºC 
[135]. The coated silicon was implanted into rats and there were significantly fewer 
cases of infection with the coated sections compared with uncoated sections [135]. The 
nitrofurazone coating for urinary catheters is an example of covalently attached coatings. 
Nitrofurazone is a nitrofuran derivative chemically related to nitrofurantoin. The 
nitrofurazone is incorporated in a silicone matrix on the surface of the catheter [136].  
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1.6.4 Hydrogels 
Hydrogels are polymer networks with hydrophilic structures, meaning they are able to 
retain large amounts of water [137]. The nature of hydrogels being wet and slippery is 
advantageous for use in a catheter since this helps prevent damage to the urethral 
mucosa when inserted, in situ, and removed [134]. Vimala, et al created a hydrogel-
based coating that releases silver nanoparticles [138]. The hydrogels were shown to be 
antimicrobial with potency increasing with smaller nanoparticle size.  Hydrogels are 
increasingly being used to create nanoparticles as the free spaces within them can be 
used to synthesise and contain the nanoparticles [139].  
A study by Ahearn et al. [140] compared the anti-adhesion properties of 
hydrogel/silver-all-silicone-, and hydrogel/silver- latex-Foley urinary catheters compared 
with non-coated catheters. Interestingly, results varied depending on the bacteria tested, 
for example: there was a greater reduction in adhesion of E.coli to the coated latex 
catheter than the coated silicone catheter, whereas for P. aeruginosa it was the coated 
silicone catheter that showed the greater reduction. This could be due to the properties 
of the material itself or the modification process.  
1.6.5 Sol-Gel 
The sol–gel process involves the formation of an inorganic colloidal suspension (sol) 
and gelation of the sol in a continuous liquid phase (gel) to form a 3D network structure 
[141]. An advantage to the sol-gel manufacturing process over other glassy coating 
processes is that it can be conducted at much lower temperatures, such as room 
temperature [142]. Formation of sol-gel starts with simultaneous hydrolysis and 
condensation of monomers to form particles, growth of particles, and finally 
agglomeration of polymers networks within the liquid [142]. Active agents can be 
added to the porous sol-gel to be eluted out.  
Research has been carried out on the application of sol-gel coatings for medical devices 
and the results are promising. Nablo et al investigated the efficacy of stainless steel 
orthopedic implants coated in sol-gel [143]. The sol-gel was infused with nitric oxide 
(NO) donors which was shown to inhibit bacterial attachment to the implant over a 
range of temperatures and bacterial species [143]. This NO releasing sol-gel was also 
incorporated onto silicone elastomer and was shown to inhibit S. aureus biofilm 
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formation on the coated silicone [123]. This implies that the sol-gel can be successfully 
used to coat silicone catheters.  
1.7.0 Summary and Aims 
CAUTI's are becoming an increasing problem within hospitals and communities, 
contributing substantially to patient morbidity and mortality rates. The increasing threat 
of antibiotic resistance, and the ability of bacteria to form biofilms in the catheter, 
means that these infections are becoming increasingly difficult to treat. New therapies 
must be developed not only for the treatment of CAUTIs but to curb the increase in 
antibiotic resistance in uropathogens by reducing the need for antibiotic treatment and 
by providing alterative therapeutic strategies. The most common causative agent of 
CAUTIs is uropathogenic E.coli and it has been shown that when UPEC form a biofilm 
within the catheter it becomes less susceptible to antibiotics and shows increased 
virulence and pathogenicity. It is the action of AI-2 that mediates the formation of the 
UPEC biofilm and activates the genes responsible for the biofilm and virulence 
associated phenotypes. 
Quorum sensing inhibitors act to block the communication between bacteria in a 
biofilm by blocking the synthesis, dissemination, or reception of AI-2, thereby 
disrupting the biofilm establishment and making the infection easier to resolve. 
Biocides have a broad mechanism of action but issues with cytotoxicity at high biocide 
concentrations have been reported. By using combinations of biocides and QSIs it may 
be possible to disrupt biofilm formation and allow bacterial eradication at lower biocide 
concentrations than would be required to eradicate an established biofilm. Whilst there 
is evidence of the emergence of biocide insusceptibility in bacteria, the phenotypic 
adaptations exhibited by UPEC in response to biocides and QSIs has received little 
investigation. In order to develop a long- lasting anti- infective coating we need to 
initially understand the long-term effects of these agents in relevant pathogenic 
microorganisms.  
The aim of this project is to evaluate the impact of prolonged biocide and QSI exposure 
in a panel of UPEC isolates. These isolates comprise of two laboratory characterised 
strains (EC958 and CFT073) and six clinical isolates (EC1, EC2, EC11, EC26, EC28, 
and EC34) previously isolated from urinary tract infections (Stepping Hill Hospital,  
Stockport, UK). The isolates EC2, EC26, and EC34 have been previously identified as 
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ESBL producers. The biocides under investigation are PHMB, triclosan, BAC, and 
silver nitrate and the QSIs are cinnamaldehyde, (Z)-4-Bromo-5(bromomethylene)-
2(5H)-furanone (C30) and 4-fluoro-5-hydroxypentane-2,3-dione (F-DPD). 
Comprehensive screening of these potential coating agents will include detailed analysis 
of (i) the broad-range antimicrobial activity against UPEC in planktonic and biofilm 
growth, (ii) the effects that long-term antimicrobial exposure has on bacterial 
susceptibility and physiology (iii) the antimicrobials' biocompatibility with a 
mammalian cell line and (v) the association of the test compounds with different 
biomaterial polymers and their resulting antimicrobial efficacy and cytotoxicity.   
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Chapter 2 
 Biocide Exposure Induces Changes in Susceptibility, 
Pathogenicity and Biofilm Formation in Uropathogenic 
Escherichia coli. 
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2.1.0 Abstract 
Background: Uropathogenic Escherichia coli (UPEC) are a frequent cause of catheter 
associated urinary tract infection (CAUTI). Biocides have been incorporated into 
catheter-coatings to inhibit bacterial colonisation whilst ideally exhibiting low 
cytotoxicity and mitigating the selection of resistant bacterial populations. The effects 
of long-term biocide exposure on susceptibility, biofilm-formation and relative-
pathogenicity were compared between eight UPEC isolates. Methods: Minimum 
inhibitory concentrations (MIC), minimum bactericidal concentrations (MBC), 
minimum biofilm eradication concentrations (MBEC) and antibiotic susceptibilities 
were determined before and after long-term exposure to triclosan, polyhexamethylene 
biguanide (PHMB), benzalkonium chloride (BAC) and silver nitrate. Biofilm-formation 
was quantified using a crystal violet assay, and relative-pathogenicity was assessed via a 
Galleria mellonella waxworm model and cell invasion assays using bladder smooth 
muscle (SMC) and urothelial cells (HUEPC). Cytotoxicity and resulting 
biocompatibility index values were determined against an L929 murine fibroblast cell 
line. Results: Biocide exposure resulted in multiple decreases in biocide susceptibility 
in planktonic and biofilm associated UPEC. Triclosan exposure induced the largest 
frequency and magnitude of susceptibility decreases at MIC, MBC and MBEC, which 
correlated to an increase in biofilm biomass in all isolates. Induction of antibiotic-cross-
resistance occurred in 6/84 possible combinations of bacteria, biocide and antibiotic.  
Relative-pathogenicity significantly decreased after triclosan exposure (5/8 isolates), 
increased after silver nitrate exposure (2/8 isolates) and varied between isolates for 
PHMB and BAC. Biocompatibility index ranked antiseptic potential as 
PHMB>triclosan>BAC>silver nitrate. Conclusion: Biocide exposure in UPEC may 
lead to reductions in biocide and antibiotic susceptibility, changes in biofilm-formation 
and alterations in relative-pathogenicity. These data indicate the multiple consequences 
of biocide adaptation that should be considered when selecting an anti- infective 
catheter-coating agent. 
2.2.0 Introduction 
Catheter-associated urinary tract infections (CAUTI) are amongst the most commonly 
acquired healthcare associated infections contributing considerably to patient morbidity 
and posing an economic burden on healthcare service providers [144]. Complications 
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associated with catheterisation often arise due to contamination of the catheter surface 
with uropathogenic Escherichia coli (UPEC) during catheter insertion, leading to the 
formation of bacterial biofilms and subsequent infection. Patients undergoing long-term 
catheterisation are at a particular risk of acquiring CAUTI, with studies indicating a 5-
8% increase in the risk of developing bacteriuria for every day that the catheter remains 
inserted [14]. The majority of patients will exhibit bacteriuria after four weeks of 
catheterisation, potentially leading to further complications such as pyelonephritis and 
septicaemia [3, 14]. 
Bacterial biofilms are often recalcitrant to antimicrobial chemotherapy and to the 
actions of the host immune system, making biofilm associated infections such as 
CAUTIs difficult to treat [5]. Biofilms show decreased susceptibility to antibiotics, 
partially due to the shielding effect of the extracellular polymeric substance (EPS) 
encasing the bacterial cells [145], the low metabolic activity of the cells within the 
biofilm [146] and the activity of membrane-bound efflux pumps that actively expel 
antimicrobial compounds from the bacterial cell [5]. Furthermore, antibiotic-resistance 
genes are frequently transferred between bacteria within a biofilm by horizontal gene 
transfer allowing the dissemination of resistance through a bacterial population [6]. 
Antibiotic treatment of CAUTIs is therefore often ineffective due to the recalcitrance of 
the biofilm in addition to the increasing prevalence of antibiotic resistant uropathogens 
[147]. There is considerable interest in developing anti- infective catheter coatings that 
are refractory to microbial colonisation and subsequent biofilm formation in an attempt 
to prevent the establishment of CAUTI.  
Biocides are broad-spectrum antimicrobial chemicals that inhibit the growth of, or kill 
microorganisms [7]. Biocide coated urinary catheters have been developed 
incorporating biocides such as silver nitrate and nitrofurazone that are eluted from the 
surface of the catheter providing an antimicrobial gradient and a potential selective 
pressure for biocide resistant populations of bacteria [8]. Current clinical trial data has 
highlighted the limited antimicrobial efficacy of silver-impregnated catheters when 
compared to those without an antimicrobial coating, whilst nitrofurazone-containing 
coatings have been shown to exhibit only short-term antimicrobial activity and may 
therefore be ineffective in patients undergoing long-term catheterisation [114, 115]. 
This has fuelled the search for further anti- infective coating agents that display broad-
spectrum activity which is maintained after prolonged use. 
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Long-term exposure of certain bacterial species to biocides may cause the induction of 
biocide insusceptibility either through the selection of intrinsically resistant mutants or 
through induced phenotypic adaptations, bringing into question the long-term 
antimicrobial activity of various biocide containing coatings [148]. Concerns have also 
been raised that long-term biocide exposure may promote cross-resistance to antibiotics 
through the acquisition of mutations in shared target sites or through the activation of 
broad-range defence mechanisms [149], such as increased cellular efflux activity [150] 
or decreased cell permeability [77].  It can, however, be argued that whilst long-term 
biocide exposure may lead to reductions in biocide or antibiotic susceptibility in 
bacteria, these reductions are small and would not impact on the susceptibility of 
bacteria to the concentrations of biocide used in practice. Furthermore, such changes in 
biocide susceptibility may be accompanied with functional deficits impacting biofilm 
formation, pathogenicity and competitive fitness in bacteria [80]. Therefore in order to 
develop an effective anti- infective catheter coating the multiple long-term effects of the 
biocide used within the coating must be taken into consideration. 
Whilst previous investigations have evaluated the impact of long-term biocide exposure 
on the antimicrobial susceptibility of many clinically relevant bacteria, there is no 
current investigation into the multiple phenotypic consequences that may occur due to 
long-term biocide exposure in UPEC. The current study therefore aims to quantify the 
effects of long-term biocide exposure in eight UPEC isolates. The commonly used 
biocides PHMB, triclosan, BAC and silver nitrate were evaluated for their long-term 
antibacterial and anti-biofilm activity and their potential to induce antibiotic cross-
resistance. The impact that biocide exposure has on bacterial relative pathogenicity was 
assessed using a Galleria mellonella waxworm model and the biocides antiseptic 
potential was determined via calculating cytotoxicity in an L929 murine fibroblast cell 
line allowing the determination of a biocompatibility index value [151].  
2.3.0 Aims and objectives 
The purpose of this chapter was to evaluate the effects of long term biocide exposure on 
eight UPEC isolates. Previous studies have indicated biocide exposure impacts 
antimicrobial resistance, biofilm formation, and fitness in bacteria [80]. Biocides have a 
broad mechanism of action therefore it is posited that adaptation to biocide exposure 
would have multiple effects on the exposed bacteria.  
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The specific aims of the chapter were to: 
 Evaluate biocide susceptibility before and after biocide exposure using MIC, 
MBC, and MBEC assays. 
 Determine antibiotic cross resistance against biocide exposed UPEC. 
 Evaluate the ability of UPEC to form biofilms before and after biocide 
exposure using crystal violet assay. 
 Investigate the pathogenicity of UPEC before and after biocide exposure using 
Galleria mellonella model and primary cell invasion assays. 
 Determine the biocompatibility of the four biocides against an L929 cell line. 
2.4.0 Methods 
2.4.1 Bacteria and chemicals Six UPEC clinical isolates (EC1, EC2, EC11, EC26, 
EC28 and EC34) previously isolated from urinary tract infections (Stepping Hill 
Hospital, Stockport, UK) and two laboratory characterised UPEC strains EC958 and 
CFT073 were used in the investigation. Bacteria were cultured on Muller-Hinton agar 
(MHA; Oxoid, UK) and Muller-Hinton broth (MHB; Oxoid, UK) and incubated 
aerobically at 37 °C for 18 h, unless otherwise stated.  Biocides were formulated as 
follows: triclosan solubilised in 5% (v/v) ethanol. Polyhexamethylene biguanide 
(PHMB) (LONZA, Blackley, UK), benzalkonium chloride (BAC) and silver nitrate 
were prepared at 1 mg/ml in water and filter sterilised prior to use. All chemicals were 
purchased from Sigma–Aldrich (Poole, UK) unless otherwise stated. 
2.4.2 Long-term exposure of bacteria to biocides Bacteria were repeatedly exposed to 
biocides using an antimicrobial gradient plating system adapted from McBain et al 
[152].  In brief, 100 µl of a 5 × MBC concentration solution of biocide was added to an 
8 x 8 mm well in the centre of a 90 mm agar plate. Bacterial pure cultures were radially 
inoculated in duplicate from the edge of the plate to the centre, prior to incubation for 2 
days aerobically at 37°C. Biomass from the inner edge of the annulus of bacterial 
growth representative of the highest biocide concentration at which growth could occur 
was removed and used to inoculate a new biocide containing plate, as outlined above. 
This process was repeated for 12 passages. Control isolates passaged 12 times on 
biocide free media were also included. Bacteria were archived at -80 °C before and after 
biocide passage for subsequent testing. 
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2.4.3 Minimum inhibitory and minimum bactericidal concentration Minimum 
inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were 
determined as described previously [80]. In brief, 2 × 5 ml overnight cultures of test 
bacteria were prepared in MHB prior to overnight incubation (18-24 h) at 37ºC and 100 
rpm. Cultures were diluted to an OD600 of 0.008 in 20 ml of sterile MHB to produce a 
bacterial inoculum for biocide susceptibility testing. Doubling dilutions (150 µl) of each 
test biocide were prepared in sterile MHB in a 96-well microtiter plate prior to addition 
of bacterial inoculum (150 µl).  Plates were incubated overnight (18-24 h) at 37ºC and 
100 rpm. The MIC was defined as the lowest concentration of biocide for which growth 
was completely inhibited (viewed as turbidity relative to a sterile negative control). To 
determine MBC aliquots (5 µl) were taken from the wells of the MIC plate and were 
spot plated onto Muller Hinton Agar (MHA) in triplicate. The plates were incubated 
statically for 18-24 h at 37ºC. The lowest test concentration for which visible bacterial 
growth was completely inhibited was deemed the MBC.  
2.4.4 Minimum biofilm eradication concentration Minimum biofilm eradication 
concentrations were determined using the Calgary biofilm device (CBD) as described 
previously [105].  Briefly, 2 × 5 ml overnight cultures of test bacteria were prepared in 
MHB and were incubated for 18-24 h at 37ºC and 100 rpm before being diluted to an 
OD600 of 0.008 in MHB to create a bacterial inoculum for biofilm susceptibility testing. 
100 μl of bacterial inoculum was added to each well of the CBD base, plates were 
incubated at 37ºC for 48 h to allow biofilm formation on the pegs. Doubling dilutions of 
biocides were prepared in sterile broth across a 96-well microtiter plate. Biofilms were 
exposed to antimicrobial compounds and incubated for 24 h at 37°C and 100 rpm. After 
incubation, the pegged lid was transferred to a 96-well plate containing 200 μl of sterile 
broth and was incubated for 24 h at 37°C and 100 rpm. MBEC was defined as the 
lowest concentration of biocide for which re-growth was completely inhibited (viewed 
as turbidity relative to a sterile negative control) indicating complete biofilm eradication.  
2.4.5 Crystal violet bacterial attachment assay 2 × 5 ml overnight cultures of test 
bacteria were diluted to an OD600 of 0.008 in MHB after incubation for 18-24h at 37º C 
and 100 rpm. 150 µl of diluted overnight bacterial culture was added to the wells of a 
sterile 96-well microtiter plate. Plates were incubated statically for 48 h at 37ºC. Media 
was removed from wells and replaced with 180 µl of crystal violet solution. The plate 
was left at room temperature for 30 minutes, crystal violet solution was decanted and 
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the wells were rinsed with 3 × 200 µl of PBS prior to drying for 1 h at 37ºC. The 
remaining crystal violet was solubilised in 250 µl of 100% ethanol. The A600 of the 
solubilised crystal violet solution was determined and compared to a sterile MHB 
negative control. 
2.4.6 Galleria mellonella pathogenicity assay The pathogenesis model was adapted 
from that of Peleg et al [153]. Final larval-stage G. mellonella (Live Foods Direct, 
Sheffield, UK) were stored in the dark at 4°C for up to 7 days, before randomly 
assigning 24 to each treatment group and incubating at 37°C for 30 min. Overnight 
suspensions of E. coli were pelleted via centrifugation at 13,000 rpm, washed twice in 1 
ml of PBS and then diluted appropriately to achieve an OD600 of 0.1 (5 × 10
5 - 8 × 105 
CFU/ml, as confirmed by colony counts on MHA). Aliquots of each suspension (5 µl) 
were injected into the hemocele of each larva via the last left proleg using a Hamilton 
syringe. Larvae were incubated in a petri dish at 37°C and the number of surviving 
individuals was recorded daily. An untreated group and a group injected with sterile 
PBS were used as controls. The experiment was terminated when at least two 
individuals in a control group had died or after 7 days of incubation. Two independent 
bacterial replicates were used to inoculate 24 caterpillars (12 per replicate) and 
significance in death rate was calculated using a log-rank reduction test (p≤0.01).  
2.4.7 Biocompatibility index Calculation of biocompatibility index (BI) was performed 
as described by Muller and Kramer [151]. To determine cytotoxicity, Neutral Red (NR) 
(3-amino- 7-dimethylamino-2-methylphenazine hydrochloride) assays and MTT [3-
(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetra-zolium bromide] assays were performed 
on an L929 cell line to establish IC50.  Procedures for the NR assay and the MTT test 
have been described in detail elsewhere [151]. The bacterial quantitative suspension 
tests were done in accordance with the guidelines for testing disinfectants and 
antiseptics of the European Committee for Standardization [154]. Suspension tests were 
performed in the presence of serum to determine the rf value, defined as the 
concentration of biocide that achieved a reduction in bacterial load of at least 3log10 
(99.9%). Suspension tests were conducted as follows, overnight bacterial cultures were 
diluted to 108-109 CFU/ml as determined by colony counts on MHA. Aliquots of 15 µl 
of inoculum were then transferred into 135 µl of biocide containing cell culture medium 
prior to incubation for 30 min at 37ºC.  For PHMB, BAC, and triclosan, the biocide was 
subsequently inactivated by transfer of 15 µl of the suspension into 135 µL of TSHC 
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(3% (w/v) Tween 80, 3% (w/v) saponin, 0.1% (w/v) histidine and 0.1% (w/v) cysteine). 
Silver nitrate was inactivated using TLA-thio (3% [w/v] Tween 80, 0.3% lecithin from 
soy bean, 0.1% [w/v] histidine and 0.5% [w/v] sodium thiosulphate). After 30 min of 
inactivation, 5 µl aliquots were spot plated onto MHA in triplicate. The plates were 
incubated statically for 18-24 h at 37ºC and CFU/ml was determined. The lowest test 
concentration which achieved at least a 3log10 (99.9%) reduction in bacterial load was 
deemed the rf value. BI is calculated as IC50/rf for each combination of biocide and 
isolate and indicates the antiseptic potential of the test compound.  
2.4.8 Antibiotic susceptibility Bacterial susceptibility was determined for trimethoprim 
sulfamethoxazole (25 µg), nitrofurantoin (50 µg), ciprofloxacin (10 µg), and gentamicin 
(200 µg). Antibiotic susceptibility tests were performed according to the standardized 
British Society for Antimicrobial Chemotherapy (BSAC) disc diffusion method for 
antimicrobial susceptibility testing [155]. 
2.4.9 Determination of mutation rate frequency Mutation rate frequency was 
determined as described by Miller et al [156]. In brief, 100 µl aliquots of diluted 
overnight culture obtained from single bacterial colonies were plated onto antibiotic free 
MHA plates and MHA plates containing 50µg/ml rifampicin in triplicate. Plates were 
incubated for 24h at 37ºC prior to determination of viable count. Mutation frequencies 
were expressed as the number of resistant mutants recovered as a fraction of total viable 
bacteria. 
2.4.10 Cell Invasion Assay Evaluation of % invasion was performed on primary 
normal bladder smooth muscle cells (SMC) and human urothelial epithelial cells 
(HUEPC). SMCs were grown in Vascular Cell Basal Medium supplemented with the 
Vascular Smooth Muscle Cell Growth Kit (ATCC, UK). HUEPCs were grown in 
urothelial cell growth medium supplemented with serum free supplements (Provitro, 
Germany). Cells were seeded in 24 well plates at a concentration of 8x104 cells/ml, with 
1ml of cell suspension per well. Plates were incubated at 37ºC, 5% CO2 for 48h. Cells 
were incubated with 500µl 2% Bovine Serum Albumin for 1 hour, at 37ºC, 5% CO2. 
Overnight bacterial cultures were diluted to 200x the number of host cells per ml in cell 
culture medium. Host cells were washed twice with PBS and 500µl bacterial suspension 
was added. Wells of bacterial suspension that did not contain host cells were also 
included ('survival' plate). All plates were incubated for 90 mins at 37ºC, 5% CO2.The 
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invasion plate was washed three times with PBS before 500µl media with 200µg/ml 
metronidazole was added. The plate was incubated for a further 60 mins at 37ºC, 5% 
CO2. The attach plate was washed three times with PBS. Cells of each well were lysed 
in the presence of 200µl dH2O for 1 minute per well. Lysate was removed and serial 
dilutions were carried out in PBS. Dilutions were plated out in triplicate onto MHA. 
This was repeated for the invasion plate and the 'survival' wells. Agar plates were 
incubated at 37ºC for 1 overnight and cfu/ ml were counted. 
2.5.0 Results 
2.5.1 Biocide susceptibility of UPEC in planktonic and biofilm states MIC (Table 
2.1), MBC (Table 2.2) and MBECs (Table 2.3) were determined for all test isolates 
before (P0) and after repeated passage either in the absence (C12) or presence of a 
specific biocide (P12). Change in biocide susceptibility after exposure was calculated as 
fold-change relative to the control (C12) (Table 2.4). Data indicates both the frequency 
of susceptibility change (≥2 fold) and the average magnitude of susceptibility change 
for each biocide.  
In terms of MIC, after repeated biocide exposure there was a ≥2 fold increase in 4/8 
isolates for BAC, 8/8 for silver nitrate and 8/8 for triclosan compared to the respective 
bacteria passaged in a biocide free environment (Table 2.1). In contrast 4/8 isolates 
showed a ≥2 fold decrease in MIC after exposure to PHMB. The average fold-change 
for MIC (C12 to P12) across the test panel of UPEC was 1.5 for BAC, 0.7 for PHMB, 2 
for silver nitrate and 807.1 for triclosan (Table 2.4). For MBC in the biocide exposed 
isolates (Table 2.2) there was a ≥2 fold increase in 4/8 isolates after BAC exposure, 8/8 
for silver nitrate and 5/8 for triclosan. In contrast 1 isolate showed a decrease in MBC 
after PHMB exposure. The average fold change in MBC after biocide exposure was 1.5 
for BAC, 0.8 for PHMB, 3.8 for silver nitrate and 5.4 for triclosan (Table 2.4). In terms 
of MBEC (Table 2.3), after repeated biocide exposure there was a ≥2 fold increase in 
7/8 isolates for BAC, 8/8 for PHMB and 8/8 for triclosan. Silver nitrate exposure led to 
a 1 increase in MBEC and 1 decrease. The average fold change in MBEC after biocide 
exposure was 4.5 for BAC, 29.2 for PHMB, 832.7 for triclosan and 7.8 for silver nitrate 
(Table 2.4). We observed a number of changes in MIC, MBC and MBEC after the 
passage of bacteria solely in a biocide free-environment when compared to the 
unpassaged parent isolate. We did not, however see any incidence of a control passaged 
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isolate (C12) exhibiting a significantly higher MIC, MBC or MBEC (P<0.05) than the 
respective biocide passaged isolate (P12) with the exception of PHMB where the 
biocide exposed isolates frequently exhibited a lower MIC and MBC than the 
unexposed parent strain and the control passaged isolate subsequently matched the 
susceptibility of the parent strain.  
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Table 2.1 Minimum inhibitory concentrations (μg/ml) for UPEC before exposure to biocide (P0), after 12 passages in the presence of the same 
biocide (P12), and after 12 passages in a biocide free environment (C12). Data represent mean MICs taken from two separate experiments each 
with four technical replicates. 
  
PHMB 
 
Triclosan 
 
BAC 
 
Silver Nitrate 
 
 
Isolate 
 
 
P0 
 
P12 
 
C12 
 
P0 
 
P12 
 
C12 
 
P0 
 
P12 
 
C12 
 
P0 
 
P12 
 
C12 
 
EC1 0.5 0.2 
 
0.5 0.00001 2 
 
0.02 (0.01) 15.6 15.6 
 
15.6 31.3 62.5 
 
31.3 
EC2 0.2 0.2 0.2 0.1 15.6 0.05 (0.02) 15.6 31.3 15.6 31.3 62.5 31.3 
EC11 0.2 0.2 0.2 0.1 2 0.05 (0.02) 15.6 31.3 15.6 31.3 62.5 31.3 
EC26 0.5 0.2 0.5 0.2 125 0.03 15.6 31.3 15.6 31.3 62.5 31.3 
EC28 0.5 0.5 0.5 0.2 3.9 0.2 (0.06) 15.6 15.6 15.6 31.3 62.5 31.3 
EC34 0.2 0.2 0.2 0.03 15.6 0.02 15.6 15.6 15.6 31.3 62.5 31.3 
EC958 1 0.2 1 0.1 7.8 0.03 15.6 31.3 15.6 31.3 62.5 31.3 
CFT073 
 
1 
 
0.2 
 
1 
 
0.1 
 
15.6 
 
0.02 
 
15.6 
 
15.6 
 
15.6 
 
31.3 
 
31.3 
 
15.6 
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Table 2.2 Minimum bactericidal concentrations (μg/ml) for UPEC before exposure to biocide (P0), after 12 passages in the presence of the same 
biocide (P12), and after 12 passages in a biocide free environment (C12). Data represent mean MBCs taken from two separate experiments each 
with four technical replicates. 
 
  
PHMB 
 
Triclosan 
 
BAC 
 
Silver Nitrate 
 
 
Isolate 
 
 
P0 
 
P12 
 
C12 
 
P0 
 
P12 
 
C12 
 
P0 
 
P12 
 
C12 
 
P0 
 
P12 
 
C12 
 
EC1 1 0.5 
 
0.7 (0.3) 0.002 7.8 
 
7.8 15.6 31.3 
 
15.6 31.3 62.5 
 
31.3 
EC2 1 0.5 1 7.8 31.3 7.8 31.3 31.3 15.6 31.3 62.5 31.3 
EC11 1 0.5 0.5 7.8 7.8 7.8 15.6 31.3 15.6 31.3 62.5 31.3 
EC26 0.5 0.5 0.5 7.8 125 7.8 62.5 31.3 15.6 31.3 62.5 31.3 
EC28 1 1 1 7.8 7.8 7.8 31.3 15.6 19.5 (8) 31.3 62.5 31.3 
EC34 1 0.5 0.7 (0.3) 7.8 62.5 7.8 15.6 15.6 15.6 31.3 62.5 31.3 
EC958 2 1 1.1 (0.5) 7.8 62.5 7.8 62.5 15.6 15.6 31.3 500 31.3 
CFT073 
 
15.6 
 
1 
 
1.1 (0.5) 
 
7.8 
 
31.3 
 
7.8 
 
15.6 
 
15.6 
 
15.6 
 
31.3 
 
31.3 
 
15.6 
 
  
 
4
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Table 2.3 Minimum biofilm eradication concentrations (μg/ml) for UPEC before exposure to biocide (P0), after 12 passages in the presence of 
the same biocide (P12), and after 12 passages in a biocide free environment (C12). Data represent mean MBECs taken from two separate 
experiments each with four technical replicates.  
  
PHMB 
 
Triclosan 
 
BAC 
 
Silver Nitrate 
 
 
Isolate 
 
 
P0 
 
P12 
 
C12 
 
P0 
 
P12 
 
C12 
 
P0 
 
P12 
 
C12 
 
P0 
 
P12 
 
C12 
 
EC1 31.3 2000 
 
93.8 (36) 7.8 31.3 
 
0.5 250 500 
 
125 2000 3000 
 
3000 
EC2 31.3 2000 93.8 (36) 3.9 250 2 125 500 62.5 3000 3000 3000 
EC11 31.3 250 7.8 2 125 0.06 125 125 13.7 (4) 3000 3000 54.7 (16) 
EC26 31.3 500 78.1 (31) 1 5000 2 250 250 93.8 (36) 2500 3000 3000 
EC28 62.5 2000 62.5 3.9 125 7.8 125 125 125 4000 3000 2750 (500) 
EC34 15.6 500 7.8 1 250 0.2 (0.07) 62.5 62.5 11.7 (5) 3000 3000 1750 (975) 
EC958 62.5 1000 23.5 (9) 7.8 125 1 250 250 62.5 4000 4000 3000 
CFT073 
 
31.3 
 
500 
 
35.2 (20) 
 
2 
 
500 
 
1 
 
62.5 
 
250 
 
62.5 
 
2000 
 
500 
 
1500 (577) 
 
  
 
4
4
 
 
Table 2.4 Fold changes are indicated for MIC, MBC, and MBEC in UPEC isolates after long-term biocide exposure compared with the 
respective isolate passaged in a biocide free-environment (C12). Changes (≥2 fold-change) are shown in bold.
  
MIC 
 
 
MBC 
 
MBEC 
 
Isolate 
 
PHMB 
 
 
Triclosan 
 
 
BAC 
 
 
Silver nitrate 
 
 
PHMB 
 
 
Triclosan 
 
 
BAC 
 
 
Silver nitrate 
 
 
PHMB 
 
 
Triclosan 
 
 
BAC 
 
 
Silver nitrate 
 
 
EC1 
 
-2.5 
 
97.7 
 
1 
 
2 
 
-1.4 
 
1 
 
2 
 
2 
 
21.3 
 
62.6 
 
2 
 
1 
EC2 1 312.5 2 2 -2 4 2 2 21.3 125 8 1 
EC11 1 39.1 2 2 1 1 2 2 32 2083.3 9.1 54.8 
EC26 -2.5 4166.7 2 2 1 16 2 2 6.4 2500 2.7 1 
EC28 1 19.5 1 2 1 1 -1.25 2 32 16 1 1.1 
EC34 1 781.3 1 2 -1.4 8 1 2 64 1250 5.3 1.7 
EC958 -5 260 2 2 -1.1 8 1 16 42.5 125 4 1.3 
CFT073 -5 
 
780 1 2 -1.1 4 1 2 14.2 500 4 -3 
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2.5.2 The impact of biocide exposure on UPEC biofilm formation Biofilm formation 
was determined via a crystal violet biofilm assay for each UPEC isolate before and after 
repeated biocide exposure and after passage in a biocide free media (Figure 2.11). 
Unexposed isolates displayed varying biofilm forming capabilities prior to biocide 
exposure with EC2 showing the highest level of biofilm formation follo wed by 
EC1>CFT073>EC11>EC28>EC34>EC26 and EC958. When repeatedly exposed to 
triclosan, all isolates (with the exception of CFT073) demonstrated a significant 
(ANOVA p≤0.05) increase in biofilm formation relative to the respective control. All 
isolates demonstrated a significant increase in biofilm formation after BAC exposure 
with the exception of EC2. For PHMB and silver nitrate, EC1 showed a significant 
increase in biofilm formation after repeated exposure to either biocide. PHMB exposure 
also induced decreases in biofilm formation in EC2 and CFT073. Differences in biofilm 
formation were determined to be irrespective of growth rate as we did not observe any 
significant (ANOVA p<0.05) change in growth rate or overall growth productivity 
when in binary culture (Figure 2.12).   
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Figure 2.1 Crystal violet biofilm assay indicating the effect of previous biocide 
exposure on biofilm formation in eight isolates of UPEC. Data shows the mean 
absorbance (A600) representative of biofilm formation for individual bacteria before and 
after long-term exposure to PHMB, triclosan, BAC or silver nitrate or after passage on a 
biocide free media (C12). Data represent samples taken from two separate experiments 
each with four technical replicates. For data that varied between replicates, SDs are 
given as error bars. Significance was determined using ANOVA; * p≤0.05. 
 47 
 
 
Figure 2.2 Planktonic growth for eight UPEC isolates after exposure to four biocides. 
Control isolates passaged without biocide (C12) are also shown. 
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2.5.3 Relative pathogenicity of UPEC after long-term biocide exposure  A G. 
mellonella waxworm model was used to determine relative pathogenicity in UPEC 
isolates (Figure 2.3). Data indicate that prior to biocide exposure, EC2 was the least 
pathogenic and EC1 and EC958 were the most pathogenic isolates.  PHMB exposure 
induced significantly (log-rank p≤0.05) decreased relative pathogenicity in 3/8 isolates 
(EC11, EC34 and EC958) and a significant increase in pathogenicity for EC2 when 
compared to the respective control isolate (C12). BAC exposure induced significantly 
decreased pathogenicity in 6/8 isolates (EC1, EC11, EC26, EC28, EC34 and EC958) 
and significantly increased pathogenicity in EC2. Silver nitrate was the only biocide to 
only induce significant increases in pathogenicity which occurred in 2/8 isolates (EC11 
and EC28) and triclosan was the only biocide to induce only significant decreases in 
pathogenicity which occurred in 5/8 isolates (EC11, EC26, EC34, EC958 and CFT073).    
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Figure 2.3 G. mellonella survival curves for larvae injected with unexposed and 
biocide-exposed UPEC. Data represents 24 biological replicates. Control data from non-
injected larvae, larvae injected with PBS alone, and larvae injected with control isolates 
passaged on a biocide free media (Control) are also shown. * indicates a significant 
difference in pathogenicity when comparing biocide adapted isolates to the respective 
control strain (p≤0.05, log-rank reduction test). 
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2.5.4 Cell invasion Bacterial invasion of human cells was determined by cell invasion 
assay with each UPEC isolate before and after exposure for bladder smooth muscle 
(Figure 2.4) and urothelial cells (Figure 2.5). For the unexposed isolates, EC1 showed 
the highest percentage of invasion followed by EC11, EC2, EC28, EC34, EC958, 
CFT073 and EC26 in SMC. When exposed to PHMB, EC1, EC2, EC11, EC28, and 
EC34 showed an increase in SMC invasion. Exposure to BAC induced an increase in 
SMC invasion in EC958. Exposure to triclosan and silver nitrate had no significant 
effect on SMC invasion.  
For HUEPC, EC958 showed the highest rate of invasion of the unexposed isolates, 
followed by, CFT073, EC1, EC26, EC11, EC34, EC28, and EC2. Exposure to PHMB 
induced significantly increased cell invasion in EC26. Triclosan exposure induced 
increased invasion in EC1 and EC28. BAC exposure induced increases in cell invasion 
for EC26 and EC34. Exposure to silver nitrate induced increases in cell invasion for 
CFT073. 
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Figure 2.4 SMC invasion of eight strains of unexposed and biocide adapted UPEC.  * 
indicates significant (ONE –WAY ANOVA p<0.05) change in cell invasion compared 
with relative control. 
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Figure 2.5 HUEPC invasion of eight strains of unexposed and biocide adapted UPEC.  
* indicates significant (ONE –WAY ANOVA p<0.05) change in cell invasion 
compared with relative control. 
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2.5.5 Changes in antibiotic susceptibility after biocide exposure  Isolates were 
classed as resistant or sensitive to each antibiotic as defined by BSAC breakpoints [155]. 
Antibiotic susceptibility was determined for UPEC isolates before and after exposure to 
each biocide (Table 2.5). Data indicate that PHMB exposure induced CFT073 to 
become resistant to trimethoprim sulfamethoxazole and EC26 to become resistant to 
gentamicin. Exposure to triclosan induced nitrofurantoin resistance in EC958 and 
ciprofloxacin resistance in EC2. Triclosan exposure also induced intermediate resistance 
to gentamicin in EC2. Silver nitrate exposure induced EC2 to become resistant to 
ciprofloxacin as did BAC exposure. There were cases where isolates that were initially 
resistant to trimethoprim sulfamethoxazole became more susceptible after biocide 
exposure. This occurred in EC2 after exposure to PHMB, BAC, or silver nitrate and in 
EC11 after exposure to triclosan or BAC. This was also observed in EC11 for 
ciprofloxacin after triclosan exposure and CFT073 after BAC, triclosan or silver nitrate 
exposure.
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Antibiotic  
Exposure 
 
 
EC1 
 
EC2 
 
EC11 
 
EC26 
 
EC28 
 
EC34 
 
EC958 
 
CFT073 
T
r
im
e
th
o
p
r
im
 
S
u
lf
a
m
e
th
o
x
a
z
o
le
  
Unexposed 
 
31.8 (1.3) S 
 
0 R 
 
0 R 
 
0 R 
 
0 R 
 
0 R 
 
0 R 
 
30 (0.6) S 
PHMB 31.7 (0.8) S 30.3 (0.6) S 0 R 0 R 0 R 0 R 0 R 0 R 
Triclosan 31.5 (0.6) S 0 R 32.3 (0.3) S 0 R 0 R 0 R 0 R 28.8 (0.4) S 
BAC 29.7 (3.6) S 26 S 31 (0.6) S 0 R 0 R 0 R 0 R 28.8 (1.3) S   
Silver Nitrate 32.7 (0.6) S 25.5 (0.5) S 0 R 0 R 0 R 0 R 0 R 29.5 (0.5) S 
N
it
r
o
fu
r
a
n
to
in
 
 
 
Unexposed 
 
20.3 (0.3) S 
 
20.7 (0.3) S 
 
23.7 (0.3) S 
 
21.2 (1.5) S 
 
19.7 (0.5) S 
 
16.3 (1.2) S 
 
20.4 (1.4) S 
 
18 (0.6) S 
PHMB 20.3 (0.9) S 19.5 (0.5) S 25 (1) S 23.2 (3.1) S 19.2 (0.4) S 15 (0.6) S 19.8 (0.25) S 17.8 (0.8) S 
Triclosan 20 (0.6) S 20.5 (0.6) S 24.7 (0.3) S 24.2 (1.5) S 18.7 (1.4) S 18 (0.6) S 0 R 21.2 (0.4) S 
BAC 19.3 (0.3) S 18.5 (0.5) S 23.8 (0.3) S 23.3 (3.1) S 19.5 (1.5) S 15.2 (1.2) S 20.4 (0.1) S 17.2 (0.4) S 
Silver Nitrate 20.3 (0.3) S 18.8 (0.3) S 23.5 (1.6) S 23.3 (2.1) S 21.3 (0.5) S 15.8 (0.8) S 20 S 17.2 (0.4) S 
 
C
ip
r
o
fl
o
x
a
c
in
 
 
 
Unexposed 
 
31.2 (0.8) S 
 
34 (0.6) S 
 
13.8 (0.6) R 
 
0 R 
 
30 S 
 
0 R 
 
0 R 
 
0 R 
PHMB 31.3 (0.8) S 35 (0.6) S 0 R 0 R 30 S 0 R 0 R 0 R 
Triclosan 32.5 (0.5) S 0 R 29.5 (0.8) S 0 R 30.7 (1) S 0 R 0 R 33.2 (1.9) S 
BAC 30 (0.3) S 0 R 0 R 0 R 29.7 (0.8) S 0 R 0 R 31.2 (1.8) S 
Silver Nitrate 31.2 (0.3) S 0 R 0 R 0 R 29.7 (0.8) S 0 R 0 R 31.7 (2.1) S 
 
G
e
n
ta
m
ic
in
 
 
 
Unexposed 
 
26 (0.5) S 
 
27.7 (0.3) S 
 
25.5 (0.6) S 
 
14.3 (1.2) I 
 
18.2 (1) S 
 
16.5 (0.5) I 
 
26 S 
 
24.8 (0.4) S 
PHMB 25.5 (0.6) S 28.1 (0.4) S 27.3 (0.3) S 11.8 (0.8) R 18.5 (1.6) S 16.2 (1.2) I 26.4 (0.5) S 25 S 
Triclosan 25.8 (0.3) S 16 I 23.5 (0.6) S 15.8 (3.5) I 20.8 (1) S 20 (0.9) S 27 (0.6) S 28.3 (1.4) S 
BAC 26.5 (0.5) S 25.8 (0.8) S 25.3 (0.3) S 16.8 (0.8) I 18.8 (0.8) S 18 S 26.7 (0.6) S 24.7 (0.5) S 
Silver Nitrate 27.8 (0.3) S 27.2 (0.1) S 27 (0.3) S 15.2 (1.5) I 18.7 (0.8) S 17 (1.3) S 26.2 (0.3) S 24 S 
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Table 2.5 Data show the mean antibiotic inhibition zones (mm) or UPEC before and 
after biocide exposure (mm) and represent samples taken from two separate 
experiments each with three technical replicates. For data that varied between replicates, 
SDs are given in parentheses. S = Sensitive, I = Intermediate, R = Resistant, as defined 
by BSAC breakpoint (23). 
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2.5.6 Biocompatibility Index Cytotoxicity data for the four biocides against an L929 
cell line are shown in Table 2.6, rf values, indicating antimicrobial activity, and the 
corresponding BI values, highlighting the antiseptic potential of the compounds, are 
shown in Table 2.7. The order of cytotoxicity in relation to the biocide concentration 
was silver nitrate>PHMB>BAC>triclosan. The only isolate for which an rf value could 
be determined for silver nitrate was CFT073 as the rf values for the other isolates 
exceeded the maximum solubility of the biocide. Similarly, an rf value could not be 
determined in EC28 and CFT073 for triclosan as the rf value was greater than the 
highest achievable test concentration. BI values for the eight isolates were averaged for 
each biocide and the final ranked order of BI was PHMB>triclosan>BAC>silver nitrate 
indicating the antiseptic potential of the biocides. 
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Table 2.6 Mean concentration of biocides allowing 50% survival (IC50) of murine 
fibroblasts after 30 min at 37ºC as determined via Neutral Red (NR) and [3-(4,5-
dimethylthiazol-2-yl)-2, 5-diphenyltetra-zolium bromide] (MTT) assays. Mean IC50 
based on mass and molecular weight (m.w.). Data indicates two separate experiments 
each with six replicates. 
 
 
 
 
 
 
 
 
 
Biocide 
 
NR IC50  
 
MTT IC50  
 
m.w. 
 
 
           Mean IC50 
 
 
 
PHMB 
 
0.02  
 
0.03 
 
2800 
 
0.026 0.000009 
Triclosan 0.19  0.14  289.54 0.16 0.00057 
BAC 0.07  0.03  340 0.047 0.00014 
Silver Nitrate 0.002  0.003  169.87 0.0027 0.000016 
 
mg/ ml                  mmol/ ml 
  
 
5
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Table 2.7 Data shows the concentration of biocide (mg/l) producing 3 log10 reduction (rf) after 30 min of exposure at 37ºC on eight isolates of 
UPEC and the resulting BI value. NC- not calculable, for certain combination of biocide and bacterial isolate the rf value exceeded the maximum 
solubility of the biocide. Data represent mean rf  values taken from two separate experiments each with four technical replicates. 
 
Biocide 
 
 
EC1 
 
 
EC2 
 
EC11 
 
EC26 
 
EC28 
 
EC34 
 
EC958 
 
CFT073 
  
rf  
 
BI 
 
rf  
 
BI 
 
rf  
 
BI 
 
rf  
 
BI 
 
rf  
 
BI 
 
rf  
 
BI 
 
rf  
 
BI 
 
rf  
 
BI 
 
 
PHMB  
 
0.02 
 
1.6 
 
0.06 
 
0.4 
 
0.01 
 
1.6 
 
0.02 
 
1.6 
 
0.3 
 
0.1 
 
0.1 
 
0.2 
 
0.5 
 
0.05 
 
0.02 
 
1.6 
 
Triclosan 
 
 
0.2 
 
0.7 
 
1.1 
 
0.1 
 
0.2 
 
0.7 
 
1.1 
 
0.1 
 
NC 
 
NC 
 
0.6 
 
0.3 
 
2.3 
 
0.07 
 
NC 
 
NC 
BAC 
 
0.07 0.7 0.2 0.2 0.2 0.2 0.2 0.2 0.1 0.3 0.2 0.2 0.6 0.08 0.07 0.7 
Silver 
Nitrate 
 
NC NC NC NC NC NC NC NC NC NC NC NC NC NC 0.01 0.2 
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2.5.7 Mutation rate frequency in UPEC isolates Mutation rate frequency was 
determined with regards to rifampicin resistance. We observed rifampicin resistant 
mutants from all UPEC isolates (Table 2.8). Mutation frequencies varied from 1.7 x 10-8 
for CFT073 up to 3 x 10-7 for EC2 with an overall mutation frequency rank order of 
EC2>EC28>EC11>EC1>EC34>EC958>EC26>CFT073.  
 
 
Isolate 
 
 
Mutation Rate  
 
EC1 
 
7.97 x 10-8 
EC2 3 x 10-7 
EC11 1.36 x 10-7 
EC26 3.41 x 10-8 
EC28 1.86 x 10-7 
EC34 6.81 x 10-8 
EC958 3.49 x 10-8 
CFT073 
 
1.69 x 10-8 
 
Table 2.8 Mutation rate frequencies of eight strains of UPEC for rifampicin resistance 
given as a fraction of the population.  
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2.6.0 Discussion 
The current investigation aimed to explore the phenotypic changes that occur in 
genetically mixed populations of UPEC as a result of long-term biocide exposure. 
Susceptibility of eight UPEC isolates to a panel of test biocides was determined in 
planktonic and biofilm states before and after long-term biocide exposure. Changes that 
biocide exposure had on biofilm formation, relative pathogenicity and antibiotic 
susceptibility were assessed. Furthermore, cytotoxicity and the corresponding BI values 
were determined for each biocide against an L929 murine fibroblast cell line indicating 
the antiseptic potential of the test agents.  
2.6.1 Biocide exposure induces changes in antimicrobial susceptibility in 
planktonic UPEC The data in this investigation highlights that long-term exposure to 
biocides may influence biocide susceptibility in UPEC. Bacterial susceptibility to 
biocides can be markedly affected by structural variations in the bacterial cell that (i) 
impact attraction of the biocide to the cell [77] (ii) lead to changes in cell permeability 
to the biocide [157] and (iii) cause modification in efflux activity allowing the bacteria 
to expel the biocide from the cell [158]. These modifications may account for some of 
the changes in biocide susceptibility observed in the current study, however the exact 
mechanisms that govern each specific adaptation depends upon a multitude of factors 
inherent to both the particular biocide and the bacterium [77]. Furthermore, previous 
studies have indicated that biocide exposure in bacteria may result in reversible 
phenotypic adaptations that occur as a consequence of temporary changes in gene 
expression, for instance the induction of stress responses [95]. In contrast, other 
investigations highlight that biocide exposure may lead to the selection of biocide 
resistant mutants with stable phenotypes that do not revert in the absence of the biocide 
[159]. This may reflect diversity within the mechanisms of action of biocides 
particularly with regards to target site specificity. Bacterial exposure to target site 
specific biocides such as triclosan readily appears to lead to the selection of mutations 
in target enzyme FabI [159] whilst induced insusceptibility towards membrane active 
compounds such as biguanides (PHMB) and quaternary ammonium compounds (BAC)  
is often associated with the induction of stress responses [160, 161]. 
In terms of initial antimicrobial efficacy, silver nitrate demonstrated the lowest activity 
against planktonic UPEC when compared with other test biocides at MIC and MBC. 
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We observed a high frequency of small magnitude decreases (≤2-fold) in silver nitrate 
susceptibility after long-term exposure resulting in comparatively high MIC and MBC 
values.  Silver is widely considered as an effective anti- infective urinary catheter 
coating agent and is used in currently marketed anti- infective urinary catheters [113]. 
However, previous investigations have also documented the selection of silver 
resistance in Gram negative pathogens [101] including E. coli and other invasive 
Enterobacteriaceae [102]. This resistance has been correlated to increased efflux 
activity [103] or a loss of outer membrane porins [116] thereby decreasing cell 
permeability, which may explain the induced reductions in silver nitrate susceptibility 
observed in our UPEC isolates.  
PHMB exposure induced a high frequency of small magnitude (≤2-fold) increases in 
susceptibility in planktonic UPEC at MIC and MBC. Previous data indicate that 
changes in bacterial susceptibility in response to membrane active compounds, such as 
biguanides, is usually attributed to alterations in the structural integrity of the bacterial 
cell envelope impacting cell permeability, modifications in the structure of LPS 
interfering in electrostatic interactions between the cationic biocide and cell envelope 
and due to increased cellular efflux activity, expelling the biocide from the cell [95], 
these mechanisms of resistance are in contrast with the data in the current investigation. 
Whilst other studies have also highlighted increases in PHMB susceptibility in bacteria 
after long-term exposure the underlying mechanisms that govern this adaptation 
remains unknown. It has been suggested that long-term exposure to biocides in bacteria 
may result in cumulative cellular damage and a resulting loss of fitness increasing 
bacterial susceptibility over time [148].  
Triclosan was the most potent antimicrobial before repeated biocide exposure in 
planktonic UPEC. However triclosan induced the largest frequency and magnitude of 
susceptibility decreases in MIC and MBC. Resistance of E. coli to triclosan has been 
widely documented and is believed to be due to a mutation in the target enzyme FabI 
[159], due to increased cellular efflux [150] and changes in the cell membrane 
composition that reduce permeability [162]. Triclosan- impregnated catheters have 
demonstrated marked efficacy in in vitro studies [108], and show little reduction in 
antimicrobial activity even after long-term use [163]. This may be due to the fact that 
whilst large susceptibility changes may occur in bacteria following triclosan exposure, 
as indicated in our data, the initial potency of triclosan means that the catheter maintains 
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a high level of antimicrobial activity even after the bacteria adapt to the presence of the 
biocide likely due to its multi-target site mode of action.  
BAC demonstrated lower initial antimicrobial activity against planktonic UPEC 
compared to triclosan and PHMB (MIC and MBC) and only induced minor reductions 
(≤2-fold) in susceptibility after long-term exposure. Changes in gene expression in BAC 
adapted E. coli have been previously identified revealing an upregulation of efflux 
pump membrane transporter yhiV and downregulation of the outer membrane porin 
ompA thereby increasing cellular efflux of BAC and reducing cell permeability towards 
the biocide [99].  
Repeated passage of bacteria on a biocide free media occasionally led to changes in 
biocide susceptibility within planktonic culture, however these changes occurred at a 
substantially lower magnitude and frequency than those observed after biocide 
adaptation and were predominantly increases in susceptibility. This potentially 
reemphasises the fitness costs associated with repeated culture. Significantly, we 
observed only five cases of significant reduction in biocide susceptibility when 
comparing the isolate passaged in the absence of biocide to the unexposed parent strain. 
This reduction in susceptibility could be attributed to the stress of repeated passage 
leading to protective stress responses. For example, reduced amino acid availability 
leading to the stringent response has been shown to cause reduced penicillin 
susceptibility in E.coli [164]. 
2.6.2 Biofilm formation and susceptibility in UPEC after biocide exposure  Bacteria 
that have adapted to the presence of biocides may exhibit further phenotypic alterations 
such as changes in growth rate, biofilm formation and competitive fitness, which may 
influence pathogenicity [13, 17]. After biocide exposure several UPEC isolates in the 
current study exhibited significant changes in biofilm formation. Whilst this biofilm 
formation is a complex multifactorial process, these changes could potentially be 
attributed to the selection of mutants with alterations in factors involved in the 
establishment of biofilms, such as adhesion, EPS production or maturation.  
Biocide exposure largely led to increases in biofilm formation particularly after 
exposure to BAC and triclosan. Of the 7 UPEC isolates that demonstrated an increase in 
biofilm formation after BAC exposure 6 had a corresponding increase in MBEC. All 7 
isolates that increased in biofilm formation after triclosan exposure also exhibited an 
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elevation in MBEC. PHMB exposure led to a significant decrease in biofilm formation 
for EC2 and CFT073 which did not correspond with decreases in MBEC, possibly 
indicating the recalcitrance of persister populations within the biofilm irrespective of 
biofilm biomass [165].  
BAC adaptation has been previously correlated to an increase in biofilm biomass in E. 
coli which is believed to be due to an increase in protein and polysaccharide content  
within the extracellular polymeric substance (EPS) [166]. This change in EPS 
composition may lead to reduced BAC susceptibility, as observed in our BAC adapted 
isolates.  
Yu et al. [93] utilised a genome-wide enrichment screen to demonstrate the genes 
involved in triclosan adaptation in E. coli. Microarray analysis revealed that triclosan 
exposure resulted in an increase in fimDFHI which encodes proteins involved in 
fimbrial biosynthesis, that have been shown to be positively associated with an increase 
in biofilm formation [167].  This may provide a potential link between the increase in 
biofilm formation and thus resistance caused by triclosan exposure in the UPEC isolates 
used in the current investigation.  
2.6.3 Changes in antibiotic susceptibility after biocide exposure in UPEC Concerns 
have been raised that biocide exposure may induce cross-resistance to clinically relevant 
antibiotics. In the current study we observed the generation of antibiotic resistance in 7 
out of a possible 84 combinations of bacteria, biocide and antibiotic. The biocide that 
induced the highest number of cases of cross-resistance in a previously susceptible or 
intermediate isolate was triclosan, which was to nitrofurantoin, gentamicin and 
ciprofloxacin. PHMB exposure led to trimethoprim sulfamethoxazole and gentamicin 
cross resistance. BAC and silver nitrate exposure led to one observed case of cross-
resistance each which was towards ciprofloxacin.  
There have been previous reports into efflux mediated cross-resistance between 
antibiotics and to triclosan reportedly due to upregulation of acrAB, encoding the 
AcrAB efflux pump [168]. Efflux pumps have also been correlated to observed cross-
resistance to between quaternary ammonium compounds and antibiotics in E. coli. Bore 
et al observed reduced antibiotic susceptibility in BAC-adapted E. coli which also 
coincided with an increase in the expression of acrAB and a downregulation in multiple 
outer membrane porins including OmpA, OmpF and OmpT [99]. Whilst there is 
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relatively sparse evidence on the generation of antibiotic cross-resistance due to PHMB 
exposure in bacteria, the mechanisms of uptake of PHMB is similar to that of 
aminoglycosides involving destabilisation of the bacterial cell membrane and LPS 
reorganisation [169]. Interaction between LPS and PHMB is known to be a key step in 
the initial interaction of the biocide with the bacterial cell in E. coli (31). This may 
suggest why an induced reduction in PHMB susceptibility in our UPEC isolates also led 
to a similar reduction in susceptibility towards gentamicin. Studies on silver resistance 
in E. coli have revealed acquired low-level cross-resistance to cephalosporins, similarly 
due to increased efflux and reduced porin expression [116].  In this study, there were 10 
cases of biocide exposure eliciting increased susceptibility to antibiotics namely 
towards trimethoprim sulfamethoxazole and ciprofloxacin. This display of "cross-
protection" has been noted in previous studies and has been suggested to be due to a 
potential increase in cell permeability in response to biocide adaptation however the 
underlying mechanisms remain unclear [80].  
2.6.4 Biocompatibility of test biocides in an L929 cell line To assess the suitability of 
an antiseptic agent both the antimicrobial activity and cytotoxicity must be considered. 
Silver nitrate showed the highest level of cytotoxicity in an L929 cell line and the 
lowest antimicrobial efficacy in the corresponding quantitative suspension test (rf value). 
Reduced activity of silver when in the presence of serum has been previously at tributed 
to binding of the silver cations to the electronegative serum components, which may 
explain the low level of antimicrobial activity in silver nitrate observed in the 
quantitative suspension test in the current study [170]. Silver ions have been 
demonstrated to interact with components of mammalian cells including the 
mitochondria, nuclei, endoplasmic reticulum and the cell membrane [171]. Interaction 
of silver ions with mitochondria reportedly causes mitochondrial damage and the 
release of reactive oxygen species (ROS) resulting in apoptosis suggesting a mechanism 
of silver-mediated cytotoxicity [172]. Whilst PHMB was shown to be the second most 
cytotoxic biocide tested, it exhibited a relatively low rf value resulting in the highest BI 
value out of all the test biocides. PHMB has previously shown low level cytotoxicity 
towards mammalian cells, including L929 cells, which is suggested to be due to the 
interaction of the biocide with the mammalian cell membrane leading to membrane 
damage [173]. BAC was the second least cytotoxic biocide tested and the showed the 
second highest level of antimicrobial activity in the presence o f serum in the 
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quantitative suspension tests. BAC has been shown to interact with guanine nucleotide 
triphosphate-binding proteins (G proteins) impacting cell signalling transduction in 
mammalian cells and causing DNA damage [174]. Cytotoxicity data indicated triclosan 
to be the least cytotoxic of all the test biocides. However the rf values were high 
resulting in the second highest BI value. Triclosan has previously shown reduced 
antimicrobial efficacy in the presence of serum, this is believed to be due to the 
bacteria’s ability to gain an exogenous supply of fatty acids from the serum, thereby 
bypassing the inhibitory effects of the biocide [175]. Additionally, previous studies 
report on triclosan interference with mitochondrial respiration [176] in addition a 
damaging effect on the plasma membrane and induced apoptotic cell death [177] 
suggesting a potential mechanism of cytotoxicity.  
2.6.5 Altered relative pathogenicity in biocide adapted UPEC Repeated biocide 
exposure to silver nitrate induced an increase in relative pathogenicity in 2/8 isolates of 
UPEC whilst PHMB exposed isolates exhibited a decrease in pathogenicity in 3/8 and 
an increase in pathogenicity in 1/8 isolates respectively. A decrease in pathogenicity 
was observed after triclosan exposure in 5/8 isolates and in 6/8 isolates after exposure to 
BAC. BAC also induced an increase in pathogenicity in 1 further isolate. Triclosan 
exposure has previously been shown to reduce relative pathogenicity in a G. mellonella 
waxworm model in certain bacterial species [104]. These pathogenicity changes were 
suggested to be due to changes in virulence factor production, specifically reduced 
DNase activity and a down-regulation in cell surface adhesins [178]. It has been shown 
that triclosan exposure specifically downregulates genes encoding the outer membrane 
proteins P-fimbriae and protein X in E. coli [179] which are integral for UPEC 
attachment to cell surfaces [180] and entry into host cells [181]. Isolates of E. coli that 
have been exposed to BAC have been shown to have increased hemolysin activity and 
enhanced virulence [182] which may explain the increase in pathogenicity for the BAC 
exposed isolates in the current study. To our knowledge there are no current studies 
regarding the effects of silver or PHMB exposure on bacterial virulence factor 
production and resulting pathogenicity. 
2.6.6 UPEC invasion into human cells after exposure to biocides It was observed 
that, on average, invasion was higher in HUEPC than in SMC. This would make sense 
as UPEC express genes that encode P fimbriae/ pyelonephritis associated pili (PAP)  
[24] and type 1 pili which both adhere specifically to uroepithelium [26, 183].When 
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exposed to PHMB, 5/8 showed an increase in SMC invasion. For HUEPC, exposure to 
PHMB induced increased invasion in 1/8 isolates. Exposure to PHMB has been shown 
to induce expression of adhesion gene ycgV and increase production of pili which are 
used as adherence factors [95]. This would explain increases in cell invasion. 
For HUEPC invasion triclosan exposure induced increased invasion in 2/8 isolates. 
Triclosan exposure has previously been shown to specifically downregulate genes 
encoding outer membrane proteins (P-fimbriae and protein X in E. coli) [179] which are 
integral for UPEC attachment to cell surfaces [180] and entry into host cells [181]. This 
data is therefore in contrast to what we see in the current investigation. 
Exposure to BAC induced an increase in invasion in 1/8 isolates for SMC. BAC 
exposure induced increases in HUEPC invasion for 2/8 isolates. BAC exposure has 
been shown to increase expression of efflux pumps [100] and decrease expression of 
motility associated genes [184]. But to our knowledge there are no studies that have 
investigated the effects of BAC on E.coli cell invasion or have identified genes 
associated with invasion/adhesion that are associated with BAC exposure.  
When exposed to silver nitrate, 1/8 isolates showed increases in HUEPC invasion. A 
study into the effects of ionic silver on E.coli found an upregulation of ydeS,R which is 
putatively involved in cell adhesion [185]. Bacteria first have to adhere to cells before 
being able to invade so an increase in cell adhesion could explain the increased invasion 
seen in this study.  
2.6.7 Consequence of variance in mutation rate frequency in UPEC Elevated 
mutation rates have been previously reported in E. coli strains [186]. Furthermore, the 
adapting populations generated in the current investigation may lead to the selection of 
hypermutators due to the selective pressures created during biocide exposure. We 
evaluated the mutation frequencies in our parent isolates to determine whether this 
correlated to a higher frequency of phenotypic adaptations after biocide exposure. 
Mutation rate frequency was determined to be ordered 
EC2>EC28>EC11>EC1>EC34>EC958>EC26>CFT072. When comparing mutation 
rate to incidences of biocide susceptibility change (MIC, MBC and MBEC) EC11 and 
CFT073 showed the highest frequency of changes in biocide susceptibility whilst EC28 
showed the least. We observed two cases of significant change in biofilm formation for 
each isolate with the exception of EC1 for which we observed four. In terms of 
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significant changes in relative pathogenicity, EC11 demonstrated four significant 
changes after biocide exposure, EC34 and EC958 showed three, EC2, EC26 and EC28 
showed 2 and EC1 and CFT073 showed one. These data indicate a lack of correlation 
between the frequency of mutation rate in the parent strain and the rate of phenotypic 
adaptation in the respective isolate after biocide exposure.  
2.7.0 Conclusion 
The use of biocides for the purpose of antisepsis has led to concern over the selection of 
biocide resistance in clinically relevant pathogens. Here it is demonstrated that long-
term exposure of UPEC to commonly used biocides can result in changes in biocide 
susceptibility which may be accompanied by further phenotypic alterations impacting 
biofilm formation, antibiotic susceptibility and relative pathogenicity. The multiple 
consequences of bacterial adaptation towards biocides should therefore be evaluated 
when considering a potential anti-infective catheter coating agent. 
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Chapter 3 
Impact of long-term quorum sensing inhibition in uropathogenic 
Escherichia coli 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I acknowledge the following people for contributing to the work presented in this 
chapter: L Jaques (MSci student) who helped with the MIC, MBC, MBEC, 
pathogenicity, and antibiotic sensitivity experiments for the cinnamaldehyde and 
furanone C30 exposed isolates. P.G Chirila (PhD student) and C Whiteoak (academic) 
who synthesised the furanone C30. M Kadirvel (academic) who synthesised the F-DPD.  
 69 
 
3.1.0 Abstract 
Background: Quorum sensing is a cell-cell communication system utilised in the 
density-dependent regulation of gene expression in bacteria and the subsequent 
development of biofilms. Biofilm-formation has been implicated in the establishment of 
catheter-associated urinary tract infections (CAUTIs) therefore quorum sensing 
inhibitors (QSIs) have been suggested as anti-biofilm catheter coating agents to prevent 
CAUTI. The long-term effects of QS inhibition in uropathogens are, however, not 
clearly understood. The effects of long-term exposure to potential QSIs cinnamaldehyde, 
(Z)-4-Bromo-5(bromomethylene)-2(5H)-furanone (C30) and 4-fluoro-5-
hydroxypentane-2,3-dione (F-DPD) were evaluated on susceptibility, biofilm-formation 
and relative-pathogenicity in eight uropathogenic Escherichia coli (UPEC) isolates. 
Methods: Minimum inhibitory, bactericidal and biofilm eradication concentrations 
were determined before and after QSI exposure. Biofilm-formation was quantified using 
crystal-violet and relative-pathogenicity was assessed in a Galleria mellonella model. 
Cytotoxicity and resulting biocompatability index values were determined in an L929 
murine fibroblast cell line. Cell invasion assays were performed against bladder smooth 
muscle (SMC) and urothelial (HUEPC) cell lines. Results: Cinnamaldehyde and 
furanone C30 led to multiple increases in susceptibility in planktonic and biofilm-
associated UPEC. Relative pathogenicity increased after cinnamaldehyde exposure (4/8 
isolates), decreased after furanone C30 exposure (6/8 isolates) and varied after F-DPD 
exposure (2/8 increases and 2/8 decreases). Cinnamaldehyde and furanone C30 both 
induced 1/8 increase in HUEPC invasion whilst F-DPD induced 1/8 decrease in SMC 
invasion. 9 out of 21 possible cases of antibiotic cross-resistance were generated. The 
order of biocompatibility was furanone C30 > cinnamaldehyde > F-DPD. Conclusion: 
The impact of long-term QS inhibition in UPEC should be considered when selecting an 
anti-infective catheter coating agent. 
3.2.0 Introduction 
Urinary tract infection (UTI) is the most common healthcare associated infection 
(HCAI), with between 43% and 56% of cases associated with the presence of an 
indwelling urethral catheter [15]. Long-term catheterisation carries a significant risk of 
symptomatic catheter associated urinary tract infection (CAUTI), which can lead to 
complications such as pylonephritis and subsequent blood stream infection [14]. 
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Uropathogenic Escherichia coli (UPEC) is a frequent cause of catheter-associated 
urinary tract infection (CAUTI). Currently E. coli is the leading cause of blood stream 
infection in the UK with a mortality rate of 14.8% [17]. Of these cases, 21% are linked 
to urethral catheterisation [17]. With an ageing population in the UK it is likely that the 
need for urinary catheters will continue to rise resulting in an increasing risk to health 
and an escalating cost for healthcare service providers. 
The treatment of CAUTI is complicated by the emergence of UPEC exhibiting multiple 
antibiotic resistances. In Europe and the US 50,000 people a year lose their lives due to 
antibiotic resistant pathogens with that number rising to 700,000 worldwide [187]. This 
number is predicted to reach 10 million deaths by 2050 if alternative therapies are not 
found [187]. There has therefore been significant interest in the development of 
strategies to help prevent infection that avoids the use of antibiotics. A novel approach 
in the production of anti- infective catheter coatings is to use quorum sensing inhibitors 
(QSIs).  
Quorum sensing  (QS) is a process by which bacteria produce and detect signalling 
molecules and thereby coordinate their behaviour in a cell density dependent manner 
[10]. It has been shown to be an important contributor to the formation of a bacterial 
biofilms in certain bacterial species and may be involved in the expression of various 
virulence factors [5]. QSIs act to disrupt this communicative process and provide a 
potential strategy to prevent the establishment of biofilm associated infections such as 
CAUTI, whilst exhibiting limited cytotoxic effects due to their bacterial target site 
specific mode of action.  
Quorum sensing in UPEC is mediated by acyl-homoserine lactone (AHL) and 
autoinducer-2 (AI-2) [43]. AI-2 consists of derivatives of 4,5-dihydroxy-2,3-
pentanedione (DPD) [47] with LuxS, the DPD synthase, present in more than 500 
bacterial species [43]. It has been shown that AI-2 production is directly correlated to 
biofilm production in E.coli [48].  DPD analogues have been used to prevent AI-2 
binding to the periplasmic receptor LsrB [64] and disrupt AI-2 based transduction.  4-
fluoro-5-hydroxypentane-2,3-dione (F-DPD) a fluoro DPD analogue has been shown to 
disrupt AI-2 based QS and biofilm formation in  Vibrio harveyi. A small variety of 
naturally produced compounds have also been shown to inhibit AI-2 based signalling. 
Cinnamaldehyde is a natural product from the bark of the cinnamon tree and furanone is 
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a naturally produced QSI produced by red algae Delisea pulchra [10]. Both furanone 
C30 and cinnamaldehyde have been suggested to inhibit AI-2 based QS by decreasing 
the DNA binding ability of the response regulator LuxR [10]. Both compounds have 
been shown to affect biofilm-formation and increase biofilm susceptibility towards 
antibiotic treatment in a range of bacterial species in vivo [71]. As well as demonstrating 
QSI activity these compounds have also shown bacteriostatic and bactericidal effects 
[188, 189]. 
The gradient created by the release of an antimicrobial agent from a coated medical 
device creates a selective pressure that may induce phenotypic adaptations within 
individual bacterial cells or select for intrinsically resistant mutants altering both the 
bacteria itself and the surrounding microbial community composition. The risks 
associated with long-term exposure of bacteria to broad-spectrum antimicrobials has 
been extensively studied [9, 83], however there has been significantly lesser research 
into the long-term impact of QSIs. The current study therefore aimed to quantify the 
effects of QSI exposure in eight UPEC isolates. Specifically we will determine impact 
on antimicrobial and anti-biofilm susceptibility, the induction of antibiotic cross-
resistance, level of biocompatibility in addition to changes in biofilm-formation, relative 
pathogenicity and capacity for cell invasion.  
3.3.0 Aims and objectives 
Quorum sensing inhibitor treatment has been shown to reduce biofilm formation in 
E.coli by inhibiting the cell signalling required to initiate the genetic switch to biofilm 
growth [190]. There have also been reports of other effects of QSI treatment, for 
example increased antibiotic resistance [63]. There have not been any major studies into 
the impact of long term exposure to QSIs on bacteria. As quorum sensing is involved in 
the control of hundreds of genes in E.coli it is hypothesised that UPEC adaptation to 
QSI exposure will result in multiple phenotypic changes. 
The specific aims of this chapter were to: 
 Determine the efficacy of the QSIs cinnamaldehyde, furanone C30, and F-DPD 
in a Vibrio harveyi reporter system. 
 Evaluate QSI susceptibility before and after QSI exposure using MIC, MBC, 
and MBEC assays. 
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 Determine antibiotic cross resistance against QSI exposed UPEC. 
 Evaluate the ability of UPEC to form biofilms before and after QSI exposure 
using crystal violet assay. 
 Investigate the pathogenicity of UPEC before and after QSI exposure using 
Galleria mellonella model and primary cell invasion assays. 
 Determine the biocompatibility of the three QSIs against an L929 cell line. 
3.4.0 Methods 
3.4.1 Bacteria and chemical reagents Six UPEC clinical isolates (EC1, EC2, EC11, 
EC26, EC28 and EC34) previously isolated from urinary tract infections (Stepping Hill 
Hospital, UK) and two laboratory characterised  UPEC isolates (EC958 and CFT073) 
were used in the investigation. Bacteria were cultured onto Muller-Hinton agar (MHA; 
Oxoid, UK) or Muller-Hinton broth (MHB; Oxoid, UK) and incubated aerobically at 
37 °C for 18 h unless otherwise stated.  Furanone C30, cinnamaldehyde and F-DPD 
were prepared at 1 mg/ml in water and filter sterilised prior to use. Cinnamaldehyde was 
purchased from Sigma–Aldrich (Poole, UK). (Z)-4-Bromo-5(bromomethylene)-2(5H)-
furanone C30 (furanone C30) was synthesised at Sheffield Hallam University by P.G 
Chirila and C. Whiteoak as described previously [191]. 4-fluoro-5-hydroxypentane-2,3-
dione (F-DPD) was synthesised at University of Manchester by M. Kadirvel as 
described previously [192]. 
3.4.2 Vibrio model for determination of QSI activity Overnight cultures of Vibrio 
harveyi BB170 were grown in 20ml marine broth (Difco) at 37ºC 200rpm prior to 
dilution to OD600 0.008 and exposure to doubling dilutions of QSI in a 96-well 
microtitre plate. Plates were incubated at 37ºC for 40 h at 200rpm in a ClarioStar plate 
reader (BMG Labtech). Bioluminescence and the corresponding OD600 were recorded 
every 30 minutes.  
3.4.3 Long-term exposure of bacteria to quorum sensing inhibitors Bacteria were 
repeatedly exposed to QSIs using an antimicrobial gradient plating system as described 
in McBain et al [152].  In brief, 100 µl of a 5 × MBC concentration solution of QSI was 
added to an 8 x 8 mm well in the centre of a 90 mm agar plate. Bacterial pure cultures 
were radially inoculated in duplicate from the edge of the plate to the centre, prior to 
incubation for 2 days aerobically at 37°C. Biomass from the inner edge of the annulus 
 73 
 
of bacterial growth representative of the highest QSI concentration at which growth 
could occur was removed and used to inoculate a new QSI containing plate, as outlined 
above. This process was repeated for 12 passages. Control isolates passaged 12 times on 
QSI free media were also included. Bacteria were archived at -80 °C before and after 
QSI passage for subsequent testing. 
3.4.4 Minimum inhibitory and minimum bactericidal concentration Minimum 
inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were 
determined as described previously [80]. The MIC was defined as the lowest 
concentration of QSI for which growth was completely inhibited (viewed as turbidity 
relative to a sterile negative control). To determine MBC aliquots (5 µl) were taken 
from the wells of the MIC plate and were spot plated onto Muller Hinton Agar (MHA) 
in triplicate. The plates were incubated statically for 18-24 h at 37ºC. The lowest test 
concentration for which visible bacterial growth was completely inhibited was deemed 
the MBC.  
3.4.5 Minimum biofilm eradication concentration Minimum biofilm eradication 
concentrations were determined using the Calgary biofilm device (CBD) as described 
previously [105]. MBEC was defined as the lowest concentration of QSI for which re-
growth was completely inhibited (viewed as turbidity relative to a sterile negative 
control) indicating complete biofilm eradication.  
3.4.6 Crystal violet bacterial attachment assay 2 × 5 ml overnight cultures of test 
bacteria were diluted to an OD600 of 0.008 in MHB after incubation for 18-24h at 37º C 
and 100 rpm. 150 µl of diluted overnight bacterial culture was added to the wells of a 
sterile 96-well microtiter plate. Plates were incubated statically for 48 h at 37ºC. Media 
was removed from wells and replaced with 180 µl of crystal violet solution. Plates were 
left to dry at room temperature for 30 minutes, crystal violet solution was decanted and 
the wells were rinsed with 3 × 200 µl of PBS prior to drying for 1 h at 37ºC. The 
remaining crystal violet was solubilised in 250 µl of 100% ethanol. The A600 of the 
solubilised crystal violet solution was determined and compared to a sterile negative 
control. 
3.4.7 Galleria mellonella pathogenicity assay The pathogenesis model was performed 
as described in Peleg et al [153]. Final larval-stage G. mellonella were obtained from 
Live Foods Direct, Sheffield, UK. Treated larvae were incubated in a petri dish at 37°C 
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and the number of surviving individuals was recorded daily. An untreated group and a 
group injected with sterile PBS were used as controls. The experiment was terminated 
when at least two individuals in a control group had died or after 7 days of incubation. 
Two independent bacterial replicates were used to inoculate 24 caterpillars (12 per 
replicate) and significance in death rate was calculated using a log-rank reduction test 
(p≤0.05).  
3.4.8 Biocompatibility index Calculation of biocompatibility index (BI) was performed 
as described by Muller and Kramer [151]. To determine cytotoxicity, Neutral Red (NR) 
(3-amino- 7-dimethylamino-2-methylphenazine hydrochloride) assays and MTT [3-
(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetra-zolium bromide] assays were performed 
on an L929 cell line to establish IC50.  Procedures for the NR assay and the MTT test 
have been described in detail elsewhere [151]. The bacterial quantitative suspension 
tests were done in accordance with the guidelines for testing disinfectants and 
antiseptics of the European Committee for Standardization [154]. Suspension tests were 
performed in the presence of serum to determine the rf value, defined as the 
concentration of QSI that achieved a reduction in bacterial load of at least 3log10 
(99.9%). BI is calculated as IC50/rf for each combination of QSI and isolate and 
indicates the antiseptic potential of the test compound. 
3.4.9 Antibiotic susceptibility Bacterial susceptibility was determined for trimethoprim 
sulfamethoxazole (25 µg), nitrofurantoin (50 µg), ciprofloxacin (10 µg), and gentamicin 
(200 µg). Antibiotic susceptibility tests were performed according to the standardized 
British Society for Antimicrobial Chemotherapy (BSAC) disc diffusion method for 
antimicrobial susceptibility testing [155]. 
3.4.10 Cell Invasion Assay Evaluation of % invasion was performed on primary 
normal bladder smooth muscle cells (SMC) and human urothelial epithelial cells 
(HUEPC). SMCs were grown in Vascular Cell Basal Medium supplemented with the 
Vascular Smooth Muscle Cell Growth Kit (ATCC, UK). HUEPCs were grown in 
urothelial cell growth medium supplemented with serum free supplements (Provitro, 
Germany). Cells were seeded in 24 well plates at a concentration of 8x104 cells/ml, with 
1ml of cell suspension per well. Plates were incubated at 37ºC, 5% CO2 for 48h. Cells 
were incubated with 500µl 2% Bovine Serum Albumin for 1 hour, at 37ºC, 5% CO2. 
Overnight bacterial cultures were diluted to 200x the number of host cells per ml in cell 
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culture medium. Host cells were washed twice with PBS and 500µl bacterial suspension 
was added. Wells of bacterial suspension that did not contain host cells were also 
included ('survival' plate). All plates were incubated for 90 mins at 37ºC, 5% CO2.The 
invasion plate was washed three times with PBS before 500µl media with 200µg/ml 
metronidazole was added. The plate was incubated for a further 60 mins at 37ºC, 5% 
CO2. The attach plate was washed three times with PBS. Cells of each well were lysed 
in the presence of 200µl dH2O for 1 minute per well. Lysate was removed and serial 
dilutions were carried out in PBS. Dilutions were plated out in triplicate onto MHA. 
This was repeated for the invasion plate and the 'survival' wells. Agar plates were 
incubated at 37ºC for 1 overnight and cfu/ ml were counted. 
3.5.0 Results 
3.5.1 Efficacy of QSI's QS reporter strain Vibrio harveyi BB170  was used to determine 
QS inhibitory activity of furanone C30, F-DPD and cinnamaldehyde. The lowest 
concentration of QSI where bioluminescence was significantly (One-Way ANOVA) 
reduced without significantly reducing planktonic growth was termed the minimum 
quorum sensing inhibitory concentration (MQSIC). The MQSICs for the three test QSI's 
were: 39.06 µg/ml for cinnamaldehyde, 0.098 µg/ml for furanone C30 and 31.2 µg/ml 
for F-DPD (Figure 3.1). 
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Figure 3.1 Graphs showing the planktonic growth (absorbance) and QSI activity 
(luminescence) of Vibrio harveyi BB170 in the presence of increasing concentrations of 
a) cinnamaldehyde, b) furanone C30, and c) F-DPD as a % relative to the negative 
control (0µg/ml). The lowest concentration where QS was significantly (* p < 0.05, 
n=3) reduced without significantly reducing growth was termed the minimum quorum 
sensing inhibition concentration (MQSIC).  
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3.5.2 QSI susceptibility of UPEC in planktonic and biofilm states  MIC (Table 3.1), 
MBC (Table 3.2) and MBECs (Table 3.3) were determined for all test isolates before 
and after repeated QSI exposure and were compared to the respective control passaged 
on QSI free media. Change in QSI susceptibility after exposure was calculated as fold-
change relative to the control (Table 3.4). Data indicates both the frequency of 
susceptibility change (≥2 fold) and the average magnitude of susceptibility change for 
each QSI.  
After repeated cinnamaldehyde exposure there was a ≥2 fold-decrease in MIC in 8/8 
isolates for cinnamaldehyde indicating an increase in susceptibility (Table 3.1). The 
same results for furanone C30 susceptibility were seen after furanone C30 exposure. 
There were no significant changes in MIC induced by F-DPD exposure. The average 
fold-change in MIC was -2.5 for cinnamaldehyde and -3 for furanone C30 (Table 3.4). 
For MBC (Table 3.2) QSI exposure led to a ≥2 fold-decrease in 8/8 isolates for 
cinnamaldehyde and 6/8 isolates for furanone C30. In contrast 1/8 isolates showed a ≥2 
fold- increase in MBC after exposure to F-DPD indicating reduced susceptibility. The 
average fold-change in MBC was -2.56, -2.59, and 2 for cinnamaldehyde, furanone C30 
and F-DPD respectively. In terms of MBEC (Table 3.3) there was a ≥2 fold-decrease in 
8/8 isolates for cinnamaldehyde and 6/8 isolates for furanone C30. There were no 
significant changes in MBEC induced by F-DPD exposure. The average fold-change in 
MBEC was -3.5 for cinnamaldehyde and -2.56 for furanone C30 (Table 3.4).
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Cinnamaldehyde  
 
Furanone C30 
 
F-DPD 
 
 
Isolate 
 
 
P0 
 
P12 
 
C12 
 
P0 
 
P12 
 
C12 
 
P0 
 
P12 
 
C12 
 
EC1 
 
250 
 
125 
 
500 
 
125 
 
125 
 
500 
 
125 
 
125 
 
125 
EC2 250 250 500 125 125 375 (144) 125 125 125 
EC11 250 250 500 125 125 375 (144) 62.5 125 125 
EC26 250 125 500 125 125 313 (125) 62.5 125 125 
EC28 250 250 500 125 125 500 62.5 125 125 
EC34 250 250 500 125 125 313 (125) 62.5 125 125 
EC958 250 250 500 125 125 375 (144) 62.5 125 125 
CFT073 
 
250 250 500 125 125 250 125 250 250 
Table 3.1 Minimum inhibitory concentrations (µg/ml) for UPEC before exposure to QSI (P0), after 12 passages in the presence of the same QSI 
(P12), and after 12 passages in a QSI free environment (C12). Data represent mean MICs taken from two separate experiments each with four 
technical replicates. SDs are given in parentheses.  
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Table 3.2 Minimum bactericidal concentrations (µg/ml) for UPEC before exposure to QSI (P0), after 12 passages in the presence of the same 
QSI (P12), and after 12 passages in a QSI free environment (C12). Data represent mean MBCs taken from two separate experiments each with 
four technical replicates. SDs are given in parentheses.  
 
 
 
Cinnamaldehyde  
 
Furanone C30 
 
F-DPD 
 
 
Isolate 
 
 
P0 
 
P12 
 
C12 
 
P0 
 
P12 
 
C12 
 
P0 
 
P12 
 
C12 
 
EC1 
 
1000 
 
500 
 
1750 (500) 
 
250 
 
250 
 
500 
 
250 
 
500 
 
500 
EC2 1000 1000 2000 250 125 500 250 500 500 
EC11 250 1000 2000 125 250 437.5 (125) 250 500 500 
EC26 250 1000 2000 125 125 375 (144) 250 250 250 
EC28 250 1000 2000 250 125 500 250 500 500 
EC34 250 1000 2000 125 125 312.5 (125) 250 250 125 
EC958 250 1000 2000 250 250 375 (144) 250 500 500 
CFT073 
 
250 250 1250 (500) 125 125 250 250 500 500 
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Cinnamaldehyde  
 
Furanone C30 
 
F-DPD 
 
 
Isolate 
 
 
P0 
 
P12 
 
C12 
 
P0 
 
P12 
 
C12 
 
P0 
 
P12 
 
C12 
 
EC1 
 
250 
 
250 
 
1000 
 
250 
 
250 
 
312.5 (125) 
 
500 
 
500 
 
500 
EC2 250 250 1000 250 250 437.5 (125) 250 250 250 
EC11 250 250 500 125 125 437.5 (375) 62.5 15.6 15.6 
EC26 250 250 1000 125 250 500 250 250 250 
EC28 250 250 1000 250 125 500 500 250 250 
EC34 250 250 1000 125 93.75 (44.2) 187.5 (72.2) 62.5 62.5 62.5 
EC958 250 250 1000 250 125 500 500 500 500 
CFT073 
 
250 250 500 250 125 250 500 500 500 
Table 3.3 Minimum biofilm eradication concentrations ( µg/ml) for UPEC before exposure to QSI (P0), after 12 passages in the presence of the 
same QSI (P12), and after 12 passages in a QSI free environment (C12). Data represent mean MBECs taken from two separate experiments each 
with four technical replicates. SDs are given in parentheses.  
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Table 3.4 Fold changes are indicated for MIC (Table 3.9), MBC (Table 3.10), and MBEC (Table 3.11) in UPEC isolates after long-term QSI 
exposure compared with the respective isolate passaged in a QSI free-environment (C12). Changes (≥2 fold-change) are shown in bold.
  
MIC 
 
MBC 
 
MBEC 
 
 
Isolate 
 
Cinnamaldehyde 
 
 
Furanone  
C30 
 
 
F-DPD 
 
  
Cinnamaldehyde 
 
 
Furanone  
C30 
 
 
F-DPD 
 
  
Cinnamaldehyde 
 
 
Furanone  
C30 
 
 
F-DPD 
 
 
 
EC1 
 
-4 
 
-4 
 
0 
  
-3.5 
 
-2 
 
0 
  
-4 
 
-1.25 
 
0 
 
EC2 -2 -3 0  -2 -4 0  -4 -1.75 0  
EC11 -2 -3 0  -2 -1.75 0  -2 -3.5 0  
EC26 -4 -2.5 0  -2 -3 0  -4 -2 0  
EC28 -2 -4 0  -2 -4 0  -4 -4 0  
EC34 -2 -2.5 0  -2 -2.5   2  -4 -2 0  
EC958 -2 -3 0  -2 -1.5 0  -4 -4 0  
CFT073 -2 
 
-2 0  -5 -2 0  -2 -2 0  
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3.5.3 The impact of QSI exposure on UPEC biofilm-formation Biofilm formation 
was determined via a crystal violet biofilm assay for each UPEC isolate before and after 
repeated QSI exposure (Figure 3.2). Unexposed isolates displayed varying biofilm 
forming capabilities with EC2 showing the highest level of biofilm-formation followed 
by EC1>CFT073>EC11>EC28>EC34>EC26 and EC958. When repeatedly exposed to 
cinnamaldehyde, 6/8 isolates (EC1, EC11, EC26, EC28, EC34, EC958) demonstrated a 
significant (ANOVA p≤0.05) increase in biofilm-formation relative to the respective 
control. Exposure to furanone C30 induced one significant increase in biofilm-
formation (EC958) and one decrease (EC26). When exposed to F-DPD, EC1 showed a 
significant increase in biofilm-formation. Differences in biofilm-formation were 
determined to be irrespective of growth rate as we did not observe any significant 
change in rate or overall growth productivity when in binary culture (Figure 3.3; 
ANOVA p<0.05). 
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Figure 3.2 Crystal violet biofilm assay indicating the effect of previous QSI exposure 
on biofilm-formation in eight isolates of UPEC. Data shows the mean absorbance (A600) 
representative of biofilm-formation for individual bacteria before and after long-term 
exposure to cinnamaldehyde, furanone C30, and F-DPD or after passage on a QSI free 
media (C12). Data represent samples taken from two separate experiments each with 
four technical replicates. For data that varied between replicates, SDs are given as error 
bars. Significance was determined using ANOVA; * p≤0.05. 
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Figure 3.3 Planktonic growth for eight UPEC isolates after exposure to three QSIs. 
Control isolates passaged without QSI (C12) are also shown.  
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3.5.4 Relative pathogenicity of UPEC after long-term QSI exposure A G. mellonella 
waxworm model was used to determine relative pathogenicity in UPEC isolates (Figure 
3.4). Data indicate that prior to QSI exposure, EC2 was the least pathogenic and EC1 
and EC958 were the most pathogenic isolates. Cinnamaldehyde exposure induced 
significantly (log-rank p≤0.05) increased relative pathogenicity in 4/8 isolates (EC2, 
EC11, EC26, EC28) when compared to the respective control isolate. F-DPD exposure 
induced significantly increased pathogenicity in 2/8 isolates (EC11, EC26) and 
significantly decreased pathogenicity in 2/8 isolates (EC34, CFT073). Furanone C30 
was the only QSI to induce only significant decreases in pathogenicity which occurred 
in 6/8 isolates (EC1, EC11, EC26, EC34, EC958, and CFT073). 
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Figure 3.4 G. mellonella survival curves for larvae injected with QSI-exposed 
and -unexposed UPEC. Data represents 24 biological replicates. Control data from non-
injected larvae, larvae injected with PBS alone, and larvae injected with control isolates 
passaged on a QSI free media (Control) are also shown. * indicates a significant 
difference in pathogenicity when comparing QSI adapted isolates to the respective 
control strain (p≤0.05, log-rank reduction test). 
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3.5.5 Cell invasion Bacterial invasion of human cells was determined via cell invasion 
assay for bladder smooth muscle (SMC) (Figure 3.5) and urothelial cells (HUEPC) 
(Figure 3.6). For the unexposed isolates, EC1 showed the highest percentage of invasion 
followed by EC11, EC2, EC28, EC34, EC958, CFT073 and EC26 in SMC. F-DPD 
induced a decrease in SMC invasion in EC26 when compared to the respective control. 
For HUEPC, EC958 showed the highest rate of invasion of the unexposed isolates, 
followed by, CFT073, EC1, EC26, EC11, EC34, EC28, and EC2. Cinnamaldehyde led 
to increased HUEPC cell invasion in EC26 whilst furanone C30 exposure induced 
increased cell invasion in EC34. 
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Figure 3.5 Data show the % invasion of eight UPEC isolates before and after exposure 
to three QSIs (Cinnamaldehyde, Furanone C30, F-DPD) into SMCs. Control isolates 
passaged on QSI free media are also shown. * indicates a significant difference in 
pathogenicity when comparing QSI adapted isolates to the respective control strain 
(p≤0.05, ANOVA).  
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Figure 3.6 Data show the % invasion of eight UPEC isolates before and after exposure 
to three QSIs (Cinnamaldehyde, Furanone C30, F-DPD) into HUEPCs. Control isolates 
passaged on QSI free media are also shown. * indicates a significant difference in 
pathogenicity when comparing QSI adapted isolates to the respective control strain 
(p≤0.05, ANOVA). 
 90 
 
3.5.6 Changes in antibiotic susceptibility after QSI exposure  Isolates were classed as 
resistant, intermediate, or sensitive to each antibiotic as defined by EUCAST 
breakpoints [155]. Antibiotic susceptibility was determined for UPEC isolates before 
and after exposure to each QSI (Table 3.5). Data indicate that cinnamaldehyde exposure 
induced EC26 to become resistant to gentamicin and EC28 to become intermediately 
resistant to gentamicin. Exposure to furanone C30 induced gentamicin resistance in 
EC26 and EC34 and intermediate resistance in EC28. F-DPD exposure induced 
gentamicin resistance in EC26 and EC28. Cinnamaldehyde exposure induced CFT073 
to become intermediately resistant to trimethoprim sulfamethoxazole as did furanone 
C30 exposure. There were cases where isolates that were initially resistant to 
trimethoprim sulfamethoxazole became more susceptible after QSI exposure. This 
occurred in EC2 after exposure to furanone C30 and F-DPD. This was also observed in 
EC28 for ciprofloxacin after cinnamaldehyde and F-DPD exposure.  
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Table 3.5 Data show the mean antibiotic inhibition zones (mm) for UPEC before and after QSI exposure (mm) and represent samples taken from two separate experiments 
each with three technical replicates. For data that varied between replicates, SDs are given in parentheses. S = Sensitive, I = Intermediate, R = Resistant, as defined by BSAC 
breakpoint.
 
Antibiotic 
 
Exposure 
 
 
EC1 
 
EC2 
 
EC11 
 
EC26 
 
EC28 
 
EC34 
 
EC958 
 
CFT073 
T
r
im
e
th
o
p
r
im
 
S
u
lf
a
m
e
th
o
x
a
z
o
le
 
 
Unexposed 
 
14.4 (1.8) S 
 
0 R 
 
0 R 
 
0 R 
 
0 R 
 
0 R 
 
0 R 
 
15.3 (1) S 
Cinnamaldehyde 14.3 (0.8) S 11 (5.5) R 0 R 0 R 0 R 0 R 0 R 12.8 (1.9) I 
Furanone C30 14.2 (1.5) S 11.3 (1.4) I 0 R 0 R 0 R 0 R 0 R 13 (3.5) I 
F-DPD 
 
29.7 (0.5) S 29 (0.6) S 0 R 3.7 (4) R 0 R 0 R 0 R 36.7 (0.8) S 
N
it
r
o
fu
r
a
n
to
in
 
 
 
Unexposed 
 
20.3 (0.3) S 
 
20.7 (0.3) S 
 
23.7 (0.3) S 
 
21.2 (1.5) S 
 
19.7 (0.5) S 
 
16.3 (1.2) S 
 
20.4 (1.4) S 
 
18 (0.6) S 
Cinnamaldehyde 23 (1) S 22.3 (1.5) S 26.7 (1.2) S 25 (1) S 20.3 (4.7) S 18 (3) S 20.7 (0.6) S 22 (1) S 
Furanone C30 24 (1) S 24.7 (0.6) S 22.3 (0.6) S 21.7 (0.6) S 18.3 (2.1) S 17.3 (0.6) S 19.7 (1.5) S 17.7 (2.3) S 
F-DPD 
 
22.3 (0.6) S 24.7 (0.6) S 23.7 (1.2) S 26.3 (2.5) S 19.3 (0.6) S 18.7 (1.5) S 21.7 (2.1) S 19.7 (0.6) S 
C
ip
r
o
fl
o
x
a
c
in
 
 
 
Unexposed 
 
33 (0.6) S 
 
0 R 
 
0 R 
 
0 R 
 
25 (0.9) I 
 
0 R 
 
0 R 
 
35 (1.3) S 
Cinnamaldehyde 35.5 (0.8) S 0 R 0 R 0 R 29 (1.3) S 1.7 (4.1) R 0 R 33.3 (1) S 
Furanone C30 29.9 (1) S 0 R 0 R 0 R 25 (2.5) I 0 R 0 R 32.2 (1.2) S 
F-DPD 
 
33 (1.3) S 0 R 0 R 0 R 27.5 (1.4) S 0 R 0 R 47.7 (2.5) S 
G
e
n
ta
m
ic
in
 
 
 
Unexposed 
 
26 (0.5) S 
 
27.7 (0.3) S 
 
25.5 (0.6) S 
 
14.3 (1.2) I 
 
18.2 (1) S 
 
16.5 (0.5) I 
 
26 S 
 
24.8 (0.4) S 
Cinnamaldehyde 20.2 (0.8) S 20.2 (1) S 20.2 (1) S 12.3 (0.8) R 15 I 14.3 (0.8) I 20 S 21.8 (1.8) S 
Furanone C30 19 (1.1) S 19.8 (0.4) S 20 S 11 (0.9) R 14.5 (0.8) I 13.3 (1.5) R 20.7 (1.6) S 23.9 (2.1) S 
F-DPD 
 
17.5 (0.5) S 19 (0.6) S 19 (0.9) S 13.7 (0.5) R 13.3 (0.8) R 14.3 (0.8) I 19.2 (1) S 23 (1.7) S 
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3.5.7 Biocompatibility Index Cytotoxicity data for the three QSIs against an L929 cell 
line are shown in Table 3.6. rf values indicating antimicrobial activity and 
corresponding BI values, highlighting the antiseptic potential of the compounds, are 
shown in Table 3.7. The order of cytotoxicity in relation to the QSI concentration was 
F-DPD > cinnamaldehyde > furanone C30. BI values for the eight isolates were 
averaged for each QSI and the final ranked order of BI was furanone C30 > 
cinnamaldehyde > F-DPD indicating the antiseptic potential of the QSIs. 
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Table 3.6 Mean concentration of QSIs allowing 50% survival (IC50) of murine fibroblasts 
after 30 min at 37ºC as determined via Neutral Red (NR) and [3-(4,5-dimethylthiazol-2-
yl)-2, 5-diphenyltetra-zolium bromide] (MTT) assays. Mean IC50 based on mass and 
molecular weight (m.w.). Data indicates two separate experiments each with six 
replicates. 
 
QSI 
 
NR IC50  
 
MTT IC50  
 
m. w. 
 
 
           Mean IC50 
 
 
 
Cinnamaldehyde 
 
0.28 
 
0.0115 
 
132.16 
 
0.1458 0.0011 
Furanone C30 0.5735 0.0217 253.877 0.2976 0.0012 
F-DPD 0.06495 0.0003 134.04 0.0326 0.0002 
 
mg/ ml                  mmol/ ml 
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Table 3.7 Data shows the concentration of QSI (mg/ml) producing 3 log10 reduction (rf) after 30 min of exposure at 37ºC on eight isolates of UPEC and the 
resulting BI value. Data represent mean rf  values taken from two separate experiments each with four technical replicates. Standard deviation is given in 
parentheses. 
 
QSI 
 
 
EC1 
 
 
EC2 
 
EC11 
 
EC26 
 
EC28 
 
EC34 
 
EC958 
 
CFT073 
  
rf  
 
BI 
 
rf  
 
BI 
 
rf  
 
BI 
 
rf  
 
BI 
 
rf  
 
BI 
 
rf  
 
BI 
 
rf  
 
BI 
 
rf  
 
BI 
 
 
 
Cinnamaldehyde  
 
0.23 
 
0.63 
 
0.23 
 
0.63 
 
0.23 
 
0.63 
 
0.23 
 
0.63 
 
0.23 
 
0.63 
 
0.23 
 
0.63 
 
6.48 (1.85) 
 
0.022 
 
0.23 
 
0.63 
Furanone C30 0.38 0.79 0.5 0.60 0.38 0.79 0.5 0.60 1 0.30 0.5 0.60 0.5 0.60 0.5 0.60 
F-DPD 
 
0.5 0.07 0.5 0.07 0.5 0.07 0.5 0.07 1 0.04 0.5 0.07 0.5 0.07 0.5 0.07 
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3.6.0 Discussion 
3.6.1 QSI activity in a V. harveyi reporter system Blocking the AI-2 based signaling 
pathway is often primarily achieved by synthetically creating analogues that act as 
competitive inhibitors of the AI-2-binding site [60]. F-DPD is a 4- fluoro analogue of the 
AI-2 precursor (S)-4,5-Dihydroxypentane-2,3-dione (S)-DPD and has been previously 
shown to inhibit AI-2 based QS systems through such competitive inhibition[192]. Both 
furanone C30 and cinnamaldehyde reportedly inhibit AI-2 QS in Vibrio harveyi by 
decreasing the DNA binding ability of a response regulator LuxR [10]. In addition, the 
natural furanone C30 covalently modifies and inactivates LuxS and accelerates LuxR 
turnover [66]. All test compounds showed QSI activity at concentrations below that 
required for growth inhibition. Our data suggests that furanone C30 displayed the 
highest level of QS inhibitory activity whilst cinnamaldehyde displayed the least. This 
may be due to the multiple proposed mechanisms of QS disruption exhibited by 
furanone C30 leading to a combinatorial effect.  
3.6.2 QSI exposure induces changes in susceptibility in planktonic UPEC Exposure 
to QSI's was performed using a previously validated gradient plating system [193], 
simulating the selective conditions that may be experienced during leaching of an 
antimicrobial coating agent from a catheter surface. Cinnamaldehyde induced a high 
frequency of >2-fold increases in susceptibility at MIC, MBC, and MBEC.  
Cinnamaldehyde has been previously shown to cause oxidative damage to and alter the 
fatty acid composition of the E.coli cell membrane [194]. This compromised the 
structural integrity of the membrane and increased cell permeability [195]. This would 
explain the increased susceptibility seen here as, with the cell wall more permeable, 
more cinnamaldehyde can penetrate the cell wall and cause damage. 
There were increases in susceptibility for all of the UPEC isolates when exposed to 
furanone C30 at MIC and 6 increases observed at MBC. A previous investigation 
assessing the effects of furanone C30 on B. subtilis found that furanone C30 treatment 
increased the permeability of the cell plasma membrane [189], which could 
consequentially result in increased antimicrobial susceptibility, however there is no 
previous report of the response of E. coli to furanone C30 treatment outside of its 
immediate inhibitory influence on QS and biofilm formation [196].  
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F-DPD induced 1 decrease in susceptibility at MBC for EC34. F-DPD has been shown 
to increase mutation rate in E.coli leading to rifampicin resistance [63] by modulating 
LuxS dependant methylases. This same mechanism could lead decreases in 
susceptibility to other antimicrobials so this could explain the decreased susceptibility to 
F-DPD seen here.  
3.6.3 Biofilm-formation and susceptibility in UPEC after QSI exposure QS in E.coli 
is mediated by AI-2 and it has been shown that AI-2 production is directly correlated to 
biofilm production [48].Cinnamaldehyde is widely believed to elucidate its quorum 
sensing inhibition by blocking the binding of LuxR to its transcriptional regulator and 
can reportedly disrupt biofilm-formation by reduced formation/accumulation of EPS 
[70]. There was an increase in biofilm susceptibility for all isolates after 
cinnamaldehyde exposure in the current investigation however this was assoc iated with 
6/8 increases in biofilm formation. Genes for biofilm cell signaling protein (bhsA) have 
been shown to become upregulated in E.coli after sub- lethal exposure to 
cinnamaldehyde [197]. In the same study, long term exposure to cinnamaldehyde 
caused increased expression of type 1 fimbriae which would increase cell adhesion 
[197]. Increases in cell signaling and cell adhesion would increase biofilm formation, 
this could be the explanation for the results seen in this study. 
Furanone C30 also reportedly decreases the DNA binding activity of LuxR [198] and 
was the most potent quorum sensing inhibitor within the V. harveyi reporter system. 
Small magnitude increases in biofilm susceptibility were observed in 6/8 isolates and 
the effect on biofilm formation was variable (one increase and one decrease). E.coli 
biofilm formation has been shown previously to be inhibited by furanone C30 [67, 68] 
partially due to a down regulation in genes associated with chemotaxis, flagella 
synthesis, and motility. These are examples of immediate effects so not necessarily 
indicative of the adaptive responses that have been observed in the work reported in this 
chapter. 
F-DPD is an analogue of AI-2 and inhibits quorum sensing by blocking the AI-2 
receptor [192]. Isobutyl-DPD has been shown to inhibit biofilm-formation in E.coli [65]. 
In this study, exposure to F-DPD did not induce any increase or decrease in biofilm 
susceptibility and only one significant increase in biofilm-formation.  
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3.6.4 Changes in antibiotic susceptibility after QSI exposure in UPEC Cross-
resistance to antibiotics occurred in 9 out of a possible 63 cases. Previous studies have 
shown that exposure to cinnamaldehyde upregulated the expression of several antibiotic 
resistance genes including marRAB and mdtEF  in E.coli [197]. Furanone C30 exposure 
has been shown to reduce expression of AmpC  (beta-lactamase) [199] and caused 
increased antibiotic resistance to 10 antibiotics in P. aeruginosa due to overexpression 
of multidrug efflux pumps [200]. Treatment with F-DPD has been previously shown to 
increase rifampicin resistance in E.coli [63]. Inhibition of the QS pathway by F-DPD 
increased mutation rate plasticity via increased modulation of mutational hotspots by 
Dam methylase (which itself is modulated by LuxS) [63]. There were also 4 cases 
where exposure to the QSI increased the susceptibility of certain isolates (EC2, and 
EC28) to certain antibiotics (trimethoprim and ciprofloxacin). Antibiotic cross 
protection after antimicrobial exposure has been demonstrated previously [193], and is 
likely to be caused due to increased membrane permeability. Exposure to F-DPD 
induced the most increases in antibiotic susceptibility. Other AI-2 analogues have been 
shown to increase bacterial susceptibility to antibiotics when used in combination (e.g 
phenyl-DPD combined with gentamicin was more effective at clearing P.aeruginosa 
biofilms than gentamicin alone [201]). Also, LuxS mutants have been shown to have 
increased susceptibility to antibiotics [202], it was hypothesised that AI-2 QS is 
associated with the ability to cope with environmental stress and so inhibition of this 
communication increased bacterial sensitivity to antibiotics. 
3.6.5 Biocompatibility of test QSIs in an L929 cell line To assess the suitability of an 
antiseptic agent both the antimicrobial activity and cytotoxicity must be considered. F-
DPD was shown to be the most cytotoxic compound followed by cinnamaldehyde and 
furanone C30. Cinnamaldehyde has been shown to upregulate Fas/CD95 expression and 
decrease mitochondrial transmembrane potential (Δψm) [203]. Fas/FasL is an important 
death receptor pathway and induces apoptosis by activation of caspase 8 [204]. The 
activation of subsequent processes by caspase 8 induce apoptosis in cells causing 
nuclear degradation and cellular morphological change [204].The cytotoxic mechanisms 
of furanone compounds have been shown to be the production of reactive oxygen 
species and breakage of DNA, in a study by Murakami et al. (5H)-Furanone 
(structurally similar to furanone C30) did not inhibit aconitase and so was concluded to 
not have superoxide radical generation activity [205]. This would explain why furanone 
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C30 was the least cytotoxic QSI tested. F-DPD was the most cytotoxic QSI tested and 
also had the lowest calculated BI value. To our knowledge, there are no previous studies 
into the cytotoxicity of DPD associated analogues. 
3.6.6 Altered relative pathogenicity in QSI adapted UPEC Many virulence factors, 
such as flagellar motility, surface adhesion and toxin production have been shown to be 
regulated by QS in E.coli [206]. Exposure to cinnamaldehyde induced increased 
pathogenicity in 4 UPEC isolates. Cinnamaldehyde treatment has been also been 
associated with reduced virulence in Vibrio spp towards Artemia franciscana shrimp , 
possibly due to reduced protease expression [70]. Furanone C30 was the only QSI to 
induce only decreases in pathogenicity. Furanone C30 has been shown to repress major 
virulence factors (proteasases (lasA and lasB), chitinase (chiC), and pyocyanine 
synthesis (phzABCDEFG)) in P.aeruginosa [207], 80% of the genes that were 
downregulated by furanone C30 were controlled by QS. Experiments with Vibrio spp. 
show that exposure to furanone C30 decreases the virulence of the bacteria towards A. 
franciscana [208]. This was hypothesised to occur due to reduced virulence factor 
production such as proteases, haemolysin, and siderophores [209]. Increases in relative 
pathogenicity were observed in 2/8 isolates (EC11 and EC26) when exposed to F-DPD. 
DPD has been shown to upregulate QS associated virulence factors lasB encoding 
elastase and xcpP encoding a type II protein secretion apparatus in P. aeruginosa but 
there is no previous investigation in E. coli [210].  
3.6.7 UPEC invasion into human cells after exposure QSIs It was observed that, on 
average, invasion was higher in HUEPC than in SMC. This is likely due to UPEC 
expressing genes that encode P fimbriae/ pyelonephritis associated pili (PAP) [24] and 
type 1 pili which both adhere specifically to uroepithelium [26, 183]. Cinnamaldehyde 
induced increases in HUEPC invasion in 1/8 isolates. In contrast, in previous studies, 
cinnamaldehyde exposure has been associated with reduced virulence in UPEC due to 
decreased expression in cell surface adhesins fimA, fimH, and papG [211] impacting 
adhesion to the cell.  
Furanone C30 induced increased HUEPC invasion in 1/8 isolates. Furanone C30 has 
been shown to repress major virulence factors (proteasases (lasA and lasB), chitinase 
(chiC), and pyocyanine synthesis (phzABCDEFG)) in P.aeruginosa [207]. These 
reductions were proposed to be directly controlled by inhibition of QS. Again this 
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demonstrates that the effects of short term exposure can be very different to those seen 
after long term exposure. F-DPD induced decreases in SMC invasion in 1/8 isolates. As 
far as we are aware, there have been no studies into the effect of F-DPD exposure on 
UPEC virulence.  
3.7.0 Conclusion 
Quorum sensing inhibitors (QSIs) are a novel class of anti-biofilm agents and are being 
increasingly studied to investigate their potential uses in medical device coatings. 
Uropathogenic E.coli is the major causative of CAUTI so it is important to research the 
effects of QSIs on this pathogen to be able to develop a catheter coating. In this study, 
the long term effects of three QSIs were tested on eight strains of UPEC. The changes in 
susceptibility, biofilm-formation, pathogenicity, and virulence were varied between 
each QSI and each UPEC isolate indicating the complex responses to these agents. It is 
therefore very important to continue to research the long term effects of these 
compounds to properly evaluate the suitability of these antimicrobials for use in a 
catheter coating. 
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Chapter 4 
Evaluation of Biocidal Coating Agents in Uropathogenic 
Escherichia coli Urinary Catheter Biofilms 
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4.1.0 Abstract 
Background: Catheter associated urinary tract infections (CAUTIs) are an increasing 
burden on healthcare providers and a substantial risk to the health of the population. As 
antibiotic resistance in uropathogens in on the rise, a new approach is needed to help 
prevent these infections and reduce the need to further antibiotic treatment. One such 
approach is to use antimicrobial impregnated catheters to reduce bacterial contamination 
and subsequent biofilm formation on the catheter surface. Methods: In this study seven 
antimicrobial agents (PHMB, triclosan, benzalkonium chloride (BAC), silver nitrate, 
cinnamaldehyde, furanone C30, and F-DPD) were incorporated into three coating 
agents (sol gel, polyethylene glycol diacrylate (PEG), and 
Poly(hydroxyethymethacrylate) (pHEMA). The biocompatibilities of the coatings were 
determined by comparing antimicrobial activity to cytotoxicity in an L929 murine 
fibroblast cell line. After this initial screen, the sol gel coating was determined to have 
the best biocompatibility. In order to evaluate the sol gel coating combinations further, 
we determined the antimicrobial efficacy of urinary catheter segments coated with sol 
gel against uropathogenic E. coli in a continuous culture drip-flow reactor. In order to 
determine the long-term efficacy of the antimicrobials used within the catheter coating, 
8 strains of uropathogenic E.coli (UPEC) were repeatedly exposed to the antimicrobials 
to simulate long-term adaptation to the coating agent. The subsequent effects of 
antimicrobial exposure on biofilm formation on the catheter surface were evaluated in a 
catheter biofilm model. Biofilm biomass was determined using crystal violet and 
metabolic activity was determined using XTT. Results: In the antimicrobial inhibition 
assay, the coating agent with the highest average antimicrobial efficacy when 
impregnated with the seven antimicrobials, was PEG followed by sol gel and pHEMA, 
whereas cytotoxicity was ordered PEG > sol gel > pHEMA indicating the different 
release strategies of these polymers. Therefore, the coating agent with the highest 
biocompatibility was sol gel followed by PEG and pHEMA. In the drip flow reactor, the 
order of antimicrobial efficacy for the sol gel coated catheter segments was found to be 
PHMB > furanone C30 > silver nitrate > F-DPD > cinnamadlehyde > BAC > triclosan. 
With regard to the effects of long-term exposure to the test compounds, we saw a 
number of isolates that reduced in their ability to form biofilms on the catheter surface, 
however the biofilm that did form was often highly metabolically active as determined 
through the use of XTT. Conclusion: This study highlights the importance of assessing 
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the biocompatibility and antimicrobial efficacy of coating agents in a range of 
experimental systems and investigating the long term effects of the coating agents on 
relevant bacteria. 
4.2.0 Introduction  
Catheter associated urinary tract infections (CAUTIs) account for the highest proportion 
of hospital acquired infections [15] with uropathogenic Escherichia coli (UPEC) 
reportedly responsible for  65% of complicated UTI cases [23]. CAUTIs often show 
recalcitrance to antimicrobial treatment due to the formation of bacterial biofilms within 
the catheter in addition to the increasing prevalence of antibiotic resistance in 
uropathogens [3, 4]. Biofilms are adhered microbial communities encased in a 
protective gel like matrix of extracellular polymeric substance secreted from the 
bacterial cell and are frequently associated with chronic infection that persists despite 
immune response or antibiotic therapy [5]. The catheter provides the surface for the 
initiation of biofilm formation which following maturation may occlude the central 
lumen of the catheter obstructing urine outflow in addition to providing a continuous 
reservoir for infection. 
In order to reduce the incidence of CAUTI approaches for the production of anti-
infective catheter coatings have been developed including (i) surfaces containing 
antimicrobials that may be eluted into the surrounding environment [125] (ii) surfaces 
containing covalently bound antimicrobials [132] and (iii) surfaces coated in an anti-
adhesive material to reduce bacterial attachment [118]. Biocides are often considered as 
anti- infective coating agents due to their broad-spectrum of antimicrobial activity and 
their multiple site-targeted mode of action [105], meaning the risk of selecting resistant 
microorganisms is comparatively low when compared  to antibiotics. Biocide coated 
urinary catheters incorporating biocides such as silver nitrate and nitrofurazone have 
been developed but have shown limited efficacy during clinical trial partly due to their 
short lived antimicrobial activity resulting in low efficacy in patients undergoing long-
term catheterisation [114]. This has fuelled the search for further anti- infective catheter 
coating agents that display broad -spectrum activity which is maintained after prolonged 
use.  
A novel approach in the production of anti- infective catheter coatings is to use quorum 
sensing inhibitors (QSIs). Quorum sensing  (QS) is a extracellular signalling process 
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utilised by bacteria to coordinate their behaviour through cell density dependent gene 
expression [10]. QS involves the production and detection of autoinducer molecules that 
can be divided into Autoinducer-1 (AI-1) and Autoinducer 2 (AI-2). AI-1 type QS 
molecules are acyl homoserine lactones produced by LuxI- like synthases and detected 
by a LuxR transcriptional regulator [43]. In comparison AI-2 are DPD-derived 
molecules dependent on LuxS- like synthases, detected by a LuxPQ receptor and 
regulatory complex [47]. Two quorum sensing systems in E. coli, AI-2/LsrR and 
AHL/SdiA, have been shown to play a role in both biofilm formation and virulence 
factor production [48]. 
'Active' release coatings incorporate antimicrobials that are released over a period of 
time to reduce bacterial attachment to the surface [118]. Compounds that have been 
incorporated into active release coatings include conventional antibiotics [122] in 
addition to broad-spectrum antimicrobials such as silver [121] and nitric oxide [123] as 
well as  antibodies [124]. Antibiotics have been incorporated into a variety of polymers 
including hydroxyapatite [122], polyurathane [126], and biodegradable polymers such 
as polylactide-co-glycolide (PLGA) [127]. Hydrogels are polymer networks with 
hydrophilic structures, meaning they are able to retain large amounts of water [137]. 
The nature of hydrogels being wet and slippery is advantageous for use in a catheter as 
this helps prevent damage to the urethral mucosa when inserted, and removed, in situ 
[134]. The sol gel process involves the formation of an inorganic colloidal suspension 
(sol) and gelation of the sol in a continuous liquid phase (gel) to form a 3D network 
structure [141]. An advantage to the sol gel manufacturing process over other coating 
processes is that it can be conducted at much lower temperatures such as room 
temperature [142], facilitating mass-production. Materials can be designed to elute 
incorporated antimicrobials using either instant or sustained release strategies. Instant 
release will deliver a higher dose of antimicrobial over a short period of time, whereas 
sustained release will deliver lower levels of antimicrobial over longer periods of time 
[118]. Using a sustained release strategy provides advantages with regards to long-term 
antimicrobial activity but concerns have been raised that this strategy increases the 
likelihood of exposing bacteria to sub-lethal concentrations of antimicrobials promoting 
the selection of antimicrobial resistance populations. 
Drip flow biofilm reactors are designed for the study of biofilms grown under low shear 
conditions and are ideal for medical material evaluations and indwelling medical device 
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testing [212]. The drip flow reactor has been used to model environments such as 
catheters, cystic fibrosis lung, and the oral cavity [213]. The reactor consists of 4 
chambers that each have their own influent and effluent ports to allow the continuous 
flow of media through the reactor. The benefit of a drip flow reactor is that the 
experimental conditions can mimic that of clinical infections more closely than standard 
biofilm assays [212].  
The phenotypic adaptations that may occur in a panel of UPEC clinical isolates as a 
consequence of long-term biocide exposure in bacteria have been demonstrated in 
previous chapters [193]. The current investigation aims to determine the efficacy of 
antimicrobial impregnated catheter coating polymers by assessing their antimicrobial 
and cytotoxic effects. The long-term effects of the antimicrobials on both biofilm 
formation and biofilm viability on the catheter surface will be evaluated utilising high-
throughput biofilm formation assays. 
4.3.0 Aims and objectives 
The previous chapters detail the phenotypic changes observed in eight strains of UPEC 
after long term exposure to seven antimicrobials (PHMB, triclosan, BAC, silver nitrate, 
cinnamaldehyde, furanone C30, and F-DPD). These effects are important to consider 
when selecting for potential catheter coating agents. How these changes impact the 
bacteria in a catheter infection must be investigated. It is also important to assess the 
performance of these antimicrobials when incorporated into coatings in conditions that 
are comparable to an in vivo infection.  
The specific aims of this chapter were to: 
 Determine the effects of antimicrobial exposure on UPEC biofilm formation and 
viability grown on urinary catheters using crystal violet and XTT assays. 
 Evaluate antimicrobial efficacy of the seven antimicrobials when incorporated 
into three different coatings (sol gel, PEG, and pHEMA) against UPEC isolate 
EC958. 
 Determine the biocompatibility of these coatings against an L929 cell line. 
 Select the most promising coating and evaluate the anti-biofilm capabilities 
using the drip flow biofilm reactor. 
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4.4.0 Methods 
4.4.1 Bacteria and antimicrobials Six UPEC clinical isolates (EC1, EC2, EC11, EC26, 
EC28 and EC34) previously isolated from urinary tract infections (Stepping Hill 
Hospital, UK) and two laboratory characterised  UPEC isolates (EC958 and CFT073) 
were used in the investigation. Bacteria were cultured onto Muller-Hinton agar (MHA; 
Oxoid, UK) or Muller-Hinton broth (MHB; Oxoid, UK) and incubated aerobically at 
37 °C for 18 h unless otherwise stated.  Antimicrobials were formulated as follows: 
triclosan and furanone C30 solubilised in 5% (v/v) ethanol. Polyhexamethylene 
biguanide (PHMB) (LONZA, Blackley, UK), benzalkonium chloride (BAC), silver 
nitrate, cinnamaldehyde, and F-DPD were prepared at 1 mg/ml in water and filter 
sterilised prior to use. Furanone C30 and F-DPD were synthesised in-house. All 
chemicals were purchased from Sigma–Aldrich (Poole, UK) unless otherwise stated. 
4.4.2 Long-term exposure of bacteria to biocides and quorum sensing inhibitors  
Bacteria were repeatedly exposed to antimicrobials using a gradient plating system 
adapted from Moore et al [152].  In brief, 100 µl of a 5 × MBC concentration solution 
of antimicrobial was added to an 8 x 8 mm well in the centre of a 90 mm agar plate. 
Bacterial pure cultures were radially inoculated in duplicate from the edge of the plate 
to the centre, prior to incubation for 2 days aerobically at 37°C. Biomass from the inner 
edge of the annulus of bacterial growth representative of the highest antimicrobial 
concentration at which growth could occur was removed and used to inoculate a new 
antimicrobial containing plate, as outlined above. This process was repeated for 12 
passages. Bacteria were archived at -80 °C before and after antimicrobial passage for 
subsequent testing. 
4.4.3 Catheter biofilm model Method adapted from Nweze et al [214]. 1cm catheter 
sections were cut with a hot scalpel lengthways and autoclaved. Overnight cultures of 
bacteria were made in MHB. In a 12 well plate, sections were pre-coated with 4ml FBS 
for 24 h at 37ºC and 30 rpm (3 sections per well). Bacteria were washed twice with PBS 
and resuspended in 5 ml PBS at OD600 0.18 (10
7 cells/ml). FBS was removed from 
sections and 4 ml bacterial suspension was added. These were incubated for 90 min at 
37ºC (Adhesion phase). Sections were removed with a sterile forceps and placed in a 12 
well plate containing MHB. Plates were incubated for 48 h at 37ºC and 30 rpm (Biofilm 
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formation phase) the sections were moved to new plates containing s terile MHB after 
the first 24 h.  
4.4.3.1 XTT A working solution containing XTT and menadione was prepared by 
adding 1200 µL of XTT from 1 mg/mL XTT stock and 88 µL of menadione from 1 mM 
menadione stock solution to 88 mL of PBS and mixing gently. MHB was carefully 
removed by aspiration from each well of the plate containing discs with formed biofilms 
and replaced with 3mL of the XTT/menadione mixture. The microtitre plates were 
covered with aluminium foil and incubated for 90mins at 37ºC. Blank wells containing 
3mL of the XTT/menadione mixture with sections and no biofilm were prepared, 
covered with aluminium foil and incubated with the biofilm plate. Next, the catheter 
sections were carefully removed and the optical density (OD) read at 490 nm using a 
Microplate Reader. 
4.4.3.2 Crystal violet Catheter sections that had grown biofilm were added to a 12 well 
plate. Then 3ml of crystal violet solution was added and left the plate at room 
temperature for 30 minutes. The crystal violet solution was carefully removed and 
replaced with 4ml of PBS. This rinse step was repeated three times with PBS. Plates 
were left to dry for 1h in a 37ºC incubator. The remaining crystal violet was solubilised 
in 4ml of 100 % ethanol and the catheter section was removed. The A600 of the 
solubilised crystal violet solution was measured using a microplate reader. 
4.4.4 Evaluation of biocompatibility of catheter coatings Three polymer coatings 
were assessed: Polyethylene glycol diacrylate (PEG), Poly(hydroxyethymethacrylate) 
(pHEMA), and sol gel. The polymers were prepared as follows: 
PEG was prepared using 6.57 ml PBS, 1.43 ml Polyethylene glycol and 48 μl 2-
hydroxy-2-methyl-propiophenone (Darocur 1173). The reagents were combined in a 96 
well plate with 6mm glass coverslips placed on the bottom of the wells. The plate was 
placed under a UV lamp for 90 seconds to induce polymerisation and the discs were 
stored for later use.  
pHEMA gels containing 2% methacrylic acid were prepared using 9.78 ml 2-
hydroxyethymethacrylate (HEMA), 19 μl ethylene glycol dimethacrylate (EGDMA), 50 
μl Daracur 1173 and 0.2 ml methacrylic acid. The mixture was aliquoted into the wells 
of a 96-well microtiter plate with 6mm glass coverslips placed on the bottom of the 
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wells. Polymerisation was carried out under a UV lamp for 30 seconds. Discs were 
submerged in 70% ethanol for 48 h followed by 30% ethanol for 48 h. Gels were 
continuously washed in water for 24 h until transparent, and stored in water for later use.  
Sol gel was prepared by first mixing 0.5 ml tetraethylorthosilicate, 1ml 
tetramethylorthosilicate, 2.18 ml Isopropanol (anhydrous) for 5 mins. Added to this 
mixture was 1ml trimethoxymethysilane slowly (5 x 200 µl). In a separate universal, 
2.18 ml Isopropanol was added to 2.5 ml 0.07M Nitric acid. 2.35 ml of the acid/solvent 
mixture was added dropwise (approx 1 drop per second). 0.2 ml polydimethylsiloxane 
(mwt 162) was slowly (4 x 50 µl) added as was the remaining acid/solvent mix 
dropwise (approx 1 drop/sec). This was left stirring for 5 - 10 mins then a further 2.4 ml 
of Nitric acid was added dropwise (approx 1 drop/sec). Sol gel was aliquoted onto 6mm 
circular coverslips, left to dry, and stored in the fridge until needed. 
4.4.4.1 Disc diffusion Overnight cultures of EC958 were diluted to OD600 0.008 and 
were used to inoculate MHA plates. Polymer discs (as prepared above) containing 
concentrations of 10, 50, 100, 250 X MBC (determined previously) of antimicrobials 
were placed onto the inoculated plates and incubated at 37ºC for 24 h. Zones of 
inhibition were measured in mm. Untreated discs acted as negative controls. 
4.4.4.2 Agar overlay To determine the direct cytotoxicity of antimicrobial impregnated 
polymers we performed an agar overlay assay using an L929 cell line according to ISO 
standards [215]. In brief, 2.4 x 106 cells in 10 ml of EMEM were seeded into 60 mm 
diameter cell culture plates. Cells were incubated for 48 h at 37ºC and 5% CO2 to form 
a monolayer on the base of the dish. After incubation media was removed by aspiration 
and cells were washed twice in 10 ml of PBS. 10 ml of EMEM containing 1% agar was 
added to each dish and was allowed to solidify at room temperature. 
After the agar set, 10 ml of a 0.1% neutral red solution was added to the centre of each 
plate, which was then rotated to evenly distribute the dye, left for 15 min, and excess 
solution was removed by aspiration. Three polymer discs were placed in an individual 
cell culture dish. Plates were incubated for 24 h at 37°C and 5% CO2 before being 
checked for cell lysis. Disc toxicity was characterised by a white colourless zone of 
dead cells around the implanted region. The diameter of the lysis zone was measured in 
mm. Untreated discs acted as negative controls. 
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4.4.5 Drip Flow Biofilm Reactor Sol gel was the best performing coating so the 
efficacy of this coating was evaluated in the drip flow biofilm reactor (BioSurface 
technologies). To mimic an in vivo catheter infection, artificial urine was pumped 
through the reactor, each chamber containing catheter pieces coated with sol gel, sol gel 
containing 1.25 mg/ml antimicrobials, and uncoated catheter controls. The protocol, in 
brief, consists of reactor assembly and sterilisation by autoclaving at 121ºC for 20 
minutes. Artificial urine was prepared as described by Brooks and Keevil [216], briefly 
this is formulated as 1 g/L peptone L37, 0.005 g/L yeast extract, 0.1 g/L lactic acid, 0.4 
g/L citric acid, 2.1 g/L sodium bicarbonate, 10 g/L urea, 0.07 g/L uric acid, 0.8 g/L 
creatinine, 0.37 g/L calcium chloride 2H2O, 5.2 g/L sodium chloride, 0.0012 g/L iron II 
sulphate 7H2O, 0.49 g/L magnesium sulphate 7H2O, 3.2 g/L sodium sulphate 10H2O, 
0.95 g/L potassium dihydrogen phosphate, 1.2 g/L di-potassium hydrogen phosphate, 
1.3 g/L ammonium chloride. Catheter sections are placed within the reactor and 
inoculated with 25 ml of bacterial culture (EC958) at OD600 0.008. The reactor was 
incubated flat (batch phase) for 6 h at 37ºC. Then the reactor was angled 10º and sterile 
one inch 23 gauge needles were inserted into the injection port valve at the top of each 
chamber. The pump was turned on (continuous phase) and artificial urine was pumped 
into the chambers at 0.83 ml/min for 48 h at 37ºC. After continuous phase the catheter 
sections were removed with sterile forceps, rinsed and placed in sterile water and 
vortexed for 30 seconds. Biofilms were serially diluted and plated onto MHA plates in 
triplicate, plates were incubated for 24 h at 37ºC and cfu/ml were determined. 
4.5.0 Results 
4.5.1 Biofilm attachment to catheter service before and after exposure  Biofilm 
formation was determined via a crystal violet biofilm assay for each UPEC isolate 
before and after repeated exposure (Figure 4.1). Unexposed isolates displayed varying 
biofilm forming capabilities prior to exposure with EC1 showing the highest level of 
biofilm formation followed by EC26 > EC11 > CFT073 > EC958 > EC2 > EC34 and 
EC28. When repeatedly exposed to PHMB, 4/8 isolates (EC11, EC28, EC34, and 
EC958) demonstrated a significant (ANOVA p ≤ 0.05) decrease in biofilm formation 
when compared with the respective control (C12). Triclosan exposure induced 
significant decreases in biofilm formation for 3/8 isolates, EC11, EC34, and EC958. 
When exposed to BAC, 3/8 isolates showed a significant decrease in biofilm formation 
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(EC11, EC28, EC34) the same results were seen in these isolates when exposed to silver 
nitrate.  When exposed to cinnamaldehyde, EC11 and EC34 showed a significant 
decrease in biofilm formation. The isolates EC28, EC34, and EC958 showed a 
significantly decreased biofilm formation when exposed to furanone C30. When 
exposed to F-DPD, 3/8 isolates (EC11, EC34, EC958) demonstrated a decreased 
biofilm formation. Triclosan was the only compound to induce a significantly increased 
biofilm formation in 1/8 isolates (EC26). 
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Figure 4.1 Crystal violet biofilm assay indicating the effect of previous biocide and QSI 
exposure on biofilm formation in eight isolates of UPEC. Data shows the mean 
absorbance (A600) representative of biofilm formation for individual bacteria before and 
after long-term exposure to PHMB, triclosan, BAC, silver nitrate, cinnamaldehyde, 
furanone, and F-DPD. Data represent samples taken from experiments each with three 
technical replicates. For data that varied between replicates, SDs are given as error bars. 
Significance was determined using ANOVA; * p≤0.05 relative to the respective control.  
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4.5.2 Biofilm viability after repeated exposure to test compounds Biofilm viability 
on the catheter surface was determined for all isolates before and after repeated 
antimicrobial exposure by XTT assay. Before exposure, EC1 was shown to form the 
highest viability biofilm with the remaining isolates ranking as: EC28 > EC2 > EC26 > 
EC11 > EC958 > EC34 > CFT073 (Figure 4.2). PHMB exposure induced significant 
increases in biofilm viability in 4/8 isolates (EC2, EC11, EC958 and CFT073). 
Triclosan exposure induced significantly increased biofilm viability in 4/8 isolates 
(EC11, EC26, EC28 and EC958). Silver nitrate was induced significantly increased 
biofilm viability in EC26. There were no significant changes in biofilm viability after 
exposure to BAC, cinnamaldehyde, furanone or F-DPD.  
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Figure 4.2 XTT biofilm assay indicating the effect of previous biocide and QSI 
exposure on biofilm viability in eight isolates of UPEC. Data shows the mean 
absorbance (A490) representative of biofilm viability for individual bacteria before and 
after long-term exposure to PHMB, triclosan, BAC, silver nitrate, cinnamaldehyde, 
furanone, and F-DPD. Data represent samples taken from experiments with three 
technical replicates. For data that varied between replicates, SDs are given as error bars. 
Significance was determined using ANOVA; * p≤0.05 relative to the respective control. 
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4.5.3 Disc Diffusion Polymer discs were formulated containing antimicrobial agents at 
concentrations of 10, 50, 100, and 250 X the MBC. F-DPD could only be formulated at 
10 X MBC due to limited availability of the compound. Polymer discs were assessed for 
their antibacterial efficacy against EC958 in disc diffusion experiments. Figure 4.3 
shows the mean zones of inhibition (Sol gel, PEG, and pHEMA) for each of the 7 
antimicrobials at increasing concentrations.  
For PHMB, incorporation into sol gel resulted in a significantly (One Way ANOVA 
p<0.05) higher level of antimicrobial activity than when incorporated into PEG or 
pHEMA at 100 X MBC and pHEMA at 250 X MBC. In contrast, PHMB impregnated 
PEG was more antimicrobial than PHMB impregnated sol gel and pHEMA at 50 and 10 
X MBC. PHMB impregnated PEG showed significantly higher antimicrobial activity 
than PHMB impregnated pHEMA at 250 and 100 X MBC.   
For triclosan, incorporation into sol gel was significantly more potent than PEG at 100 
X MBC and significantly more potent than pHEMA at 10 X MBC.  
For BAC, incorporation into PEG resulted in significantly higher antimicrobial activity 
than incorporation into pHEMA at 250 X MBC. 
For silver nitrate, incorporation into sol gel resulted in significantly higher microbial 
inhibition than pHEMA at 250, 100, and 50 X MBC. PEG was significantly more potent 
than pHEMA at 250 and 100 X MBC. 
For cinnamaldehyde, incorporation into sol gel exhibited significantly higher 
antimicrobial activity than PEG at 250 X MBC and pHEMA at 250, 100 and 50 X MBC. 
PEG was also significantly more potent than pHEMA at 250, 100 and 50 X MBC. For 
Furanone C30, incorporation into sol gel showed significantly higher levels of 
inhibition than pHEMA at 250 X MBC. The only coating to show any antimicrobial 
activity after F-DPD incorporation was PEG (at 10 X MBC). 
  
 114 
 
Figure 4.3 Disc diffusion assay for three polymer coatings containing seven 
antimicrobials at increasing concentrations. Antibacterial zone was measured in mm for 
each disc (n=3).  
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4.5.4 Agar overlay Polymer discs containing antimicrobial agents at concentrations of 
10, 50, 100, and 250 X the MBC as determined previously were assessed for their 
cytotoxicity against L929 cells in agar overlay experiments. Figure 4.4 shows the mean 
zone of inhibition of the polymer disc (Sol gel, PEG, and pHEMA) for each of the 7 
antimicrobials at increasing concentrations. 
For PHMB, incorporation into pHEMA was significantly more cytotoxic than sol gel 
and PEG at 50 X MBC. For triclosan, PEG was significantly more cytotoxic than sol gel 
at 250, 100, and 50 X MBC. pHEMA was significantly more cytotoxic than sol gel at 
250 and 50 X MBC. 
For BAC, incorporation into PEG was significantly more cytotoxic than sol gel at 100, 
50 and 10 X MBC. pHEMA was more cytotoxic than sol gel at 100 X MBC. There was 
no statistical significance between the polymer coatings for silver nitrate cytotoxicity. 
For cinnamaldehyde, sol gel was significantly more cytotoxic than PEG at 10 X MBC. 
For furanone C30, both PEG and pHEMA were significantly more cytotoxic than sol 
gel at 250, 100, 50 and 10 X MBC. For F-DPD, PEG was significantly more cytotoxic 
than pHEMA (at 10 X MBC). 
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Figure 4.4 Agar overlay assay for three polymer coatings containing seven 
antimicrobials at increasing concentrations. Cytotoxic zone was measured in mm for 
each disc (n=3). 
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4.5.5 Biocompatibility The biocompatibility of the antimicrobials were calculated by 
dividing the mean antimicrobial diffusion zone by the mean cytotoxicity diffusion zone. 
A biocompatibility value of over 1 signifies higher levels of antibacterial action than 
cytotoxicity (Table 4.1).  
For PHMB, the order of biocompatibility at both 250 and 100 X MBC was sol gel > 
PEG > pHEMA, whilst at 50 and 10 X MBC it was PEG > sol gel = pHEMA. For 
triclosan, the order of biocompatibility at 250 X MBC was sol gel > pHEMA > PEG. At 
100 X MBC it was sol gel > PEG = pHEMA, at 50 X MBC it was sol gel > pHEMA > 
PEG, and at 10 X MBC it was sol gel > PEG > pHEMA. 
For BAC, the order of biocompatibility at 250 X MBC was PEG > pHEMA > sol gel. 
At 100 X MBC it was PEG > sol gel = pHEMA, at 50 X MBC it was PEG > sol gel = 
pHEMA, and at 10 X MBC it was sol gel = PEG = pHEMA. For silver nitrate, the order 
of biocompatibility at 250 X MBC was sol gel > PEG > pHEMA. At 100 X MBC was 
sol gel > PEG > pHEMA, at 50 X MBC was sol gel > PEG > pHEMA, and at 10 X 
MBC was sol gel > PEG > pHEMA. 
For cinnamaldehyde, the order of biocompatibility at 250 X MBC was sol gel > PEG > 
pHEMA. At 100 X MBC was sol gel > PEG > pHEMA, at 50 X MBC was sol gel > 
PEG > pHEMA, and at 10 X MBC was PEG > sol gel > pHEMA. 
For furanone C30, the order of biocompatibility at 250 X MBC was sol gel > PEG > 
pHEMA. At 100 X MBC was sol gel > PEG > pHEMA, at 50 X MBC was sol gel > 
PEG > pHEMA, and at 10 X MBC was sol gel > PEG > pHEMA. For F-DPD, the order 
of biocompatibility (at 10 X MBC) was PEG > sol gel = pHEMA.
  
 
1
1
8
 
Table 4.1 Biocompatibility of seven antimicrobials at increasing concentrations for three coating agents. Biocompatibility was calculated by dividing 
the mean antimicrobial diffusion zone by the mean cytotoxicity diffusion zone (mean of n = 3 experiments). A value of 0 indicates no antimicrobial 
activity.
 
Coating 
 
Sol gel 
 
 
PEG 
 
 
pHEMA 
Concentration (X MBC) 10 50 100 250 10 50 100 250 10 50 100 250 
 
PHMB 
 
 
0 
 
0 
 
0.85 
 
0.91 
 
0.66 
 
0.81 
 
0.76 
 
0.65 
 
0 
 
0 
 
0 
 
0 
 
Triclosan 
 
 
2.04 
 
2.83 
 
3.49 
 
3.01 
 
1.94 
 
1.57 
 
1.75 
 
1.85 
 
1.13 
 
1.78 
 
1.75 
 
2.03 
 
BAC 
 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0.51 
 
0.64 
 
0.94 
 
0 
 
0 
 
0 
 
0.15 
 
Silver Nitrate 
 
 
0.7 
 
1.04 
 
1.18 
 
1.06 
 
0.32 
 
0.66 
 
0.74 
 
0.77 
 
0 
 
0 
 
0 
 
0.33 
 
Cinnamaldehyde 
 
 
0.41 
 
0.81 
 
0.83 
 
1.41 
 
0.9 
 
0.78 
 
0.81 
 
0.77 
 
0 
 
0 
 
0 
 
0 
 
Furanone  C30 
 
 
0 
 
2 
 
7.6 
 
12.3 
 
0 
 
0 
 
0.82 
 
0.74 
 
0 
 
0 
 
0 
 
0 
 
F-DPD 
 
 
0 
 
- 
 
- 
 
- 
 
0.69 
 
- 
 
- 
 
- 
 
0 
 
- 
 
- 
 
- 
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4.5.6 Biofilm formation in Drip Flow Biofilm Reactor Colony forming units (cfu) 
/ml were determined after growth on coated catheter pieces in the presence of a 
steady flow of artificial urine. The mean cfu/ml of biofilm formed on uncoated 
catheters was 2.77x10⁷ (Figure 4.5). There was a small but significant (One way 
ANOVA p < 0.005) reduction to 1.29x10⁷ cfu/ml when non antimicrobial containing 
sol gel was added to the catheter sections. All antimicrobial incorporated coatings 
induced significant (p < 0.0001) reductions in biofilm formation. The largest 
reduction occurred for PHMB which completely eradicated biofilm growth. The 
second most potent antimicrobial was furanone C30 which reduced biofilm growth 
to an average of 1.33x10² cfu/ml. Silver nitrate reduced the biofilm growth to an 
average of 3.33x10² cfu/ml. F-DPD incorporated sol gel gave a reduction to 
9.56x10⁴ cfu/ml. When cinnamaldehyde was added to the sol gel coating the biofilm 
formation was reduced to 2.4x10⁵ cfu/ml and BAC incorporation reduced biofilm 
growth to 1.13x10⁶ cfu/ml. Triclosan incorporation was the least potent 
antimicrobial which reduced cfu/ml to 1.64x10⁶.  
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Figure 4.5 Biofilms of EC958 were grown on urinary catheter pieces coated in sol 
gel containing seven antimicrobials. Controls coated in sol gel only and uncoated 
catheters were also used. Colony forming units (cfu/ml) were evaluated after 48 
hours and mean cfu/ml was calculated (n=3). Statistical analysis by One Way 
ANOVA: ** p < 0.005 and **** p < 0.0001.  
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4.6.0 Discussion 
CAUTIs are becoming an increasing concern due to the aging population and the rise 
of antibiotic resistant uropathogens which has resulted in these infections becoming 
more difficult to treat [217]. Preventing these infections with the use of catheters 
coated with anti- infective agents is one area of research that has produced seemingly 
positive results in vitro [218] but has not been as successful in practice [114, 117]. It 
is clear that a more thorough screening of anti- infective agents needs to be employed 
when attempting to select for a novel coating for catheters to make sure that the 
components chosen will display long lasting efficacy. Three coating agents were 
screened in this study. PEG is a hydrogel based polymer that has been shown to elute 
antimicrobials in a sustained release profile [219]. pHEMA is also a hydrogel which, 
although has been used in controlled release of antimicrobials, exhibits an instant 
'burst' release strategy when initially hydrated [220]. Sol gel coatings can vary in 
their properties depending on their preparation [221], the preparation used in this 
study has been shown to have a sustained release profile [222]. In this investigation 
we have exposed UPEC isolates to four biocides and three QSI's with the aim to 
assess which of these compounds would prove suitable as a catheter coating agent 
through the use of a series of high through put assays and a continuous culture 
catheter biofilm model. 
4.6.1 Formation of bacterial biofilms grown on urinary catheters after long-
term antimicrobial adaptation There was no significant effect on biofilm 
formation for the isolates EC1, EC2, CFT073 after exposure to any compound. In 
contrast, PHMB exposure decreased biofilm formation in 4/8 isolates (EC11, EC28, 
EC34, and EC958). Long term exposure to PHMB has been shown to reduce biofilm 
formation in UPEC previously [193]. It has been suggested that PHMB exposure 
induced downregulation of genes associated with flagella which are essential for 
initiation of biofilm formation [95]. If the PHMB exposed isolates have 
downregulated flagella this may impair the ability of those isolates to form biofilms, 
which may explain the reduction in overall biofilm found in the PHMB exposed  
isolates in the current investigation. 
Triclosan exposure decreased biofilm formation in 3/8 (EC11, EC34, and EC958) 
isolates and increased biofilm formation in EC26. Sublethal exposure to triclosan has 
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been shown to impair biofilm formation in S. aureus, possibly due to repression of 
the extracellular matrix component PIA [104], a similar mechanism may occur in 
E.coli. Contrastingly, triclosan was also the only antimicrobial to induce any increase 
in biofilm formation after exposure. Studies on the effect of sub-lethal concentrations 
of triclosan on S. mutans biofilm formation showed that biofilm formation was 
increased by the upregulation of biofilm formation genes such as gtfB, gtfC, and luxS 
[223]. If a similar mechanism occurs in E. coli this could explain the increase in 
biofilm formation seen here. This demonstrates a strain specific response in the 
presence of triclosan. 
When repeatedly exposed to BAC, 3/8 isolates (EC11, EC28, and EC34) 
demonstrated a significant decrease in biofilm formation. One possible explanation 
for a decrease in biofilm formation is a decrease in motility, as flagellar and 
chemotaxis proteins have been associated with biofilm initiation (attachment) [224]. 
Exposure to BAC has previously lead to a decrease in motility of E.coli [184], which 
RNA-sequencing revealed was due to a decrease in the expression of genes 
associated with flagella synthesis. A reduction in motility associated genes may 
explain the decreased biofilm formation in our BAC exposed isolates.  
Silver Nitrate exposure decreased biofilm formation in 3/8 isolates (EC11, EC28, 
and EC34). It has been shown that bacteria that have been exposed to silver have 
downregulated adhesion factors and chemotaxis genes [225], further suggesting a 
possible mechanism for biofilm reduction. 
Biofilm formation in EC11 and EC34 decreased when exposed to cinnamaldehyde. 
A study by Yuan et al [226] showed that exposure to cinnamaldehyde caused an 
upregulation in genes associated with metabolism but virulence genes associated 
with biofilm formation were repressed in E.coli. This could explain the decrease in 
biofilm formation after exposure to cinnamaldehyde.  When exposed to furanone C30, 
EC28, EC34, and EC958 showed a significant decrease in biofilm formation. Genes 
for chemotaxis, flagella, and motility have been shown to be repressed by furanone  
C30 [69]. These genes are important for the initiation of biofilm formation [224]. If 
this has occurred in the furanone C30 exposed isolates then this could explain the 
decrease in biofilm formation seen here. 
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Exposure to DPD induced decreased biofilm formation in 3/8 isolates (EC11, EC34, 
and EC958). F-DPD is an AI-2 analogue and therefore inhibits quorum sensing by 
binding to the AI-2 receptor [64] and has been shown to inhibit biofilm formation in 
E.coli [65]. As far as we are aware there is no previous data on the effects of E.coli 
biofilm formation after adaptation to F-DPD. 
Although these responses are not measuring the direct effect of the QSI on biofilm 
formation, undergoing long-term QS inhibition may have resulted in selecting for 
isolates with alterations in normal AI-2 based signalling, which are known to play a 
role in biofilm establishment [227]. 
4.6.2 Viability of bacterial biofilms grown on urinary catheters XTT assays were 
used to evaluate the viability of the UPEC biofilms grown in the catheter model. 
XTT is a redox dye that works by colour change due to the metabolisation of XTT to 
formazan in the presence of metabolic activity (mainly mitochondrial succinoxidase, 
cytochrome P450 systems, and flavoprotein oxidases) [228].  Exposure to PHMB 
caused increased biofilm viability in 4/8 isolates. A study by Allen et al examined 
the effects of PHMB exposure on E.coli and found upregulation of genes associated 
with energy and amino acid metabolism [95] if this has occurred in the PHMB 
exposed isolates this could explain the increase in viability seen in this study. 
Triclosan exposure induced significantly increased biofilm viability in isolates EC11, 
EC26, EC28 and EC958. Triclosan has been shown to be effective at controlling 
E.coli infection in catheter models previously [229, 230]. E.coli that are tolerant to 
triclosan have been shown to have upregulated fatty acid, glyoxylate, dicarboxylate, 
and butanoate metabolism compared to the wild type [231]. This adaptive response 
likely occurs in an attempt to subvert the inhibitory effects of triclosan on fatty acid 
synthesis. If this has occurred in the triclosan exposed isolates, this upregulation in 
metabolism could increase the conversion of XTT to formazan and therefore show 
increased viability results for these isolates.  
BAC exposure did not induce any changes in biofilm viability. In previous studies 
XTT assays were unaffected by previous BAC exposure in E.coli biofilms [166] 
which corroborates this study. Silver Nitrate induced one significant increase in 
biofilm viability (EC26). Silver has been shown to act on enzyme activity as one of 
the mechanisms of bactericide [232]. To adapt to the presence of silver, the bacteria 
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would have to overcome this enzyme inhibition, perhaps by attempting to increase 
enzymic activity. An increase in enzyme activity, especially respiratory enzymes, 
would cause increased metabolism of XTT to formazan which would lead to 
increased viability results seen here.  
4.6.3 Biocompatibility of polymer coatings Out of the three coating agents tested, 
sol gel was calculated to have the highest biocompatibility values overall. Sol gel 
coatings are generally considered to have high biocompatibility [233] and are the 
subject of increasing interest in use for medical device coatings. For the most part, 
all polymer coatings were measured to have a similar level of cytotoxicity but the 
calculated BI score was mainly influenced by the variable antimicrobial activity of 
the coatings. pHEMA gels were observed to have the lowest antimicrobial activity 
for the majority of the antimicrobials tested and therefore lowest biocompatibility. 
Drug elution by pHEMA has been previously studied and it was found that 
unmodified pHEMA has poor capacity for drug loading and delivery [234].  
As mentioned earlier, pHEMA hydrogels initially elute the majority of incorporated 
antimicrobial when first hydrated. Due to the method of synthesising pHEMA gels, 
the discs were washed in water for 24 hours before being used in experiments. It 
could be that the antimicrobials incorporated into these discs were partially eluted 
out during the washing process. This highlights the variability of pHEMA as a 
catheter coating agent. PEG and sol gel coatings both have a sustained release profile, 
sustained release is associated with higher biocompatibility [235] as the 
antimicrobial dose can be lower to avoid cytotoxicity and longer elution periods are 
beneficial if the medical device is in situ for a longer period of time [236].  The 
biocompatibility of furanone C30 when incorporated into sol gel were the highest 
values seen in this study, mainly due to the fact that there was no zone of 
cytotoxicity recorded for this coating combination. 5H-furanones have been shown 
to be less cytotoxic than other furanone derivatives possibly due to their inability to 
reduce transition metals and so cannot produce reactive oxygen species [205].  
4.6.4 Evaluation using Drip Flow Biofilm Reactor Within the continuous culture 
system, the order of antimicrobial efficacy in terms of reduction in biofilm growth 
was found to be PHMB > furanone C30 > silver nitrate > F-DPD > cinnamadlehyde 
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> BAC > triclosan. The sol gel coating itself was also found to be mildly effective at 
reducing biofilm growth.  
For the previous diffusion experiments triclosan performed the best out of the seven 
antimicrobials tested when incorporated into sol gel. However it performed the worst 
for the drip flow biofilm reactor, which was surprising considering the high 
concentration of triclosan in the biofilm reactor. Triclosan is a potent antimicrobial 
[193] but it is also a small, hydrophilic molecule which means that it can easily elute 
out of polymer gels [237]. It could be hypothesised that either all the triclosan eluted 
out of the sol gel in a short period of time and was washed away, allowing any 
residual bacteria to repopulate or that the bacteria quickly developed  resistance to the 
triclosan coating.  Triclosan is well documented to induce resistance in both 
planktonic and biofilm growth [193]. It could also be that triclosan is less effective 
against biofilms compared with planktonically growing cells, however triclosan has 
been shown to be effective against E.coli biofilms [230] so it is more likely that the 
results observed in the current investigation are due to rapid elution of triclosan from 
the coating or due to the selection of resistant bacterial populations, potentially 
having acquired mutations in the well document triclosan target enzyme FabI [80]. 
Conversely, BAC performed better in the flow reactor experiments than the disc 
diffusion (50, 100, and 250 X MBC are higher concentrations than 1.25mg/ml for 
BAC). BAC is a very large molecule and has both hydrophilic and hydrophobic 
regions [238] so it is less likely to be able to elute out of coatings easily when under 
static conditions such as found in the disc diffusion assay (which would explain the 
low biocompatibility values for BAC). It is possible that under continuous flow and 
increased polymer hydration that BAC was able to release more readily from the 
impregnated sol gel. It is also important to note, that the biocompatibility assays 
were only conducted over a period of 24 hours. Quaternary ammonium salts (which 
are similar to BAC) have been incorporated onto catheter coatings and were shown 
to have activity over longer periods of time [239] so it could be that BAC simply 
takes longer than 24 hours to elute out and therefore would show less activity in the 
inhibition assay experiments.  
Cinnamaldehyde and F-DPD are both QSIs so it is likely that they were able to 
prevent biofilm formation on the coated catheters. We have previously tested the 
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potency of these QSIs in terms of antimicrobial and anti-biofilm activity and how 
they perform at disrupting AI-2 based signalling. These compounds possessed 
similar anti-biofilm activity in the drip flow reactor, however cinnamaldehyde was 
the least potent QSI overall. It may be that the QSIs performance as catheter coatings 
in this model is directly proportionate to their quorum sensing inhibitory activity. 
The National Institute of Health and Care Excellence (NICE) recommends that cfu 
counts of > 10³ of E.coli should be used to diagnose CAUTI in adults [19]. Sol gel 
coatings containing silver nitrate, furanone C30, and PHMB were able to reduce the 
cfu/ml to beneath this guideline.  Silver nitrate was one of the best performing 
antimicrobials in the flow reactor system, however, in clinical practice silver coated 
catheters have been shown to not be any more effective than uncoated catheters 
[114]. It is our hypothesis that silver works for a short term in vitro however in vivo 
bacteria develop resistance to the coating [103], it is possible that the silver elutes 
out of the coating over a short period of time so is not suitable for long term 
catheterisation.  It is also possible that sol gel is a more appropriate delivery system 
for silver than current coatings, hence the improved efficacy of the sol gel coating. 
More investigation would be needed before drawing these conclusions. 
Furanone C30 was the best performing QSI and is also the most potent QSI with 
regards to dirupting AI-2 basted signalling (Chapter 3). Furanone C30 has been 
shown to be an effective antimicrobial when incorporated into coatings [240] and the 
results seen in this study corroborates that. 
Sol gel containing PHMB was the best performing coating as it completely 
eradicated all biofilm in the flow reactor model. A study showed PEG co ntaining 
PHMB coatings were also particularly effective at reduce biofilm formation [241]. 
PHMB did not exhibit high antimicrobial activity in the disc diffusion assays, 
however this shows the importance of evaluation using a model that more 
realistically mimics in-use conditions. 
4.7.0 Conclusion  
When evaluating antimicrobials to be used in medical device coatings it is important 
to not only assess the antimicrobial efficacy and biocompatibility of the coating but 
also the long term effects of exposure to the coating agent on the bacteria it will 
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encounter. In this study, PHMB was found to perform the best in an in vitro catheter 
biofilm model and induced the most decreases in biofilm formation after long term 
biocide exposure. However it was also observed that PHMB induced increases in 
biofilm viability and had generally low biocompatibility. When considering all 
experiments, furanone C30 was the best performing QSI, induced decreased biofilm 
formation in 3/8 isolates and had the highest biocompatibility values for sol gel. 
Further investigation is warranted to further evaluate the potential of these coatings.  
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Chapter 5 
Genomic and transcriptomic analysis of antimicrobial exposed 
uropathogenic Escherichia coli EC958 
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5.1.0 Abstract 
Background: Catheter associated urinary tract infections (CAUTIs) are a major 
burden on healthcare providers and can lead to fatal complications such as 
pyelonephritis and bacteremia. The major causative agent of CAUTI is 
uropathogenic E.coli (UPEC) which forms biofilms on the catheter surface making 
the infection difficult to treat. Anti- infective coatings have been developed and are in 
clinical use however they demonstrate limited efficacy at preventing CAUTI during 
long term catheterisation due to the emergence of insusceptible bacterial populations. 
The genomic and transcriptomic changes that occur as a consequence of long term 
exposure to a panel of antimicrobials were characterised in UPEC strain EC958, a 
well characterised ESBL producing strain of the ST131 subgroup. Methods: 
Genome sequencing and RNA sequencing were performed before and after exposure 
to the biocides PHMB, triclosan, benzalkonium chloride (BAC), and silver nitrate, 
and the QSI's cinnamaldehyde, furanone C30, and F-DPD using an antimicrobial 
gradient plating system. Comparative genomics and differential gene expression 
analysis was utilised to evaluate the molecular mechanisms that govern antimicrobial 
adaptation in EC958. Results: Impaired motility by downregulation of flagella 
associated genes occurred after exposure to PHMB, BAC, cinnamaldehyde and F-
DPD which correlated to a reduction in biofilm formation on the catheter surface for 
the PHMB and F-DPD exposed isolates. Multidrug efflux pumps were upregulated 
after exposure to PHMB (mdtE) and cinnamaldehyde (marA and mdtN). Triclosan 
exposure induced a mutation in fabI which conferred decreased susceptibility to 
triclosan. However antimicrobial susceptibility to PHMB, cinnamaldehyde, and 
furanone C30 increased potentially due to downregulation of murein 
transglycosylase mltA. MltA is is involved in peptidoglycan synthesis, reduced 
synthesis may impair the structure of the cell wall leading to increased membrane 
permeability and increased antimicrobial susceptibility. Multiple virulence factors 
were upregulated after exposure to triclosan (Type 1 fimbriae fimA,C,D) and 
cinnamaldehyde (tonB which is involved in iron transport) which did not correlate to 
changes in pathogenicity in this case. Antigen 43 (ag43) was upregulated after 
exposure to BAC and cinnamaldehyde which correlated with increased biofilm 
formation in these isolates. Ag43 was downregulated after exposure to F-DPD which 
correlated to reduced biofilm formation on the catheter surface. Conclusion: The 
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multiple and varied effects that occur after exposure to broad-spectrum 
antimicrobials must be taken into consideration when developing a new 
antimicrobial coating as these effects have impacts on resistance, virulence, biofilm 
formation, and antibiotic resistance. 
5.2.0 Introduction 
Catheter associated urinary tract infections (CAUTIs) cause 20% of all episodes of 
health-care acquired bacteremia in acute care facilities, and over 50% in long term 
care facilities [242]. It is estimated that approximately 3% of people over the age of 
65 will require a catheter and, with an aging population, this figure is likely to 
increase [16]. The major causative agent of CAUTI is uropathogenic E.coli which is 
distinct from the gastrointestinal serotypes of E. coli in its virulence factor 
production.  UPEC encode P fimbriae/ pyelonephritis associated pili (PAP) [24] 
which facilitate attachment and invasion of the uroepithelia. P fimbriae mediate the 
internalisation of UPEC into host cells to form intracellular biofilm communities 
(IBCs) [40] allowing the bacteria within to proliferate inside the cell and form a 
persistent reservoir, often leading to recurrent UTI [41]. Other key virulence factors 
in UPEC may include: Type 1 pili, lipopolysaccharide (LPS), flagella, curli, secreted 
toxins, secretion systems, and tonB-dependent iron-uptake receptors [25]. 
EC958 is a UPEC isolate belonging to subgroup ST131 [243]. This bacteria was 
isolated from the urine of a patient presenting with a urinary tract infection in the 
Northwest region of England and is a leading contributor to urinary tract and 
bloodstream infections in clinical and community settings [243]. The E.coli ST131 
subgroup is associated with resistance to fluoroquinolones, high virulence gene 
content, the possession of the type 1 fimbriae FimH30, and the production of the 
CTX-M-15 extended spectrum β-lactamase (ESBL) [244]. 
UPEC form biofilms on the surface of the catheter which exacerbates infection as  
biofilms are reportedly recalcitrant to many antimicrobial agents in addition to the 
actions of the host immune system making them far less susceptible compared to 
their planktonic counterparts [5]. Quorum sensing is density dependent bacterial 
communication whereby bacterial cells sense the concentration of signal molecules 
and activate QS-controlled genes in response [42]. As bacterial density increases the 
biofilm develops new characteristics that are different to the planktonic cells, 
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specifically the biofilm tends to be more virulent and less susceptible to 
antimicrobial treatment.  
Antimicrobial catheter coatings have been developed as an attempt to prevent 
CAUTIs from occurring, with silver coated catheters currently in clinical use. 
However there is little evidence to suggest that the current coated catheters are any 
more effective at preventing bacterial growth than uncoated catheters [113]. A novel 
approach in the production of anti- infective catheter coatings is to use quorum 
sensing inhibitors (QSIs). These molecules disrupt the communication between 
bacterial cells and so inhibit biofilm formation. Another approach is to use biocides, 
broad-spectrum antimicrobial chemicals whose purpose is to inhibit the growth or 
kill microorganisms [7]. Catheters have been previously developed that have been 
coated with biocides [8] in order to reduce the bacterial contamination of the catheter 
but success has been limited, largely due to issue with cytotoxicity and the 
emergence of biocide resistance in bacteria during treatment.  
It is hypothesised that current antimicrobial coatings become ineffective due to 
bacteria developing resistance to the coating over time [114]. It is important, then, 
that new coating agents should be assessed using long-term exposure to elucidate the 
effects of these antimicrobials over an extended amount of time. Research into the 
long-term effects of biocides has shown multiple phenotypic and genotypic changes 
occurring as bacteria respond to the antimicrobial challenge, which has been 
correlated with phenotypic effects such as changes in antimicrobial susceptibility, 
biofilm formation and relative pathogenicity [80, 184, 193].  
The previous chapters have detailed the phenotypic changes that have occurred after 
exposure to the biocides PHMB, triclosan, benzalkonium chloride (BAC), and silver 
nitrate, and the QSI's cinnamaldehyde, furanone C30, and F-DPD in eight UPEC 
isolates. For the EC958 isolate these have included: decreased susceptibility after 
triclosan, BAC, and silver nitrate exposure, increased susceptibility after exposure to 
PHMB, cinnamaldehyde, and furanone C30, increased biofilm formation in 96 well 
plates after triclosan, BAC, cinnamaldehyde, and furanone C30 exposure, decreased 
biofilm formation on catheter surface after exposure to PHMB, triclosan, furanone 
C30, and F-DPD, and decreased pathogenicity after PHMB, triclosan, BAC, and 
furanone C30 exposure.  In this chapter, we assess the genotypic and transcriptomic 
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changes that occur in UPEC isolate EC958 after long term exposure PHMB, 
triclosan, benzalkonium chloride (BAC), silver nitrate, cinnamaldehyde, furanone 
C30, and F-DPD.  
5.3.0 Aims and objectives 
In the previous chapters, multiple phenotypic changes have been observed in UPEC 
after exposure to seven antimicrobials (PHMB, triclosan, BAC, silver nitrate, 
cinnamaldehyde, furanone C30, and F-DPD). In light of the phenotypic data, there is 
a need for transcriptomic and genomic analysis to attempt to understand the 
mechanisms of UPEC adaptation to these antimicrobials. The isolate EC958 and the 
antimicrobial exposed strains of EC958 were selected for genome and RNA 
sequencing, the resulting data can be used to explain the corresponding phenotypic 
observations reported in previous chapters. As many phenotypic changes have been 
observed in this isolate, it is expected that there will also be a significant amount of 
genomic and transcriptomic changes revealed in the analysis of the sequencing data. 
The specific aims of this chapter were to: 
 Compare the genome sequencing data of EC958 and the antimicrobial 
exposed strains of EC958 to determine mutations that have occurred as a 
result of antimicrobial exposure. 
 Compare the RNA sequencing data of EC958 and the antimicrobial exposed 
strains of EC958 to determine transcriptomic changes that have occurred as a 
result of antimicrobial exposure. 
 Relate these genomic and transcriptomic changes to phenotypic observations. 
5.4.0 Methods 
5.4.1 Bacteria and chemical reagents Laboratory characterised UPEC isolate 
EC958 was used in the investigation. Bacteria were cultured onto Muller-Hinton 
agar (MHA; Oxoid, UK) or Muller-Hinton broth (MHB; Oxoid, UK) and incubated 
aerobically at 37 °C for 18 h unless otherwise stated. Furanone C30, cinnamaldehyde 
and F-DPD were prepared at 1 mg/ml in water and filter sterilised prior to use. 
Cinnamaldehyde was purchased from Sigma–Aldrich (Poole, UK). (Z)-4-Bromo-
5(bromomethylene)-2(5H)-furanone C30 (furanone C30) was synthesised at 
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Sheffield Hallam University by P.G Chirila and Dr C. Whiteoak as described 
previously [191]. 4- fluoro-5-hydroxypentane-2,3-dione (F-DPD) was synthesised at 
University of Manchester by Dr M. Kadirvel as described previously [192]. 
5.4.2 Long-term exposure of bacteria to antimicrobials Bacteria were repeatedly 
exposed to antimicrobials using an antimicrobial gradient plating system as 
described in McBain et al [152].  In brief, 100 µl of a 5 × MBC concentration 
solution of antimicrobial was added to an 8 x 8 mm well in the centre of a 90 mm 
agar plate. Bacterial pure cultures were radially inoculated in duplicate from the edge 
of the plate to the centre, prior to incubation for 2 days aerobically at 37°C. Biomass 
from the inner edge of the annulus of bacterial growth representative of the highest 
antimicrobial concentration at which growth could occur was removed and used to 
inoculate a new antimicrobial containing plate, as outlined above. This process was 
repeated for 12 passages. Control isolates passaged 12 times on antimicrobial free 
media were also included. Bacteria were archived at -80 °C before and after 
antimicrobial passage for subsequent testing. 
5.4.3 Whole genome sequencing Exposed isolates of EC958 and unexposed and 
control isolates were sent to MicrobesNG (Birmingham, UK) to be sequenced. 
MicrobesNG sequencing protocol is as follows:   
Three beads were washed with extraction buffer containing lysozyme and RNase A, 
incubated for 25 min at 37ºC. Proteinase K and RNase A were added and incubated 
for 5 min at 65ºC. Genomic DNA was purified using an equal volume of SPRI beads 
and resuspended in EB buffer.  
DNA was quantified in triplicates with the Quantit dsDNA HS assay in an Ependorff 
AF2200 plate reader. Genomic DNA libraries were prepared using Nextera XT 
Library Prep Kit (Illumina, San Diego, USA) following the manufacturer’s protocol 
with the following modifications: two nanograms of DNA instead of one were used 
as input, and PCR elongation time was increased to 1 min from 30 seconds. DNA 
quantification and library preparation were carried out on a Hamilton Microlab 
STAR automated liquid handling system. Pooled libraries were quantified using the 
Kapa Biosystems Library Quantification Kit for Illumina on a Roche light cycler 96 
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qPCR machine. Libraries were sequenced on the Illumina HiSeq using a 250bp 
paired end protocol.  
Reads were adapter trimmed using Trimmomatic 0.30 with a sliding window quality 
cutoff of Q15 [245]. De novo assembly was performed on samples using SPAdes 
version 3.7 [246], and contigs were annotated using Prokka 1.11 [247].  
Each genome of exposed bacterial strain of EC958 was compared to the genome of 
EC958 prior to exposure with a minimum of 30 x genome coverage. 
5.4.4 RNA sequencing RNA from each exposed strain of EC958 was extracted 
using the TRIzol plus RNA purification kit (Thermofisher, UK). RNA integrity and 
quality was assessed using the NanoDrop (Thermofisher, UK), Qubit fluorometer 
(Thermofisher, UK), and Affymetrix Genechip microarray system (Thermofisher, 
UK).  
Library preparations, sequencing reactions, and bioinformatics analysis were 
conducted at GENEWIZ, LLC. (South Plainfield, NJ, USA). rRNA depletion was 
performed using Ribozero rRNA Removal Kit (Illumina, San Diego, CA, USA). 
RNA sequencing library preparation used NEBNext Ultra RNA Library Prep Kit for 
Illumina by following the manufacturer’s recommendations (NEB, Ipswich, MA, 
USA). Briefly, enriched RNAs were fragmented for 15 minutes at 94 °C. First strand 
and second strand cDNA were subsequently synthesized. cDNA fragments were end 
repaired and adenylated at 3’ends, and universal adapter was ligated to cDNA 
fragments, followed by index addition and library enrichment with limited cycle 
PCR. Sequencing libraries were validated using the Agilent Tapestation 4200 
(Agilent Technologies, Palo Alto, CA, USA), and quantified by using Qubit 2.0 
Fluorometer (Invitrogen, Carlsbad, CA) as well as by quantitative PCR (Applied 
Biosystems, Carlsbad, CA, USA).  
The sequencing libraries were multiplexed and clustered on one lane of a flowcell 
and loaded on the Illumina HiSeq instrument according to manufacturer’s 
instructions. The samples were sequenced using a HiSeq 2x150 Paired End (PE) 
configuration. Image analysis and base calling were conducted by the HiSeq Control 
Software (HCS). Raw sequence data (.bcl files) generated from Illumina HiSeq was 
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converted into fastq files and de-multiplexed using Illumina's bcl2fastq 2.17 software. 
One mis-match was allowed for index sequence identification.  
After demultiplexing, sequence data was checked for overall quality and yield. Then, 
sequence reads were trimmed to remove possible adapter sequences and nucleotides 
with poor quality using Trimmomatic v.0.36. The trimmed reads were mapped to the 
Escherichia coli reference genome available on ENSEMBL using the STAR aligner 
v.2.5.2b. The STAR aligner is a splice aware aligner that detects splice junctions and 
incorporates them to help align the entire read sequences. BAM files were generated 
as a result of this step. Unique gene hit counts were calculated by using 
featureCounts from the Subread package v.1.5.2. Only unique reads within exon 
regions were counted.  
After extraction of gene hit counts, the gene hit counts table was used for 
downstream differential expression analysis. Using DESeq2, a comparison of gene 
expression between the groups of samples was performed. The Wald test was used to 
generate p-values and Log2 fold changes. Genes with adjusted p-values < 0.05 and 
absolute log2 fold changes > 1 were called as differentially expressed genes for each 
comparison. A gene ontology analysis was performed on the statistically significant 
set of genes by implementing the software GeneSCF v1.1. The GO list was used to 
cluster the set of genes based on their biological process and determine their 
statistical significance. A PCA analysis was performed using the "plotPCA" function 
within the DESeq2 R package. The plot shows the samples in a 2D plane spanned by 
their first two principal components. The top 500 genes, selected by highest row 
variance, were used to generate the plot.  RNA expression of each exposed isolate 
was compared with the control isolate. Analysis of genes was conducted using 
PANTHER [248]. 
5.5.0 Results 
5.5.1 Mutations in antimicrobial adapted UPEC isolate EC958 
5.5.1.1 PHMB There were no genes that acquired mutations that were specific to 
PHMB exposure alone. All of the genes that acquired mutations after exposure to 
PHMB also acquired mutation after exposure to the other test antimicrobials (Table 
5.1). These mutations were as follows: missense mutation in exodeoxyribonuclease 8 
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(recE1), missense mutation in 50S ribosome binding GTPase (yeeP), missense 
mutation in ISEc9 family transposase (tnpA), missense mutation in EntS/YbdA MFS 
transporter (entS), missense mutation in IS1 transposase (insB), missense mutation in 
increased serum survival gene (iss), missense mutation in putitative sulfertransferase  
(yeeD), missense mutation in positive regulator (alpA). 
5.5.1.2 Triclosan Mutations that occurred after triclosan exposure (Table 5.1) 
include missense mutation in fabI enoyl-[acyl-carrier-protein] reductase (Table 5.2), 
nonsense mutation in wbbL rhamnosyltransferase (Table 5.18), missense mutation in 
lipid II flippase (murJ), and silent mutation in glutamate decarboxylase beta (gadB). 
5.5.1.3 BAC Mutations that occurred after BAC exposure (Table 5.1) included 
missense mutation in cspE cold-shock like protein and missense mutation in ldrD2 
small toxic polypeptide. The BAC exposed isolate was one of the only isolates to not 
acquire a yeeD mutation. 
5.5.1.4 Silver Nitrate Mutations that occurred after silver nitrate exposure (Table 
5.1) included missense mutation in fadA (3 ketoacyl CoA thiolase) (Table 5.2) and a 
silent mutation in glutamate decarboxylase beta (gadB). 
5.5.1.5 Cinnamaldehyde Mutations that occurred after cinnamaldehyde exposure 
(Table 5.1) include nonsense mutation in proQ RNA chaperone, frame shift mutation 
in dihydrolipoyl dehydrogenase (ipd), missense mutation in dnaX DNA polymerase 
III subunit tau (Table 5.2), missense mutation in TONB protein (tonB), and a silent 
mutation in glutamate decarboxylase beta (gadB). 
5.5.1.6 Furanone C30 Mutations that occurred after furanone C30 exposure (Table 
5.1) include silent mutation in probable manganese efflux pump (mntP), and silent 
mutation in glutamate decarboxylase beta (gadB). 
5.5.1.7 F-DPD Mutations that occurred after F-DPD exposure (Table 5.1) include 
silent mutation in negative regulator (rsxC), missense mutation in uncharacterized 
HTH-type transcriptional regulator (yfhH), missense mutation in ldrD3 small toxic 
polypeptide, and a silent mutation in glutamate decarboxylase beta (gadB). The F-
DPD exposed isolate was one of the only isolates to not acquire a yeeD mutation. 
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Antimicrobial Gene name Type of 
mutation 
Function 
All recE1 Missense Exodeoxyribonuclease 8 
hydrolyses 
phosphodiester bonds in 
DNA and is mainly 
involved in 
recombination and 
damage repair 
All yeeP Missense 50S Ribosome binding 
GTPase. Era mutant 
era1 suppresses some 
temperature-sensitive 
mutations that affect 
DNA replication and 
chromosome 
partitioning and 
segregation 
All tnpA Missense ISEc9 family 
transposase. 
Transposase is an 
enzyme that binds to the 
end of a transposon and 
catalyzes its movement 
to another part of the 
genome 
All entS Missense EntS/YbdA MFS 
transporter. The 
transporter is mainly 
involved in efflux of 
enterobactin 
All insB Missense IS1 transposase. 
Transposase is an 
enzyme that binds to the 
end of a transposon and 
catalyzes its movement 
to another part of the 
genome 
All iss Missense ISS (increased serum 
survival gene). ISS has 
role in the complement 
resistance associated 
with a ColV plasmid 
and is an outer 
membrane protein 
PHMB, 
triclosan, silver 
nitrate, 
cinnamaldehyde, 
furanone C30 
yeeD Missense yeeD encodes a 
putitative 
sulfertransferase 
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All alpA Missense AlpA is a positive 
regulator of the 
expression of the slpA 
gene. SlpA encodes 
surface layer protein A. 
Triclosan fabI Missense Enoyl-[acyl-carrier-
protein] reductase is a 
key enzyme of the type 
II fatty acid synthesis 
(FAS) system 
Triclosan wbbL Nonsense Rhamnosyltransferase is 
involved bacterial outer 
membrane biogenesis 
(O antigen) 
Triclosan murJ Missense Lipid II flippase is 
involved in 
peptidoglycan 
biosynthesis 
BAC cspE Missense cspE encodes cold-
shock like protein which 
regulates expression of 
genes encoding stress 
response proteins but 
can also perform an 
essential function during 
cold acclimation 
BAC ldrD2 Missense Small toxic polypeptide 
is the toxic component 
of a type I toxin-
antitoxin (TA) system 
F-DPD ldrD3 Missense Small toxic polypeptide 
is the toxic component 
of a type I toxin-
antitoxin (TA) system 
Silver nitrate fadA Missense 3 ketoacyl CoA thiolase  
enzyme catalyzes the 
final step of fatty acid 
oxidation 
Triclosan, silver 
nitrate, 
cinnamaldehyde, 
furanone C30, 
F-DPD 
gadB Silent Glutamate 
decarboxylase beta 
converts glutamate to 
gamma-aminobutyrate 
(GABA) 
Cinnamaldehyde proQ Nonsense RNA chaperone with 
significant RNA 
binding, RNA strand 
exchange and RNA 
duplexing activities 
Cinnamaldehyde ipd Frame Shift Dihydrolipoamide 
dehydrogenase is a 
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bacterial enzyme that is 
involved in the central 
metabolism and is a 
component of the 
glycine cleavage system 
as well as of the alpha-
ketoacid dehydrogenase 
complexes 
Cinnamaldehyde dnaX Missense DNA polymerase III 
subunit tau. DNA 
polymerase III is a 
complex, multichain 
enzyme responsible for 
most of the replicative 
synthesis in bacteria 
Cinnamaldehyde tonB Missense TONB protein involved 
with the transport of 
iron-containing 
compounds and colicins 
into the cell 
Furanone C30 mntP Silent Probable manganese 
efflux pump 
F-DPD rsxC Silent Negative regulator of 
soxS transcription 
F-DPD yfhH Missense Uncharacterized HTH-
type transcriptional 
regulator 
 
Table 5.1 Summary of genes that acquired mutations after antimicrobial exposure, 
type of mutation and brief overview of function. 
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5.5.2 Alterations in UPEC transcriptome after antimicrobial exposure  
5.5.2.1 PHMB Following PHMB exposure 268 genes were significantly (p<0.05) 
upregulated and 137 genes were significantly downregulated compared to the control 
strain. The largest fold increase (3.82) was allantoin permease ybbW and the largest 
fold decrease (-4.93) was PTS trehalose transporter subunit IIBC (treB). PANTHER 
analysis revealed functional groups of genes that had altered expression in the 
PHMB exposed mutant. These were genes associated with TCA cycle such as gltA 
(1.26) and fumC (1.13). Genes associated with flagella structure 
(flgB,C,D,E,F,G,H,I) (-1.00 to -2.35) and function (fliF,G,H,I,J,K,LM,N,P) were all 
downregulated (-1.09 to -2.55). There were increases in the expression of genes 
associated with membrane transport such as dppD (2.75), dppF (2.17) and 
sufA,B,C,E (1.17 to 1.37). Changes were observed in the expression of genes 
associated with cell membrane synthesis such as mltA (-1.2) and lysM (1.21). Genes 
associated with DNA repair such as recR were downregulated (-1.17). BolA, a 
transcription factor associated with cellular stress response, was upregulated (1.24) 
(Table 5.2). 
5.5.2.2 Triclosan Following triclosan exposure 172 genes were significantly 
(p<0.05) upregulated and 155 genes were significantly downregulated. The largest 
fold increase (5.48) was 2-hydroxy-3-oxopropionate reductase (garR) and the largest 
fold decrease was (-4.37 and -4.06) for nitrate reduction associated genes napH and 
napG respectively. PANTHER analysis revealed functional groups of genes that had 
altered expression in the triclosan exposed isolate. These were genes involved in 
purine biosynthesis such as purH (1.11) and purE (1.36) (Table 5.18). Genes that 
contribute to cellular transport systems such as dppD (3.34), dppF (2.44), 
sufB,C,D,E (1.08 to 1.25), dcuC (-1.12), potE (-1.66) and malE,F,K (-1.49 to -2.05) 
(Table 5.2). Genes associated with cell adhesion such as fimA,C,D were upregulated 
(1.25 to 2.2), and genes involved in the PTS system such as srlE (-2.08) and srlA (-
2.03) were downregulated. Genes associated with cell wall synthesis such as mltA 
were downregulated (-1.22) (Table 5.2). 
5.5.2.3 BAC Following BAC exposure 195 genes were significantly (p<0.05) 
upregulated and 248 genes were significantly downregulated. The largest fold 
increase (4.47) was antigen 43 (ag43) an autotransporter outer membrane protein 
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(Table 5.2) and the largest fold decrease (-6.48) was flagellin (fliC) (Table 5.2). 
PANTHER analysis revealed groups of genes that had altered expression in the BAC 
exposed isolate. These were genes involved in purine synthesis such as purH (1.49), 
purN (1.14), and purE (2.16) (Table 5.2). Genes associated with motility such as 
fliA,D,F,G,H,I,J,K,L,M,N,O,P,R,S,T,Z (-1.31 to -3.24), flgC,D,E,G,H,I,J,K,L,N (-
1.06 to -3.83), motA (-2.97), motB (-3.38) and cheA,R,W,Z (-3.99 to -3.14) were 
downregulated. Genes involved in transport systems such as dppD (1.53), dppF  
(1.18) were upregulated and potE (-1.19) was downregulated. 
5.5.2.4 Silver Nitrate Following silver nitrate exposure 225 genes were significantly 
(p<0.05) upregulated and 141 genes were significantly downregulated. The largest 
fold increase (4.8) was antigen 43 (ag43) (Table 5.2). The largest fold decrease (-
5.43) was PTS trehalose transporter subunit IIBC (treB). PANTHER analysis 
revealed functional groups of genes that had altered expression in the silver nitrate 
exposed isolate. These were genes involved in purine synthesis such as purH (1.34), 
purN (1.1), and purE (1.34) (Table 5.2) and genes associated with the TCA cycle 
such as gltA (1.25) and fumC (1.07). Genes involved in fatty acid degradation such 
as fadA (1.13) and fadB (1.57) were upregulated. Genes associated with transport 
such as dppD (2.59), actP (1.59), potG (1.02), and artP (1.06) were upregulated, 
malF (-3.9) (Table 5.18) and dcuC (-1.55) were downregulated. Genes involved in 
cell wall synthesis such as mltA were downregulated (-1.84). 
5.5.2.5 Cinnamaldehyde Following cinnamaldehyde exposure 368 genes were 
significantly (p<0.05) upregulated and 329 genes were significantly downregulated. 
The largest fold increase (4.64) was 2-hydroxy-3-oxopropionate reductase (garR) 
and the largest fold decrease (-5.74) was mexE family multidrug efflux RND 
transporter periplasmic adaptor subunit (Table 5.2). PANTHER analysis revealed 
groups of genes that had altered expression in the cinnamaldehyde exposed isolate. 
These were gltA (1), fumC (1.36), and sucA (1.14) involved in the TCA cycle. Genes 
involved in ribonucleotide synthesis upp (-1.31), pyrG (-1.17) and carB (-2.54), and 
purine synthesis adk (-1.29) and guaA (-1.32) were all downregulated. Flagella 
associated genes flgB,C,D,E,H,I,J,K,L (-1.09 to -2.64) and 
fliA,D,F,G,H,J,K,L,M,N,P,S,T,Z (-1.23 to -2.75) were downregulated. Genes 
associated with chemotaxis cheA,R,W,Z were downregulated (-2.13 to -2.61). Genes 
associated with transport such as uhpT (1.05) tonB (1.13), and marA (1.5) were 
 142 
 
upregulated and sufA,B,C,D (Table 5.2) (-1.2 to -1.8) was downregulated. MdtE was 
downregulated (-2.73) whereas mdtN was upregulated (1.87). Genes associated with 
adhesion such as Antigen 43 (ag43) (1.14) and yfcV (1.83) were upregulated. Genes 
associated with DNA transcription and repair such as proQ (-1.44), recR (-1.62) and 
dnaK (-2.34) were downregulated. Genes associated with cell wall synthesis such as 
mltA (-1.02) were downregulated. 
5.5.2.6 Furanone C30 Following furanone C30 exposure 122 genes were 
significantly (p<0.05) upregulated and 98 genes were significantly downregulated. 
The largest fold increase (5.02) was 2-hydroxy-3-oxopropionate reductase (garR) 
and the largest fold decrease (-2.21) was murein transglycosylase (mltA) (Table 5.2). 
PANTHER analysis revealed groups of genes that had altered expression in the 
furanone C30 exposed isolate. These were genes involved in purine synthesis such as 
purH (1.43), and purE (1.31) (Table 5.2), genes involved in cellular transport 
systems such as dppD (1.9) and dppF (1.19) were upregulated and secY (-1.4) (Table 
5.2) was downregulated. Genes associated with 50S Ribosomal subunit L20 (rplT), 
L23 (rplW), and L4 (rplD) were downregulated (-1.08, -1.33, and -1.45 respectively).  
5.5.2.7 F-DPD Following F-DPD exposure 86 genes were significantly (p<0.05) 
upregulated and 181 genes were significantly downregulated. The largest fold 
increase (2.76) was 2-hydroxy-3-oxopropionate reductase (garR) and the largest fold 
decrease (-4.76) was flagellin (fliC) (Table 5.2). PANTHER analysis revealed groups 
of genes that had altered expression in the F-DPD exposed isolate. These were genes 
involved in motility such as fliA,D,F,G,H,I,J,K,L,M,N,O,P,S,T,Z  (-1.2 to -3.17) and 
flgB,C,D,E,G,H,I,J,K,L,N (-1.2 to -4.76). Antigen 43 (ag43) was downregulated (-
1.2). Genes involved in adhesion such as AfaC and afaD increased expression (2.59 
and 2.02 respectively). Genes involved in cell membrane synthesis such as mepS was 
upregulated (1.07) and lysM was downregulated (-1.26). Transporter mdtE was 
downregulated (-1.39). 
 
 
 
 
  
 
1
4
3
 
 
 PHMB Triclosan BAC Silver 
Nitrate 
Cinnamaldehyde Furanone 
C30 
F-DPD Associated 
Genes 
MIC Fold 
Change 
-5 260 2 2 -2 -2 No Change mltA [249] 
fabI [80] 
MBC Fold 
Change 
-1.1 8 No Change 16 -2 -.1.5 No Change fadA [185] 
sufC [250] 
MBEC Fold 
Change 
42.4 125 4 1.3 -4 -4 No Change mexE [251] 
Cross 
Resistance 
No Change Nitrofurantoin 
resistance 
No Change No Change No Change No Change No Change potE [252] 
dnaX [253] 
Biofilm 
Formation 
(Plate) 
No Change Increase 
(p<0.0001) 
Increase 
(p<0.0001) 
No Change Increase 
(p<0.001) 
Increase 
(p=0.0124) 
No Change bolA [254] 
wbbL [255] 
ag43 [256] 
Biofilm 
Formation 
(Catheter) 
Decrease 
(p=0.0069) 
 
Decrease 
(p=0.0094) 
No Change No Change No Change Decrease 
(p=0.0056) 
Decrease 
(p=0.0337) 
flg [257] 
fli [257] 
Pathogenicity Decrease 
(p<0.001) 
Decrease 
(p<0.001) 
Decrease 
(p<0.001) 
No Change No Change Decrease 
(p<0.001) 
No Change wbbL [255] 
malF [258] 
secY [259] 
SMC 
Invasion 
No Change No Change Increase 
(p=0.0006) 
No Change No Change No Change No Change purE,H,N 
[260] 
 
Table 5.2 Observed changes in MIC, MBC, MBEC, biofilm formation, cross resistance, pathogenicity, and cell invasion in EC958 after 
exposure to 7 antimicrobials. Where a change was observed, the p value is given. Genes whose expression was found to be affected by 
antimicrobial exposure and that are associated with the observed changes are also shown. 
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5.6.0 Discussion 
There were certain mutations that occurred in all antimicrobial exposed EC958 isolates 
(Table 5.1). These indicate universal adaptation to antimicrobial stress. Genome 
sequencing revealed all isolates acquired mutations in the recE1 gene. RecE1 encodes 
exodeoxyribonuclease 8 which hydrolyses phosphodiester bonds in DNA and is mainly 
involved in homologous recombination and DNA damage repair [261]. Mutations in 
recE have been shown to abolish nuclease activity, which would likely  impair DNA 
repair mechanisms [262]. Any functional deficits in EC958 in response to antimicrobial 
adaptation may be attributed to impaired DNA repair.  
All EC958 isolates also acquired mutations in yeeP (Table 5.1). yeeP encodes 50S 
Ribosome binding GTPase. GTPases that are associated with ribosomes are essential to 
the function of the ribosome [263]. Mutations in yeeP have been previously associated 
with attenuated fitness in E. coli [264]. A similar GTPase (era) binds rRNA to the 30S 
ribosomal subunit, ensuring translation can take place [263]. A significant part of the 
bacterial stress response is impairment of translation and therefore protein synthesis 
[265], impacting cell division and fitness. Mutation in this GTPase may impair  
translation which could explain the reduction in pathogenicity seen in the PHMB, 
triclosan, BAC, and furanone C30 exposed isolates as a reduction in fitness would 
impair the bacteria's ability to grow and establish infection [266]. 
These mutations are deleterious (decreases fitness of the organism) and so are unlikely 
to be maintained after exposure to the antimicrobial is removed. These mutations are 
unlikely to be coincidental changes as they occurred in all seven exposured isolates so it 
is more likely that these functional deficits are universal adaptation to general 
antimicrobial challenge. 
All isolates acquired multiple mutations in entS (Table 5.1). EntS encodes the 
EntS/YbdA MFS transporter. The transporter is mainly involved in efflux of 
enterobactin - one of the most effective ferric iron chelating compounds known in 
bacteria [267]. Enterobactin has been suggested to have another role - protection against 
oxidative stress [268]. As the molecule has exposed hydroxyl groups it would be an 
effective molecule to scavenge oxygen radicals [268]. Mutations in this gene may 
therefore potentially make bacteria more sensitive to oxidative stress. Cinnamaldehyde 
is known to exert oxidative stress on bacterial cells [194], and the cinnamaldehyde 
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exposed EC958 isolate showed increased susceptibility to cinnamaldehyde after 
exposure, suggesting a potential mechanism of increased susceptibility. 
5.6.1 PHMB Exposure to PHMB induced an increase in susceptibility in planktonic 
EC958 (Table 5.2). RNA sequencing of the PHMB exposed isolate revealed a 
downregulation of murein transglycosylase (mltA). Peptidoglycan (murein) is integral to 
the structure and function of the bacterial cell wall and mltA is involved in 
peptidoglycan synthesis [249]. There was also an upregulation of peptidoglycan-binding 
protein lysM, these domain have multiple functions which include peptidoglycan 
degradation [269]. These impairments in peptidoglycan synthesis and an increase in 
degradation could drastically impair cell wall formation, the resulting loss of integrity 
increasing antimicrobial susceptibility. 
The genes gltA (citrate synthase) and fumC (fumarate hydratase II) were both 
upregulated and are both involved in the TCA cycle. The TCA (tricarboxylic acid) 
/Krebs /citric acid cycle is a series of chemical reactions used by all aerobic organisms 
to generate energy (ATP) [270]. Citrate synthase catalyzes the condensation of 
oxaloacetate and acetyl coenzyme A to produce citrate plus coenzyme A [271]. 
Fumarate hydratase II catalyzes the stereospecific interconversion of fumarate to L-
malate, fumC supplements fumA under conditions of iron limitation and oxidative stress 
[272]. PHMB is a decoupling agent and has been shown to play a role in disrupting 
respiration by altering the proton motive force (PMF) across the membrane [273].  
Upregulation of the aforementioned genes could be a response of the bacteria to the 
limitation in respiration exerted by PHMB, by boosting the TCA cycle. 
PHMB exposure led to a significant decrease in biofilm formation grown on urinary 
catheters (Table 5.2). RNA sequencing data analysis revealed downregulation of 
multiple genes associated with flagella structure and function. Flagella are an important 
factor in the initiation of bacterial biofilm formation [257] so loss of these structures 
would suggest that the ability of these isolates to form biofilms may be impaired. 
However the MBEC for this strain increased after PHMB exposure, possibly suggesting 
the presence of a small but persistent biofilm. RNA sequencing revealed an 
upregulation in the gene bolA  which is a transcription factor that downregulates flagella 
synthesis and upregulates biofilm formation [254]. BolA was shown to repress flhD and 
flhC which are major regulators for flagella synthesis, and upregulate genes associated 
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with fimbriae (yfcV) and LPS biosynthesis which favours biofilm formation [254]. BolA  
also elevates expression of enzymes involved in the TCA cycle [254]. We see 
downregulation of flhA, upregulation of yfcV and gltA and fumC as mentioned earlier. 
This is likely occurring in response to the upregulation of transcription factor bolA. As 
this isolate is less motile this would affect initiation of biofilm growth on a catheter 
since motility is an important factor in the ability of bacteria to initiate biofilm 
development [257]. 
5.6.2 Triclosan Triclosan induced the largest frequency and magnitude of susceptibility 
decreases in MIC, MBC, and MBEC (Table 5.2). Mutations in the fabI gene found in 
the triclosan exposed isolate would explain the high levels of triclosan resistance as fabI 
encodes Enoyl- [acyl-carrier-protein] reductase which is a known target of triclosan [80]. 
Genome sequencing of the triclosan exposed mutant showed mutation in the wbbL gene, 
which encodes the enzyme rhamnosyltransferase which is involved in lipopolysacharide 
(LPS) and O antigen biogenesis. Mutation in wbbL has shown to impair O antigen 
biosynthesis, when O antigen is restored in E.coli the bacteria exhibit increased 
susceptibility to triclosan, decreased biofilm formation and increased virulence [255]. O 
antigen is important in maintaining the structure of the bacterial cell wall, and it has 
been shown that loss of O antigen increases cell permeability in E.coli, hence increasing 
antimicrobial susceptibility [274]. FabI is also involved in LPS synthesis [275] and 
because triclosan is a surfactant, the amount of LPS in the cell wall could have an effect 
on triclosan susceptibility.  
Decreased pathogenicity was observed in the triclosan exposed isolate (Table 5.2). O 
antigen is an important virulence factor in UPEC [25] as it protects UPEC against 
phagocytosis by immune cells and complement mediated killing [276]. Therefore, a 
mutation in wbbL that inhibits O antigen synthesis may explain the decreased 
pathogenicity that was seen in this study. RNA sequencing showed downregulation of 
transporters dcuC and malF. MalF is a maltose transporter, knockout mutations of this 
gene caused Vibrio spp. to become less virulent by inhibiting the production and 
secretion of toxins and virulence factors [258]. This may also contribute to the 
decreased pathogenicity seen here in EC958 after triclosan exposure. 
EC958 exhibited an increase in biofilm formation after triclosan exposure as well as an 
elevation in MBEC (Table 5.2). This could be explained by the mutation in wbbL that 
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was seen in the triclosan exposed isolate. As previously stated - O antigen synthesis 
decreases biofilm formation in E.coli so a mutation in wbbL leading to impaired O-
antigen formation may increase biofilm formation [255]. 
The triclosan exposed isolate showed downregulation of srlE and srlA which are 
involved in the phosphoenolpyruvate-carbohydrate phosphotransferase system (PTS). In 
Escherichia coli, PTS is responsible for the transport and phosphorylation of sugars, 
such as glucose. PTS activity has a crucial role in the global signalling system that 
controls the preferential consumption of glucose over other carbon sources [277]. The 
enzyme IIC complex composed of srlA, srlB and srlE is involved in sorbitol transport, it 
can also transport D-mannitol [277]. Downregulation of this system could be a sign of 
reduced energy production which is common in a bacterial stress response [278].  
5.6.3 BAC EC958 was observed to form increased biofilm biomass after BAC exposure 
and had a corresponding increase in MBEC (Table 5.2). The highest increase in gene 
expression after BAC exposure was antigen 43 (ag43). Antigen 43  is a self-recognizing 
adhesin that is associated with cell aggregation and biofilm formation in E. coli K-12 
[256]. Such a large fold increase in this gene expression would undoubtedly cause 
increased biofilm production which is what we have observed. 
After BAC exposure, multiple genes responsible for synthesis of flagella were down 
regulated. In fact, the gene with the highest fold decrease in expression was flagellin. 
Exposure to BAC decreasing motility of E.coli has been demonstrated previously [184]. 
As discussed earlier this decrease in motility would negatively impact the initiation of 
biofilm formation. The flagellar motor proteins motA,B and the chemotaxis proteins 
cheA,R,W,Z have been associated with biofilm initiation (attachment) [224] all were 
downregulated in the BAC exposed strain.  
Exposure to BAC induced an increase in EC958 invasion in for SMC. Genes involved 
in purine biosynthesis: purE, purH, and purN were upregulated after BAC exposure. An 
upregulation of these genes could increase virulence by promoting increased survival 
inside the cell [260]. If the bacteria survive inside the cells they would survive until the 
end of the SMC invasion assay which would explain the increased SMC invasion 
observed for the BAC exposed isolate.  
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Increased expression of dppD and dppF which are involved in the Ntr (Nitrogen 
regulated) response was observed in this study, this was also seen after sublethal 
exposure to BAC in another UPEC isolate CFT073 [279]. It was hypothesised that 
biocide exposure depleted the bacteria of nitrogen and therefor mechanisms to scavenge 
nitrogen were upregulated.  
5.6.4 Silver nitrate It was observed that EC958 decreased in silver nitrate susceptibility 
after long-term exposure (Table 5.2). Silver nitrate exposure induced a mutation in the 
fadA gene (3-ketoacyl-CoA-thiolase) which catalyses the final step of fatty acid 
oxidation. Silver- induced shortening of the acyl chain of fatty acids occurs mostly in the 
cell membrane and one effect of ionic silver is reducing the amount of unsaturated fatty 
acids in the cell wall [185]. FadA has been shown to be downregulated by ionic silver 
[185]. So an increase in the amount of fatty acids in the cell wall could be a potential 
mechanism of withstanding the effects of prolonged exposure to silver. RNA 
sequencing of the silver nitrate exposed isolate revealed fadA and fadB expression were 
upregulated which further corroborates this. The promotor region for the fadBA operon 
is located in fadB and the direction of transcription is fadB to fadA [280]. Therefore, it is 
highly unlikely that the mutation in fadA is responsible for the increased levels of 
transcription, so the increased expression of these genes may be more adaptive than 
mutational. One of the products of the final stage of fatty acid oxidation is acetyl-CoA 
[281] which is necessary for the TCA cycle (described above). Genes involved in the 
TCA cycle gltA (citrate synthase) and fumC (fumarate hydratase II) were also 
upregulated. Silver has been shown to depolarise the outer cell membrane and therefore 
inhibit respiration [282].The upregulation of all of these genes could be a response from 
the bacteria to the disruption of the TCA cycle by membrane depolarisation caused by 
silver. 
Silver nitrate exposure led to no change in biofilm formation and a small magnitude 
increase in MBEC in EC958 (Table 5.2). The highest increase in gene expression for 
the silver nitrate exposed isolate was antigen 43 (ag43). Antigen 43 is a self-recognizing 
adhesin that is associated with cell aggregation and biofilm formation in E. coli K-12 
[256]. This could explain the increase in MBEC observed in response to silver exposure.  
5.6.5 Cinnamaldehyde Exposure to cinnamaldehyde induced an increase in 
susceptibility in planktonic EC958 (Table 5.2). RNA sequencing of the cinnamaldehyde 
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exposed isolate revealed a downregulation of murein transglycosylase (mltA). 
Peptidoglycan (murein) is integral to the structure and function of the bacterial cell wall 
and mltA is involved in peptidoglycan synthesis [249]. This impairment in 
peptidoglycan synthesis would drastically impair cell wall formation, the resulting loss 
of integrity increasing antimicrobial susceptibility. RNA sequencing also revealed a 
downregulation of sufC which is involved in iron-sulphur cluster synthesis [250]. 
Decreased activities of this enzyme have been shown to cause increased sensitivity to 
ROS and DNA damage in S. aureus [250]. As cinnamaldehyde's mechanism of action 
depends on generation of oxidative damage [194] this would explain the increase in 
sensitivity seen in this study. We also see that the largest fold decrease in gene 
expression after cinnamaldehyde exposure was mexE (efflux system). Multidrug efflux 
pumps have been shown to be able to transport AHL (QS molecules) out of the cell 
[251]. The mexEF operon is controlled by the global regulator MVAT which itself is 
activated by QS [283]. Constant inhibition of the QS signal may cause decreased 
expression of these transporters. With the cell less able to export antimicrobials, this 
could explain the increase in susceptibility. 
In the cinnamaldehyde exposed isolate, a mutation in proQ was reported. ProQ encodes 
an RNA chaperone, which are proteins that aid in RNA folding, with significant RNA 
binding, strand exchange and duplexing activities [284]. RNA sequencing of EC958 
indicated that proQ was downregulated after cinnamaldehyde exposure. ProQ has been 
shown to bind RNA to regulate transcription and prevent the degradation of mRNA, 
proQ deletion attenuated virulence in Salmonella enterica by disregulation of genes for 
chemotaxis, motility, and invasion [285]. We also observe downregulation of genes 
associated with chemotaxis (cheA,R,W,Z) and motility (flagella associated genes) in 
cinnamaldehyde exposed EC958.  
Genome sequencing also revealed a mutation in dnaX (DNA polymerase III subunit tau). 
DNA polymerase III is a complex, multichain enzyme responsible for most of the 
replicative synthesis in bacteria [253]. DnaX is the promotor for recR, which encodes a 
protein involved in DNA repair [286] which was downregulated in EC958 after 
cinnamaldehyde exposure. The expression of dnaK (chaperone involved in DNA 
replication) was also downregulated. Furthermore, genes encoding proteins involved 
ribonucleotide and purine biosynthesis: uracil phosphoribosyltransferase (upp), CTP 
synthase (pyrG), carbamoyl-phosphate synthase (carB), adenylate kinase (adk) and 
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GMP synthase (guaA) were all downregulated. Each of the four antibiotics used in the 
cross resistance experiments act on DNA replication. As all of these genes are involved 
in DNA replication and synthesis, downregulation of these genes could confer 
resistance against these antibiotics because the active processes that the antibiotic is 
targeting is reduced. Cinnamaldehyde exposure induced 3 cases of antibiotic cross 
resistance although not in the EC958 isolate specifically so we cannot say for certain 
that this is a mechanism for antibiotic cross resistance in cinnamaldehyde exposed 
bacteria.  
Cinnamaldehyde exposure induced a mutation in ipd which encodes dihydrolipoyl 
dehydrogenase. Dihydrolipoamide dehydrogenase is a bacterial enzyme that is part of 
the pyruvate dehydrogenase complex [287]. The pyruvate dehydrogenase complex 
converts pyruvate to acetyl-CoA to be used in the TCA cycle. Genes involved in the 
TCA cycle gltA (citrate synthase), fumC (fumarate hydratase II), and sucA  (2-
oxoglutarate dehydrogenase E1 component) were all upregulated. Cinnamaldehyde has 
been shown to interfere with the E.coli TCA cycle in previous studies [288] so the 
upregulation of these genes could be a response to this repression. 
There was also a mutation in tonB which encodes the TONB protein. This is involved 
with the transport of iron-containing compounds and colicins into the cell and is a key 
virulence factor in UPEC [37]. RNA sequencing of the cinnamaldehyde exposed isolate 
revealed tonB expression was upregulated, the promoter region is located within the 
tonB gene [289] so it is possible that the mutation has affected the promotor region - 
causing the upregulation. Proteins associated with iron transport have been shown to be 
upregulated in cinnamaldehyde exposed E.coli previously [226]. It was hypothesised 
that induced uptake of iron would enhance microbial survival under stress conditions 
and contribute to microbial oxidative resistance (by sequestering free irons, which 
generate ROS). This study also reported decreased expression of genes associated with 
motility and biofilm formation [226]. We have also observed downregulation of flagella 
(flgB,C,D,E,H,I,J,KL and fliA,D,F,G,H,J,K,L,M,N,P,S,T,Z) in the cinnamaldehyde 
exposed isolate. 
Biofilm formation in the cinnamaldehyde exposed strain increased when grown on a 
plastic surface (Table 5.2). Increased expression of ag43, as stated previously, would 
increase biofilm formation. Upregulation of yfcV was also observed in this isolate. YfcV 
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encodes a major fimbrial subunit and is an important virulence factor for UPEC [290]. 
Fimbriae are important for the initial formation of bacterial biofilms [291] so this could 
also explain an increase in biofilm formation. 
The highest fold increase in expression was garR (2-hydroxy-3-oxopropionate 
reductase). This enzyme is involved in glyoxylate and dicarboxylate metabolism [292]. 
This increase in expression was also seen in the triclosan, furanone C30, and F-DPD 
exposed isolates. This means that in all of the QSI exposed strains garR had the highest 
increase in expression. As far as we are aware, there has been no reported between garR 
and quorum sensing. 
In the cinnamaldehyde exposed isolate, 8 genes known to be controlled by AI-2 
signaling [293] were shown to have altered expression. Genes that are upregulated by 
AI-2: caiF and astD were also upregulated after cinnamaldehyde exposure, and motB 
was downregulated after cinnamaldehyde exposure. Genes that are downregulated by 
AI-2: cheW, fliP, and carB were downregulated, but uhpT and evgS were upregulated 
after cinnamaldehyde exposure. It would be expected that inhibition of AI-2 signaling 
would upregulate expression of genes that would normally be downregulated by AI-2 
and vice versa. This was seen in the cinnamaldehyde exposed isolate for some genes 
(motB, uhpT, and evgS) but we see the opposite in others (caiF, astD, cheW, fliP, and 
carB). E.coli do possess other QS pathways [294] so it could be that the genes that show 
the opposite of what we expected are also under the control of one of these pathways. 
Indeed, one of these genes, astD has been associated with being induced by indole 
signaling in E.coli [295]. CheW and fliP have also been shown to be downregulated by 
AI-2 inhibitors in previous studies [296]. 
5.6.6 Furanone C30 Exposure to furanone C30 induced high frequency of significant 
increases in susceptibility (Table 5.2). The highest fold decrease in gene expression for 
the furanone C30 exposed isolate was murein transglycosylase (mltA). Downregulation 
of this gene would lead to impaired cell wall formation, loss of integrity, difficulty in 
cell division [249]. This may cause increased susceptibility to antimicrobials. 
The gene secY was downregulated after furanone C30 exposure. SECY supports the 
posttranslational translocation of proOmpA across the cytoplasmic membrane [297]. 
OmpA is also an important virulence factor in UPEC (it is an invasin and adhesin [259], 
and has been shown to be integral to IBC formation in bladder cells [298]). The 
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downregulation of ompA could explain the decreased pathogenicity observed in the 
furanone C30 exposed isolate (Table 5.2). 
In the furanone C30 exposed isolate, 4 genes known to be controlled by AI-2 signaling 
[293] were shown to have altered expression. Genes that are upregulated by AI-2: astD 
were also upregulated after furanone C30 exposure. Genes that are downregulated by 
AI-2: cspE, ivbL and carB were downregulated after furanone C30 exposure. As 
previously stated, this is the opposite of what we would expect to observe during 
inhibition of AI-2 signaling. AstD is also controlled by indole signaling [295] but we 
couldn't find any literature that suggests the other genes are under the control of another 
quorum sensing system in E.coli. 
5.6.7 F-DPD Exposure to F-DPD induced decreased biofilm formation for EC958 on 
catheter pieces (Table 5.2). We observed decreased expression of genes associated with 
flagella with the largest fold decrease in expression being flagellin, and there was 
downregulation of antigen 43 (ag43). All of these would explain the decrease in biofilm 
formation observed in EC958. 
In the F-DPD exposed isolate, 4 genes known to be controlled by AI-2 signaling [293] 
were shown to have altered expression. Genes that are upregulated by AI-2: motB was 
downregulated after F-DPD exposure. Genes that are downregulated by AI-2: cheW, 
fliP, and flgN were downregulated after F-DPD exposure.  CheW, fliP, and flgN have 
been shown to be downregulated by AI-2 inhibitors in previous studies [296]. In that 
study, it was postulated that the reduction of these motility associated genes explains the 
reduction in biofilm formation when AI-2 signaling is inhibited.  
5.7.0 Conclusion 
To understand the mechanisms of the phenotypic changes reported in previous chapters, 
one isolate (EC958) and the corresponding exposed strains, was subjected to genomic 
and transcriptomic analysis. This analysis has shown that long term exposure of UPEC 
to broad spectrum antimicrobials has an impact on UPEC resistance, virulence, motility, 
biofilm formation, and antibiotic resistance. Some of these changes can be beneficial in 
terms of a response to a catheter coating agent, whilst others could give cause for 
concern. It is important to fully understand and ellucidate these effects before 
developing a catheter coating for long-term catheterisation. 
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Chapter 6 
General Discussion 
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6.1.0 Study Overview 
Catheter associated urinary tract infections (CAUTIs) account for the highest proportion 
of hospital acquired infections (17.2%) [15] with between 43% and 56% of UTIs 
associated with an indwelling urethral catheter [15]. Uropathogenic Escherichia coli 
(UPEC) is reportedly responsible for 65% of complicated UTI cases [23]. CAUTI can 
lead to serious complications such as blood stream infections [14]. Currently E. coli  is 
the leading cause of blood stream infection in the UK with 40,580 cases reported in 
2016–17 and a mortality rate of 14.8% [17]. Of these cases, 21% are linked to the 
presence of an indwelling urinary catheter [17]. CAUTIs often show recalcitrance to 
antimicrobial treatment due to the formation of bacterial biofilms within the catheter in 
addition to the increasing prevalence of antibiotic resistance in uropathogens [3, 4]. 
In order to reduce the incidence of CAUTI approaches for the production of anti-
infective catheter coatings have been developed including (i) surfaces containing 
antimicrobials that may be eluted into the surrounding environment [125] (ii) surfaces 
containing covalently bound antimicrobials [132] and (iii) surfaces coated in an anti-
adhesive material to reduce bacterial attachment [118]. The advantage of using an anti-
adhesive material is that it does not provide a selective pressure for antimicrobial 
resistant bacterial populations, however there are limited materials that can be 
effectively modified in this way and the non-specific deposition of host proteins during 
device insertion often provides sites for microbial attachment rendering the coating 
ineffective [119]. Covalently bound antimicrobials do not leach out over time, limiting 
cytotoxicity and reduces the creation of an antimicrobial gradient potentially selecting 
for resistance [132]. However, these coatings also become impaired due to host protein 
deposition and there are limitations in the number of antimicrobials that would have 
activity when covalently tethered to surfaces due to their structure. The controlled 
elution of antimicrobials is a currently considered strategy in preventing device 
associated infections as there is a wider availability of compounds that can be 
incorporated into coatings to be eluted out and avoid microbial colonisation [133]. 
Antimicrobial impregnated catheter coatings that are currently in clinical use inc lude 
hydrogel silver alloy-coated latex catheters (CR Bard Inc.) and urethral catheters 
containing covalently bound nitrofurazone (Rochester Medical Corp) [114]. There have 
been numerous studies that have concluded the limited efficacy of these coated catheters 
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in preventing CAUTI, partially due to the emergence of insusceptible bacterial 
populations [113-115]. 
Biocides are often considered as anti- infective coating agents due to their broad-
spectrum of antimicrobial activity and their multiple site-targeted mode of action [105], 
meaning the risk of selecting resistant microorganisms is comparatively low when 
compared to antibiotics. When biocide resistance does occur however, it has been 
associated with cross-resistance to third party agents such as other biocides and 
antibiotics [299]. Biocide exposure however often correlates with other functional 
deficits in bacteria such as impaired growth, reduced competitive fitness and 
pathogenicity [80] and even in some cases increased biocide susceptibility [73]. A novel 
approach in the production of anti- infective catheter coatings is to use quorum sensing 
inhibitors (QSIs). Quorum sensing (QS) is a process by which bacteria produce and 
detect signal molecules and thereby coordinate their behaviour in a cell density 
dependent manner [10]. The inhibition of quorum sensing as a strategy to prevent 
infection is a growing area of research but very little is known about the long term 
effects of QSIs in bacteria.  
In this thesis, the long-term effects of biocide and QSI exposure were measured by 
subjecting clinical isolates and laboratory strains of UPEC (unexposed) to sustained 
antimicrobial challenge using a gradient plating system (exposed). This was done with 
each test antimicrobial. Control isolates, passaged in absence of antimicrobials, were 
also generated. After bacteria had undergone long-term antimicrobial exposure we 
evaluated a range of phenotypic effects. This included changes in antimicrobial 
susceptibility, biofilm formation and pathogenicity in a Galleria mellonella waxworm 
model.  
After initial high- throughput screening of changes in biofilm formation via crystal 
violet assay we implemented a more realistic scenario whereby we determined changes 
in biofilm formation and biofilm metabolic activity on the surface of a urinary catheter. 
The capability of the bacterial isolates to invade human uroepithelial and bladder cell 
lines was also evaluated.  
The project then focussed on developing polymer coatings containing antimicrobials 
and analysing the performance of these coatings in terms of antimicrobial efficacy and 
biocompatibility. The three coating candidates were Sol gel, Poly(ethylene glycol) 
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(PEG), and Poly(hydroxyethymethacrylate) (pHEMA). Once these coatings had been 
screened for their initial activity, the sol-gel coating was deemed the most effective, we 
then determined the antimicrobial activity of antimicrobial impregnated sol-gel coated 
urinary catheters in a Drip Flow Biofilm Reactor. The comprehensive screening of the 
test compounds and polymer coatings on UPEC in this study give a detailed overview 
of the suitability of these materials as anti-infective coatings for urinary catheters. 
Following a detailed assessment of the phenotypic effects of biocide exposure, the final 
stage of the project was to investigate the underlying molecular mechanisms that govern 
such adaptations using full genome sequencing and RNA-sequencing in isolate EC958. 
6.2.0 Changes in bacterial susceptibility, pathogenicity, and biofilm formation are 
induced after biocide and QSI exposure 
Reduction in biocide susceptibility after bacterial exposure to antimicrobial agents such 
as biocides has become a growing concern especially considering the links to antibiotic 
cross-resistance [299]. In medical device coatings that contain biocides that a leachable 
into the surrounding environment this creates a gradient effect, which may expose the 
surrounding bacteria to sub-lethal biocide concentrations. This allows the bacteria to 
adapt to the presence of the antimicrobial which may induce insusceptibility in addition 
to other phenotypic changes. In this investigation, the changes in susceptibility of 
planktonic UPEC after long-term exposure to the test compounds were determined 
using MIC and MBC assays. PHMB exposure induced small magnitude (≤2-fold) 
increases in susceptibility in UPEC whilst triclosan induced a large frequency and 
magnitude of susceptibility decreases. Both BAC and silver nitrate only induced minor 
reductions in susceptibility. Exposure to cinnamaldehyde and furanone C30 induced 
high frequency of significant increases in susceptibility. For F-DPD, there was only one 
case of decreased susceptibility.  
Genomic data can be utilised to identify potential mechanisms that contribute to our 
observed reductions in biocide susceptibility. Whole genome sequencing of the parent 
EC958 isolate and antimicrobial exposed isolates, revealed mutations in the triclosan 
target enzyme fabI that could be contributing to triclosan resistance [80]. The 
transcriptomic data also revealed possible mechanisms of increased susceptibility seen 
in the PHMB, cinnamaldehyde, and furanone C30 exposed isolates. The gene mltA 
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which is involved in peptidoglycan synthesis, was downregulated in the all of the 
aforementioned isolates which would lead to impairment of cell wall formation, the 
resulting loss of integrity may increase antimicrobial susceptibility. For the PHMB 
exposed isolate there was also an upregulation of peptidoglycan-binding protein lysM, 
these domain have multiple functions which include peptidoglycan degradation [269]. 
This would also contribute to loss of integrity of the cell wall increasing susceptibility. 
It has been questioned whether bacteria can become resistant to QSI's and research has 
found that there are in fact numerous ways that bacteria can evolve to overcome QS 
inhibition such as: utilisation of multiple QS systems, efflux pumps, and mutation of QS 
system pathways [300]. There was only one case of increased resistance observed for F-
DPD exposed EC34. RNA sequencing of F-DPD exposed EC958 revealed increased 
expression of mepS, a murein endopeptidase involved in peptidoglycan synthesis, and 
downregulation of lysM which would increase peptidoglycan synthesis and 
incorporation into the cell wall. The mechanism of F-DPD bactericidal activity is not 
currently know but common resistance mechanisms such as decreased cell wall 
permeability have been previously associated with reduced antimicrobial susceptibility 
and could explain the decreased susceptibility seen in this study. 
Biofilm formation and susceptibility was assessed using crystal viole t assay and MBEC 
assay. PHMB exposure led to a significant decrease in biofilm formation for two 
isolates which did not correspond with decreases in MBEC. All isolates that increased 
in biofilm formation after triclosan exposure also exhibited an elevation in MBEC. A 
high number of isolates were observed to form increased biofilm biomass after BAC 
exposure and 6 had a corresponding increase in MBEC. Silver nitrate exposure led to 1 
increase in MBEC and 1 decrease, and 1 (non-corresponding) increase in biofilm 
formation. All isolates decreased in MBEC after cinnamaldehyde exposure which 
corresponded to 1/8 decreases in biofilm formation and 6/8 increased biofilm formation. 
For furanone C30 exposure, 6/8 decreased MBEC with 1 corresponding decrease in 
biofilm formation and a further 2 increases in biofilm formation. F-DPD did not induce 
any change in MBEC after exposure and induced only 1 increase in biofilm formation.  
In terms of the underlying molecular mechanisms that govern our observed changes in 
biofilm formation, Antigen 43 (ag43) was upregulated after exposure to BAC and 
cinnamaldehyde which correlated with increased biofilm formation in these isolates.  
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Antigen 43  is a self-recognizing adhesin that is associated with cell aggregation and 
biofilm formation in E. coli K-12 [256]. An upregulation of this gene would likely 
confer increased biofilm formation to these isolates which is what we see here. 
PHMB exposure induced significantly decreased relative pathogenicity in 3/8 isolates 
and a significant increase in pathogenicity for 1/8 in the G. mellonella model when 
compared to the respective control isolate (C12). When exposed to PHMB, 5/8 isolates 
showed an increase in SMC invasion. For HUEPC, exposure to PHMB induced 
increased invasion in 1/8 isolates. BAC exposure induced significantly decreased 
pathogenicity in 6/8 isolates and significantly increased pathogenicity in 1/8. Exposure 
to BAC induced an increase in invasion in 1/8 isolates for SMC and induced increases 
in HUEPC invasion for 2/8 isolates. Silver nitrate was the only biocide to only induce 
significant increases in pathogenicity which occurred in 2/8 isolates and 1/8 isolates 
showed increases in HUEPC invasion. Triclosan was the only biocide to induce only 
significant decreases in pathogenicity which occurred in 5/8 isolates. For HUEPC 
invasion, triclosan exposure induced increased invasion in 2/8 isolates. In the G. 
mellonella model cinnamaldehyde exposure induced significantly increased relative 
pathogenicity in 4/8 isolates and there was increased HUEPC invasion in 1/8 isolates. 
Furanone C30 was the only QSI to induce only significant decreases in pathogenicity in 
G. mellonella which occurred in 6/8 isolates. Furanone C30 exposure induced increased 
HUEPC invasion in EC34. F-DPD exposure induced significantly increased 
pathogenicity in 2/8 isolates and significantly decreased pathogenicity in 2/8 isolates in 
the G. mellonella model. F-DPD induced a decrease in SMC invasion in EC26 when 
compared to the respective control strain. 
The decreased pathogenicity in the triclosan exposed isolate could be explained by the 
mutation in wbbL that is involved in O antigen biosynthesis which is an important 
virulence factor [255]. We did observe increase in expression of Type 1 fimbriae 
fimA,C,D in the triclosan exposed isolate EC958. Type 1 fimbriae are structures that are 
used by UPEC to attach and invade into cells [25]. So an increase in expression would 
be expected to potentially cause an increase in cell invasion, however, the EC958 isolate 
did not show increased invasion after triclosan exposure.  In the cinnamaldehyde 
exposed strain EC958 there was an increased expression in tonB a key virulence factor 
[25]. Whilst it may be expected that this would correlate to increased pathogenicity, 
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EC958 did not increase in pathogenicity after cinnamaldehyde exposure. RNA 
sequencing of the furanone C30 exposed isolate revealed a decrease in expression of 
secY. SecY supports the posttranslational translocation of proOmpA across the 
cytoplasmic membrane [297]. OmpA is a very important UPEC virulence factor [298], 
it also acts as an adhesin and invasin [259] so this may explain the decreased 
pathogenicity seen after furanone C30 exposure. 
When determining sensitivity to antibiotics there were 16 cases of antibiotic cross 
resistance observed. PHMB exposure induced 2 cases of cross resistance, triclosan 
induced 3, BAC induced 1, silver nitrate induced 1, cinnamaldehyde induced 3, 
furanone C30 induced 4, and F-DPD induced 2. Antimicrobial exposure induced 
increases in the transcription of numerous transporters including multidrug resistance 
transporters, mdtE in the PHMB exposed strain of EC958 and marA and mdtN for the 
cinnamaldehyde exposed strain of EC958. Out of the isolates that were sent for genetic 
sequencing, only the triclosan exposed strain EC958 acquired full cross resistance to an 
antibiotic (nitrofurantoin). Downregulation of potE, which has been shown to be 
involved in the uptake antibiotics into the cell [252], was observed in this isolate but 
this is not a resistance mechanism for this particular antibiotic. 
On average, the QSI's induced more cases of cross-resistance than the biocides.  
Quorum sensing is thought to play a significant role in antibiotic tolerance of bacteria 
[301], inhibition of the AI-2 QS pathway by DPD analogues has been shown to increase 
rifampicin resistance by modulating LuxS mediated methylation of mutational hotspots 
[63]. In the RNA sequencing data downregulation of aidB (DNA alkylation response 
protein) was observed. Alkylation is another mechanism of DNA mutagenesis [302] so 
downregulation of this repair system could also possibly lead to cross resistance through 
increased mutation rate. In contrast, research by Brackman et al. [71] showed that use of 
QSI's increased the susceptibility of bacteria to antibiotics. However this was not long-
term exposure but combination treatment and different quorum sensing systems were 
targeted (AHL and agr systems) so is not directly comparable to this study. 
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6.3.0 The effects of long term exposure to biocides and QSI's in a catheter biofilm 
model  
When grown on a catheter surface, exposure to PHMB caused decreased biofilm 
formation in 4/8 isolates. When repeatedly exposed to BAC, 3/8 isolates demonstrated a 
significant decrease in biofilm formation. Silver Nitrate induced decreased biofilm 
formation in 3/8 isolates. Triclosan exposure decreased biofilm formation in 3/8 isolates 
and increased biofilm formation in 1/8 isolates. Biofilm formation in 2/8 isolates 
decreased when exposed to cinnamaldehyde and exposure to F-DPD induced decreased 
biofilm formation in 3/8 isolates. When exposed to furanone C30, 3/8 isolates showed a 
significant decrease in biofilm formation.  
Impaired motility by downregulation of flagella associated genes occurred after 
exposure to PHMB, BAC, cinnamaldehyde and F-DPD. Flagella are an important factor 
in the initiation of bacterial biofilm formation [257] so loss of these structures would 
suggest that the ability of these isolates to form biofilms may be impaired.  
The results for the biofilm formation on catheters differs from the biofilm formation 
experiments performed in 96 well plates (see above). The topography (the arrangement 
of physical features) of a surface has been shown to be an important factor in the ability 
of bacteria to attach to a surface and form biofilms [303]. In a study by Feng et al. 
E.coli were unable to form biofilms on surfaces with pores 15 - 25 nm in diameter [304]. 
The surface of a catheter would differ from a polystyrene plate which could explain the 
discrepancy in results. Another factor could be that the catheter pieces were transferred 
into fresh media after 24 hours. Thereby selecting the adhered bacterial populations and 
promoting biofilm growth, while the plate based assays were performed in batch culture.  
Having continuous supply of nutrients has been shown to significantly impact biofilm 
formation as opposed to limited nutrients, as traditionally found in batch culture [305].  
6.4.0 Antimicrobial efficacy and biocompatibility of biocide and QSI containing 
polymer coatings for urinary catheters 
Agar overlay and disc diffusion experiments were carried out to determine the overall 
biocompatibility of the antimicrobial agents when incorporated into three polymer 
coatings (sol gel, PEG, and pHEMA). On average, sol gel had the highest 
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biocompatibility values followed by PEG and pHEMA. Sol gel coatings are widely 
regarded as having a high degree of biocompatibility [233].  
The order of cytotoxicity in relation to the compound concentration was silver nitrate > 
PHMB > F-DPD > BAC > cinnamaldehyde > triclosan > furanone C30. BI values for 
the eight isolates were averaged for each compound and the final ranked order of BI 
was PHMB > furanone C30 > cinnamaldehyde > triclosan > BAC > silver nitrate > F-
DPD indicating the antiseptic potential of the compounds. When incorporated into the 
coatings these BI values changed to: furanone C30 > triclosan > silver nitrate > 
cinnamaldehyde > PHMB > BAC = F-DPD for sol gel, triclosan > cinnamaldehyde > 
PHMB > F-DPD > silver nitrate > BAC > furanone C30 for PEG, and triclosan > silver 
nitrate > BAC > PHMB = cinnamaldehyde = furanone C30 = F-DPD for pHEMA. This 
highlights the significant change in biocompatibility once the antimicrobials are 
changed from a planktonic suspension to a coated surface.  
The polymer coatings will have a variety of physio-chemical properties (e.g. 
hydrophilicity or hydrophobicity, lubricity, smoothness, surface energy, wettability, surface 
roughness, swelling, electrostatic effects, solubility, degradability, thermal and mechanical 
stability [306]) that would all affect the biocompatibility of the coating even without the 
addition of the antimicrobial agents. How antimicrobials elute out of the coating would also 
make a difference. For example pHEMA hydrogels initially elute the majority of 
incorporated antimicrobial when first hydrated [220], whereas PEG and sol gel coatings 
both have a sustained release profile, sustained release is associated with higher 
biocompatibility, as you are not introducing a high concentration of antimicrobial in a 
short time frame [235]. As sol gel had the highest biocompatibility values of the three 
coatings, it was taken forward for further evaluation on the drip flow biofilm reactor. 
The order of antimicrobial efficacy for the biofilm reactor in terms of reduction in 
biofilm growth was found to be PHMB > furanone C30 > silver nitrate > F-DPD > 
cinnamaldehyde > BAC > triclosan. This was intriguing as, up to this point, triclosan 
was performing as one of the most potent antimicrobials. It could be hypothesised that 
due to the fact that triclosan is a relatively small molecule that it eluted out of the sol gel 
in a short period of time and was washed away within the drip flow reactor, allowing 
any residual bacteria to repopulate. This highlights the importance of selecting a release 
strategy that complements the antimicrobial being incorporated.   
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It is well understood that as a biofilm matures antimicrobial susceptibility decreases. A 
previous study comparing biofilm eradication with antibiotics in 96 well plate and 
biofilm reactor conditions revealed that in biofilm reactor, bacteria were significantly 
more tolerant to antibiotics than in the well plate [305]. It was concluded that the main 
reason for this difference was the presence or absence of flow of nutrients to the biofilm 
[305]. Continuous fresh nutrients would allow the biofilm to continue to develop and 
would facilitate the removal of waste products. The fluid dynamics of our test systems 
may also have an effect: P. aeruginosa biofilms treated with cationic surfactant 
cetyltrimethylammonium bromide (CTAB) that were formed under laminar flow were 
more susceptible than those formed under turbulent flow [307]. Experiments with the 
drip flow biofilm reactor can produce varied data depending on environmental 
conditions e.g. biofilms of mono-culture grew in single layers whereas multi-species 
biofilms grew in multilayers [308]. It is clear that choosing the right experimental 
model with conditions closest to the clinical environment is incredibly important when 
evaluating anti-infective coatings for medical devices. 
6.5.0 Future Directions 
Although this study comprises a fairly comprehensive overview of the long term effects 
of the antimicrobial coatings tested, there is still much that could be explored. More 
detailed insight into the impact of antimicrobial exposure on bacteria could be obtained 
through proteomic analysis of the unexposed and exposed isolates selected for during 
this study. This would complement our transcriptional analysis and allow us to 
determine if the changes in gene expression that we observed translated into changes in 
protein expression. This would give information of the mechanisms that render the 
bacteria less susceptible towards an antimicrobial agent, but also of any other induced 
changes in the bacteria seen in this study.  Similarly, there are a number of genes 
identified in this study that warrant further investigation. Notably the upregulation of 
antigen 43 in numerous biocide exposed isolates correlating to changes in biofilm 
formation is an interesting phenomenon. Antigen 43 has also been linked to increased 
virulence in UPEC [256]. A more detailed investigation of role of antigen 43 in 
antimicrobial adaptation and the consequence of this on bacterial virulence, potentially 
through use of site-directed mutagenesis, would be an area for future work.  
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Inductively coupled plasma mass spectrometry (ICP-MS) can be used to measure the 
elution of the antimicrobials out of the polymer coatings; this will provide valuable 
insight into the mechanism of elution and the antimicrobial lifespan of the coatings. By 
understanding the elution profiles of our antimicrobials we would be able to manipulate 
their release through changes in the sol-gel formulation and thereby maximise their 
activity. 
Once the antimicrobial sol-gel coatings have been optimised, it would be interesting to 
more fully evaluate their anti-biofilm activity. Transfecting the UPEC isolates with a 
GFP plasmid would enable visualisation of the bacteria on the surface of coated catheter 
sections via confocal microscopy; this would give us more information about the 
efficacy of the coatings and their impact on biofilm architecture. 
Comparing the potential synergistic activity of the biocides and QSIs could provide 
beneficial data. By incorporating both agents into the device surface we may be able to 
disrupt biofilm formation allowing eradication of any residual bacteria at relatively 
lower biocide concentrations, thus avoiding any cytotoxic effects of the biocides which 
may be observed at biofilm eradication concentrations.  
The in vivo efficacy of any medically coated device would need to be evaluated, both in 
animal models and clinical trials, if the coating is to be used as a commercial product. In 
vitro susceptibility testing, whilst giving a good indication of bacterial response, is 
simplified and does not take into account the vast array of physiologica l conditions 
experienced during infection. Catheter infection models have already been developed in 
mice [309] so this would be something that could be taken further. Also, the 
experiments carried out in this study were carried out using only single isolates of 
UPEC and CAUTI is frequently associated with a mixed flora and may involve multiple 
interactions between microorganisms that cannot be accounted for in this type of 
assessment therefore experiments using mixed bacterial communities should be carried 
out. 
6.6.0 Conclusion  
Uropathogenic E.coli (UPEC) are the major causative agent of CAUTI which are 
becoming an increasing burden on healthcare providers due to antibiotic resistance and 
an aging population. Anti- infective coatings to prevent formation of bacterial biofilm on 
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the surface of the catheter are in clinical use but have limited effectiveness. The short-
lived efficacy of these coatings are in part likely to be associated with the induction of 
biocide insusceptibility in bacterial pathogens. New coatings that display good 
antimicrobial efficacy and low cytotoxicity should be developed but the long-term 
impact of these coatings needs to be adequately assessed. The effects of long term 
exposure of UPEC to 7 antimicrobials (both biocides and QSIs) was determined. 
Multiple phenotypic adaptations were observed both in planktonic and biofilm growth 
and corroborated using genotypic and transcriptomic analysis. Furthermore, three 
polymers were evaluated for their potential as a catheter coating and evaluated using a 
biofilm reactor model.  
Whilst reductions in antimicrobial susceptibility were evident, this was often coupled to 
other phenotypic effects including changes in biofilm formation and pathogenicity. This 
demonstrates the importance in both choosing appropriate methods to evaluate anti-
infective coatings and highlights a need to take a multi- faceted approach to risk 
assessment when predicting their long-term consequence in patients. 
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Table 9.1 Position of single nucleotide polymorphisms identified in the full genome sequencing of seven exposed isolates of EC958 compared 
to the unexposed control.  
Gene 
name 
Gene Size 
(bp) 
Location of SNP (bp) 
  PHMB Triclosan BAC Silver Nitrate Cinnamaldehyde Furanone C30 F-DPD 
recE1 2601 
175, 535, 536, 
830  
535, 536, 830 535, 536, 830 
175, 535, 536, 
830 
535, 536, 830 535, 536, 830 
175, 535, 536, 
830 
yeeP 864 
222, 292, 595, 
610, 822 
222, 292, 595, 
610, 822  
222, 292, 595, 
610, 822  
222, 292, 595, 
610, 822  
222, 292, 595, 610, 
822  
222, 292, 595, 
610, 822  
222, 292, 595, 
610, 822  
tnpA 1263 828 828 828 828 828 828 828 
entS 1251 448, 870, 961 448, 870, 961 961 448, 870, 961 448, 870, 961 
448, 870, 961, 
1164 
448, 870, 961 
insB 504 136, 323  136, 323 136, 323 136, 323 136, 323 136, 323 136, 323 
iss 294 144, 229 144, 229  144, 229 144, 229 144, 229 144, 229 
yeeD 228 3, 10  3, 10  3, 10 3, 10 3, 10  
alpA 213 7, 101 7, 101 7, 101 7, 101 7, 101 7, 101 7, 101 
fabI 789  604      
wbbL 795  121      
murJ 1536  806      
cspE 210   187     
ldrD2 108   86     
ldrD3 108       86 
fadA 1164    743    
gadB 1401  
370, 526, 539, 
589, 655 
 
370, 526, 539, 
589, 655 
370, 526, 539, 589, 
655 
370, 526, 539, 
589, 655 
370, 526, 539, 
589, 655 
proQ 699     328   
lpd 1425     39   
dnaX 1932     1564   
tonB 720     110   
mntP 567      427  
rsxC 2223       1883 
yfhH 849       361 
flu 389 
134, 182, 191, 
333, 364 
134, 182, 191, 
333, 364 
134, 182, 191, 
333, 364 
134, 182, 191, 
333, 364 
134, 182, 191, 333, 
364 
134, 182, 191, 
333, 364 
134, 182, 191, 
333, 364 
  
 
Gene Product Gene Name PHMB Triclosan BAC Silver nitrate Cinnamaldehyde 
Furanone 
C30 
F-DPD 
[citrate (pro-3S)-lyase] ligase citC         1.16809445     
1-(5-phosphoribosyl)-5-[(5- 
phosphoribosylamino)methylideneamino]imidazole-4- 
carboxamide isomerase hisA     -1.44642         
1,4-dihydroxy-2-naphthoyl-CoA synthase menB     -1.00867         
10 kDa chaperonin groES         -2.310612923     
1-pyrroline dehydrogenase   1.444561 1.038662   1.403760771       
2,3-bisphosphoglycerate-independent phosphoglycerate 
mutase gpmI -1.21346     -1.522463598 -1.233188273     
2,5-diketo-D-gluconate reductase A dkgA 1.420137             
23S rRNA pseudouridine synthase E rluE         -1.351049065     
23S rRNA pseudouridylate synthase B rluB           -1.116090514   
2'-5' RNA ligase   1.714171 1.578466           
2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase ispF     -1.24897   -1.063203493     
2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase ispD         1.009354875     
2-Cys peroxiredoxin tpx         1.159104772     
2-dehydro-3-deoxy-6-phosphogalactonate aldolase dgoA 2.874909 1.5404 2.236014 1.972597734 1.4771281 2.689877369   
2-deoxyribose-5-phosphate aldolase deoC           1.100350819   
2-hydroxy-3-oxopropionate reductase garR -3.23155 5.484397 3.964862 -3.131713076 -1.86660665 -1.786009102   
2-hydroxy-3-oxopropionate reductase glxR       2.941784872 4.643161487 5.018143166 2.75739 
2-methylcitrate dehydratase 
prpD; 
mmgE   -1.12799         -1.01523 
2-oxoglutarate dehydrogenase subunit E1 sucA       1.198951029 1.14293087     
2-succinyl-5-enolpyruvyl-6-hydroxy-3- cyclohexene-1-
carboxylic-acid synthase menD     -1.09244         
2-succinylbenzoate-CoA ligase menE     -1.10516         
30S ribosomal protein rpsV 1.831126             
  
 
30S ribosomal protein S1 rpsA           -1.19196478   
30S ribosomal protein S11 rpsK     -1.47585     -1.429954085   
30S ribosomal protein S13 rpsM     -1.12972     -1.180682361   
30S ribosomal protein S14 rpsN     -1.14466   -1.030232607 -1.082494456   
30S ribosomal protein S15 rpsO       -1.001262476   -1.005409204   
30S ribosomal protein S17 rpsQ   -1.21567 -1.43211     -1.666356626   
30S ribosomal protein S18 rpsR     -1.22592   -1.33652143 -1.213549098   
30S ribosomal protein S19 rpsS     -1.74934   -1.159559291 -1.532937506   
30S ribosomal protein S2 rpsB           -1.293329798   
30S ribosomal protein S20 rpsT       -1.180615927       
30S ribosomal protein S3 rpsC     -1.73253     -1.620294829   
30S ribosomal protein S4 rpsD     -1.27738     -1.224962074   
30S ribosomal protein S5 rpsE     -1.54199   -1.135784995 -1.252538051   
30S ribosomal protein S6 rpsF     -1.18541   -1.556098676 -1.076156616   
30S ribosomal protein S8 rpsH     -1.17307   -1.110666739 -1.095071297   
30S ribosomal protein S9 rpsI           -1.310800278   
3-deoxy-manno-octulosonate cytidylyltransferase kdsB -1.00144   -1.40791   -1.311342939 -1.000112264   
3-ketoacyl-CoA thiolase fadA       1.134335176       
3-oxoacyl-ACP synthase I fadB   -1.17539           
4-alpha-glucanotransferase malQ -1.51841 -1.36164   -1.864476168       
4-amino-4-deoxy-L-arabinose lipid A transferase arnT     -1.03045         
4-aminobutyrate aminotransferase gabT 1.826855 1.33875   2.120603342 -1.314105035   -1.61882 
4-deoxy-4-formamido-L-arabinose- phosphoundecaprenol 
deformylase ArnD arnD     -1.49571         
5-(carboxyamino)imidazole ribonucleotide synthase purK   1.227298 1.464015 2.127298466   1.254656717   
50S ribosomal protein L1 rplA           -1.028064134   
50S ribosomal protein L15 rplO   -1.46824 -2.04566   -1.086026821 -1.626519973 -1.44876 
  
 
50S ribosomal protein L16 rplP   -1.01205 -1.65238     -1.653473007   
50S ribosomal protein L17 rplQ     -1.04097 -1.028106502   -1.349466308   
50S ribosomal protein L18 rplR     -1.58002   -1.237951548 -1.450589297   
50S ribosomal protein L2 rplB     -1.92057   -1.200612652 -1.65122741   
50S ribosomal protein L20 rplT           -1.078353557   
50S ribosomal protein L22 rplV   -1.0069 -1.9257   -1.220454975 -1.697205488   
50S ribosomal protein L23 rplW     -1.64564   -1.050394094 -1.33320688   
50S ribosomal protein L25 rplY       -1.628564893 -1.377747225     
50S ribosomal protein L28 rpmB       -1.155478457   -1.041489705   
50S ribosomal protein L29 rpmC   -1.28014 -1.47482     -1.711052068   
50S ribosomal protein L3 rplC     -1.30582     -1.223458411   
50S ribosomal protein L30 rpmD   -1.22959 -1.79843   -1.118659501 -1.513073683   
50S ribosomal protein L31 type B ykgM         1.935360576 1.015600104   
50S ribosomal protein L4 rplD     -1.67878   -1.143041125 -1.454587806   
50S ribosomal protein L5 rplE     -1.1121     -1.081241426   
50S ribosomal protein L6 rplF     -1.29644   -1.147790715 -1.229610554   
50S ribosomal protein L9 rplI     -1.35484   -1.224486129 -1.44226617   
5-hydroxyisourate hydrolase hiuH         1.146347076     
5-keto-4-deoxy-D-glucarate aldolase garL -2.75964     -2.931733744 -2.008820976 -1.104624822   
6-phosphogluconolactonase pgl     -1.05628         
7-alpha-hydroxysteroid dehydrogenase hdhA 1.336381     1.040030273   1.308030441   
7-cyano-7-deazaguanine synthase queC   -1.20112           
ABC transporter ATP-binding protein sufC 1.341158 1.254164     -1.374102694     
ABC transporter ATP-binding protein           -1.190839498     
ABC transporter permease   1.871876 1.116964 -1.77753 1.737642908 -1.372355102 1.198658616   
ABC transporter substrate-binding protein   1.142414   -1.1976 1.209524574 1.645268116 1.995362659 -1.01297 
ABC transporter substrate-binding protein   1.066338   1.548703 2.330193863   1.286461683   
  
 
ABC transporter substrate-binding protein   2.951338     1.608735498       
ABC transporter substrate-binding protein   2.017172             
acetoacetate metabolism regulatory protein AtoC atoC         1.308087919 1.329818347   
acetyl-CoA--acetoacetyl-CoA transferase subunit alpha atoD     1.405937         
acetyl-coenzyme A synthetase acs 2.247153 2.296064 1.12442 2.440046655 1.508443584 1.063430789   
acetylesterase aes         1.076036214     
acetylglutamate kinase argB   1.103282 -1.11514         
acetylornithine aminotransferase argD 1.834893 1.600074 1.067413 1.959973467       
acetyltransferase         1.068414864       
acid stress chaperone HdeB hdeB 2.477095   -2.71022 1.038579085 -1.015538793   -1.65106 
acid stress protein IbaG ibaG         -1.127971925     
acid-resistance protein HdeA hdeA 2.266714   -2.89704 1.035602689 -1.369620592   -1.7355 
acid-resistance protein HdeD hdeD 1.658105   -3.29673   -2.297380649   -2.26446 
acid-shock protein           1.149192399     
ACP phosphodiesterase acpH         -1.131024505     
acrEF/envCD operon repressor envR     1.102309         
acyl-coenzyme A dehydrogenase fadE 1.020996       1.211244424     
adenosine deaminase add   -1.13726 -1.41387 -1.098748079 -1.407062204     
adenosylcobinamide-GDP ribazoletransferase cobS   -1.32791           
adenylate kinase adk         -1.28779872     
adenylyl-sulfate kinase cysC 1.449152   1.364652   2.111373905 1.105314339   
aerotaxis receptor         1.163153694     -1.02587 
AfaC protein afaC   -2.8207     1.43468877   2.591368 
AfaE protein afaE         1.355883772   1.004838 
alanine racemase alr       1.094049557       
alcohol dehydrogenase           1.025708304     
aldehyde dehydrogenase   1.306282     1.027312398 1.044629625   -1.35885 
  
 
aldehyde dehydrogenase           1.125533382     
aldehyde dehydrogenase           -2.147439647     
aldehyde reductase Ahr ahr   1.029725 -1.47058   -3.385406615   -1.80015 
aldose isomerase   1.168262 -2.30442 -1.57799         
alkyl hydroperoxide reductase subunit C ahpC       -1.191743323       
allantoin permease allP 3.8272 4.783063 3.190361 3.63888144 4.418254293 4.766017366 1.808667 
alpha/beta hydrolase           1.335109425     
alpha-amylase malS -1.73299   -1.45695 -1.817010463 -3.921428013   -1.94561 
alpha-glycosidase aglB -1.92397 -1.19357   -1.719947721   -1.206456678   
alpha-ketoglutarate transporter         1.077564254       
altronate hydrolase uxaA         1.312644974     
amidophosphoribosyltransferase purF     1.236614 1.676717484   1.140688513   
amino acid ABC transporter permease   1.163996         1.009576433   
amino acid ABC transporter permease   1.235737             
amino acid ABC transporter substrate-binding protein   1.249931     1.683464379 1.095464849     
amino acid ABC transporter substrate-binding protein   1.138493 1.163659   1.030154159       
amino acid permease   1.86934     1.595100469       
amino acid permease   1.081148             
amino acid transporter   1.341336 1.668109 1.046651 1.608289332 1.370168232     
aminopeptidase PepB pepB     -1.117         
ammonium transporter amtB         1.437101475     
anaerobic C4-dicarboxylate transporter DcuB dcuB -1.96738 -1.87326   -3.082431438       
anaerobic C4-dicarboxylate transporter DcuC dcuC   -1.11558   -1.550365413       
anaerobic glycerol-3-phosphate dehydrogenase subunit B glpB         1.412832318     
anaerobic sulfatase maturase       1.341162   2.182842477     
anaerobic sulfatase maturase             2.214274875   
anti-adapter protein IraD iraD         1.556798714     
  
 
antigen 43 flu     4.47401 4.803497926 1.135426671   -1.20156 
antiporter       -2.54033 1.953678198 -1.710649992 1.072925758 -2.16105 
antiporter       -1.18131 -1.73031499       
antiporter uhpT         1.05004768     
antitoxin       1.055057         
antitoxin ChpS chpS 1.209175       1.085214294     
antitoxin PrlF prlF     1.05521 -1.248050736       
apo-citrate lyase phosphoribosyl-dephospho-CoA 
transferase citX -2.21409 -1.71036 -1.55414 -2.039623371 -1.278711792     
arabinose ABC transporter substrate-binding protein araF   -1.03576     1.189737742     
AraC family transcriptional regulator           1.434049946   -1.13859 
AraC family transcriptional regulator           -1.258937216     
AraC family transcriptional regulator           1.554699817     
arginine ABC transporter ATP-binding protein   1.367328             
arginine ABC transporter permease ArtQ artQ         -1.000386038     
arginine decarboxylase           -1.028336407     
arginine N-succinyltransferase astA 1.815495 1.534846 1.084137 2.034019267 1.184467202     
arginine transport ATP-binding protein ArtP artP       1.062400873       
arginine:agmatine antiporter adiC -1.20646   -1.00099 -1.355293522 -1.020229521     
asparagine synthetase A asnA       1.363531516       
aspartate carbamoyltransferase catalytic subunit pyrB -1.06494 -1.06963   -1.222767917       
aspartate carbamoyltransferase regulatory subunit pyrI   -1.04631           
aspartate-semialdehyde dehydrogenase asd   -1.18773           
aspartate--tRNA ligase aspS         -1.142620767     
ATP-binding protein           -1.724693301   -1.26511 
ATP-dependent RNA helicase           -1.170145595     
ATP-dependent RNA helicase RhlE rhlE         -1.714668148     
  
 
ATP-dependent RNA helicase SrmB srmB         -1.127056998     
ATP-independent periplasmic protein-refolding 
chaperone spy   1.737543 1.352764         
autonomous glycyl radical cofactor GrcA grcA   -1.63167   -1.098330934       
bacterioferritin bfr 1.672041     1.122509556 -2.542938475 1.012768593 -1.50697 
bacterioferritin-associated ferredoxin bfd     1.058145         
barnase inhibitor yhcO         -1.302293212     
baseplate assembly protein           -1.059862019     
baseplate assembly protein           -1.13200352     
baseplate protein             -1.220229697   
beta-glucuronidase uidA 1.485712     1.169642002   1.047702579   
beta-hydroxydecanoyl-ACP dehydratase fabA -1.21934         -1.0930889   
bifunctional glucose-1-phosphatase/inositol phosphatase agp         1.110304254     
bifunctional imidazole glycerol-phosphate 
dehydratase/histidinol phosphatase hisB     -1.2281         
bifunctional isocitrate dehydrogenase kinase/phosphatase aceK 1.34082 1.205086   1.967817577       
bifunctional 
phosphoribosylaminoimidazolecarboxamide 
formyltransferase/inosine monophosphate 
cyclohydrolase purH   1.108741 1.486147 1.342942298   1.425663559   
bifunctional protein PutA putA 1.343935 1.314752   2.499074033       
bifunctional UDP-glucuronic acid oxidase/UDP-4-amino-
4-deoxy-L-arabinose formyltransferase       -1.73362         
biofilm regulator BssR bssR 1.514282     1.298997828 2.283179479     
biopolymer transporter ExbB exbB -1.0595             
bis(5'-nucleosyl)-tetraphosphatase (symmetrical) apaH         -1.20289525     
BlaEC family class C beta-lactamase         -1.016028515       
branched chain amino acid ABC transporter substrate-
binding protein     1.130094   1.109597307       
  
 
branched chain amino acid ABC transporter substrate-
binding protein     1.747837           
C4-dicarboxylate ABC transporter   1.171995     1.654275289       
C4-dicarboxylate ABC transporter permease   1.389984       1.18835249     
C4-dicarboxylate ABC transporter permease           1.09091475 1.22748116   
C4-dicarboxylate ABC transporter substrate-binding 
protein   1.033891     1.040680952 1.119262408     
C4-dicarboxylate ABC transporter substrate-binding 
protein   1.011859       1.383305389     
C4-dicarboxylate ABC transporter substrate-binding 
protein   1.160715             
carbamate kinase arcC 1.402666       1.084518789     
carbamoyl-phosphate synthase large chain carB -2.46304 -1.19064 -2.24938 -2.852347288 -2.543090814 -2.673487858   
carbamoyl-phosphate synthase small subunit carA -2.2989   -2.03899 -2.510304109 -2.409288058 -2.197759504   
carbohydrate kinase lyx     -2.3361   1.389227366     
carbon starvation induced protein   2.52098 1.031843   3.126593706 -1.161642353 1.095717455 -1.33747 
carbon starvation protein A yjiY 1.14129     1.708920647 1.854916762     
carboxymethylenebutenolidase         1.010945887       
carnitinyl-CoA dehydratase caiD     -1.4426     -1.304482445 -1.25623 
catalase HPII katE 1.361509     1.039827739 -1.224465247   -1.06304 
catalase peroxidase katG     -1.05596         
cation acetate symporter actP 1.017613     1.58829928       
cell division protein FtsL ftsL         1.041154951     
cell division protein ZapB zapB         1.15268834     
cell envelope biogenesis protein TonB tonB         1.130527202     
cell filamentation protein Fic fic         -1.535593392   -1.22583 
chaperone modulatory protein CbpM cbpM     -1.36464         
chaperone protein ClpB clpB         -1.170660507     
  
 
chemotaxis protein CheA cheA     -3.60171   -2.752982718   -3.75748 
chemotaxis protein CheR cheR     -3.58826   -2.137465152   -2.68669 
chemotaxis protein CheW cheW     -3.21408   -2.310815515   -2.91761 
chemotaxis response regulator protein-glutamate 
methylesterase cheB     -3.13862   -1.619025951   -2.94924 
chlorohydrolase/aminohydrolase ssnA 1.379886             
chromate reductase chrR6     -1.29943         
citrate (Si)-synthase gltA 1.257167     1.245182695 1.001889529     
citrate lyase ACP citD -3.4082 -2.26325 -1.04895 -2.437856098 -2.274517176   -1.29501 
citrate lyase subunit alpha citF -2.51412 -1.68348 -1.48412 -3.383296213 -2.144341319     
citrate lyase subunit beta citE -2.36379 -1.66913 -1.67948 -2.508339596 -2.1344036     
class II aldolase         1.296287066       
class II fumarate hydratase fumC 1.128007     1.074988488 1.356843161     
cold-shock protein   -1.39145   1.878404 -1.196464431       
cold-shock protein       1.665492     -1.666331042   
cold-shock protein CspD cspD 1.253809     1.024647882 2.368019732     
cold-shock protein CspE cspE -1.00681         -1.121094496   
cold-shock protein CspG cspG   1.783565 3.63428 -1.020701041   -1.018064208 1.214205 
cold-shock protein CspH cspH     2.231032       1.070326 
colicin V production protein cvpA     1.251708 1.641981206 1.444337727     
copper homeostasis protein CutC cutC         1.127885781     
crossover junction endodeoxyribonuclease RuvA ruvA         -1.140152678     
crossover junction endodeoxyribonuclease RuvC ruvC -1.03979             
Crp/Fnr family transcriptional regulator           1.072237187     
CTP synthase pyrG         -1.177882954     
c-type cytochrome biogenesis protein CcmF ccmF   -2.98523 -1.09124         
curli production assembly/transport component CsgE csgE         1.118975628     
  
 
cyclic amidohydrolase   3.772421 3.895695 2.366878 4.04417938 3.674727214 4.322204141 1.339718 
cyclic di-GMP phosphodiesterase       1.033999   1.066877555     
cyclic-guanylate-specific phosphodiesterase       -3.61174   -2.778750569   -3.76161 
cyd operon protein YbgE ybgE   -1.09213           
cysteine desulfurase   1.035085 1.276611     -1.053722693     
cysteine desulfuration protein SufE sufE 1.189079 1.218943           
cysteine synthase A cysK         1.781142774     
cysteine synthase B cysM   1.024106           
cysteine/O-acetylserine efflux protein eamB       -1.086798899       
cytochrome bd oxidase subunit I       -1.01743   -1.348195708     
cytochrome bd-I ubiquinol oxidase subunit 1 cydA   -1.16457           
cytochrome bd-I ubiquinol oxidase subunit 2 cydB   -1.13893           
cytochrome bd-I ubiquinol oxidase subunit X cydX   -1.21438           
cytochrome bo(3) ubiquinol oxidase subunit 3 cyoC       1.117706284       
cytochrome c nitrite reductase Fe-S protein           1.256565748     
cytochrome C nitrite reductase pentaheme subunit nrfB         1.008054035 1.09030139   
cytochrome c nitrite reductase subunit NrfD nrfD         1.238316792     
cytochrome c-type biogenesis protein CcmE ccmE   -2.08492           
cytochrome c-type biogenesis protein CcmH ccmH   -2.41762   -1.052621066       
cytochrome c-type protein NapC napC   -2.89464           
cytochrome o ubiquinol oxidase subunit IV         1.001055686       
cytochrome ubiquinol oxidase subunit I         1.297980385       
cytochrome ubiquinol oxidase subunit II         1.185581474       
cytochrome-c peroxidase           1.755665482     
D-alanyl-D-alanine carboxypeptidase dacD     -1.17813       -1.04937 
D-amino acid dehydrogenase small subunit   1.093984     1.735825869 1.205829588     
DEAD/DEAH box family ATP-dependent RNA helicase           -1.096299571 -1.148671314   
  
 
dehydratase           1.429403113     
dethiobiotin synthase bioD       -1.281803834       
D-galactarate dehydratase garD -2.44282   1.240067 -2.396151897       
dienelactone hydrolase       -1.0651   -1.150420384   -1.14432 
diguanylate phosphodiesterase yhjH   1.48369           
dihydrodipicolinate synthase family protein   1.493167       1.247962322     
dihydrolipoamide succinyltransferase sucB   1.055291           
dihydrolipoyllysine-residue acetyltransferase component 
of pyruvate dehydrogenase complex aceF -1.38858 -1.55078 -2.10756 -1.628558172 -1.136276565 -1.581398695 -1.10527 
dihydroorotase pyrC         -1.055110241     
dihydropyrimidine dehydrogenase subunit A preA   -1.0114 -1.25188   1.212241122     
dihydropyrimidine dehydrogenase subunit B preT   -1.17019 -1.38855   1.350152221     
dihydroxyacetone kinase subunit DhaK dhaK         1.091863232 1.042566592   
dihydroxyacetone kinase subunit DhaL dhaL         1.107321778 1.012549766   
dihydroxyacetone kinase subunit DhaM dhaM         1.234198049     
dimethylsulfoxide reductase   1.22579     1.08527203       
dimethylsulfoxide reductase subunit A         -1.361289092       
dipeptide transport ATP-binding protein DppF dppF 2.170213 2.443573 1.184617 1.841355913   1.194537493   
DNA alkylation response protein   1.319103   -1.34063 1.193018568 -1.276221876   -1.63113 
DNA cytosine methyltransferase           -1.167483738     
DNA cytosine methyltransferase           1.07931475     
DNA gyrase inhibitor               -1.20678 
DNA replication protein DnaC dnaC         -1.246271281     
DNA-binding protein       1.222387       1.093105 
DNA-binding response regulator     -1.01673     -1.257981199     
DNA-binding response regulator           1.050156978     
DNA-binding response regulator           -1.140963115     
  
 
DNA-binding transcriptional activator,3HPP-binding           1.151767329   -1.17397 
DNA-binding transcriptional regulator DsdC dsdC         1.280278822     
DNA-binding transcriptional regulator KdgR kdgR   -1.34876           
DNA-directed RNA polymerase subunit alpha rpoA     -1.22566     -1.367012584   
DNA-directed RNA polymerase subunit beta rpoB     -1.57035   -1.462335803 -1.005579127   
DNA-directed RNA polymerase subunit beta'     -1.17885 -1.76741   -1.158398573 -1.259022844   
DNA-invertase         -1.080803659       
D-ribose ABC transporter substrate-binding protein   1.014619       1.16819799     
D-ribose pyranase rbsD         1.676995359     
D-ribose transporter ATP-binding protein rbsA         2.371816418     
D-serine/D-alanine/glycine transporter cycA   1.235808   1.351380396 1.226726629     
dTDP-4-dehydrorhamnose 3,5-epimerase rfbC     -1.62216         
dTDP-glucose 4,6-dehydratase rmlB         -1.269313279     
DUF1107 domain-containing protein           1.060128475     
DUF1198 domain-containing protein       1.017456         
DUF1338 domain-containing protein         1.050410444 -1.585753967   -1.45669 
DUF2542 domain-containing protein           1.136701274     
DUF2810 domain-containing protein   -1.03537     -1.059478815       
DUF883 domain-containing protein       -2.3966   -3.803982618   -2.67494 
DUF903 domain-containing protein     1.153178           
D-xylose ABC transporter ATP-binding protein   1.004002       2.476900936     
ECF RNA polymerase sigma-E factor rpoE -1.0213             
electron transport complex subunit A       1.020664       1.07132 
electron transport complex subunit D rnfD         -1.230107239     
electron transport complex subunit G           -1.20821718     
elongation factor 4 lepA         -1.077270531     
elongation factor G fusA           -1.023832359   
  
 
elongation factor P-like protein YeiP yeiP         -1.262986945     
elongation factor Ts tsf           -1.269146834   
endopeptidase     4.687891           
entericidin A ecnA             1.006408 
entericidin B ecnB 1.321201     1.279626158 -3.255248342   -1.06293 
ethanolamine ammonia-lyase heavy chain eutB     -1.17646       -1.29825 
ethanolamine ammonia-lyase small subunit eutC     -1.19147       -1.10137 
ethanolamine utilization protein EutA eutA     -1.06665         
ethanolamine utilization protein EutP eutP         1.35403825     
exclusion suppressor FxsA fxsA -1.74969       -1.262649609     
exodeoxyribonuclease VII large subunit xseA         -1.14149151     
FAD-binding protein ydiJ   1.331557   1.001349126       
fatty acid oxidation complex subunit alpha fadB 1.337796     1.572931993       
Fe(2+) transport protein A feoA       -1.423248504       
Fe(3+) dicitrate transport ATP-binding protein FecE fecE         -1.299491398     
fe(3+) dicitrate transporter fecA fecA   1.105877     -1.189995838     
ferredoxin     -2.6313 2.056382     1.01868493 1.304731 
ferredoxin       1.427208         
ferredoxin-type protein NapG napG   -4.05857           
ferredoxin-type protein NapH napH   -4.37382           
ferric iron reductase involved in ferric hydroximate 
transport fhuF     1.481058   2.083685832   1.145405 
ferrichrome outer membrane transporter fhuA     1.032519   1.201332944     
ferrous iron permease EfeU efeU       1.211491178 1.126186226     
ferrous iron transporter C           1.01798874     
Fe-S cluster assembly protein SufB sufB 1.374202 1.143138     -1.208143693 1.032355199 -1.18302 
FeS cluster assembly protein SufD sufD   1.07896     -1.510962201   -1.5207 
  
 
fimbrial adhesin protein           1.227415705     
fimbrial chaperone protein FimC fimC       -1.460495477       
fimbrial outer membrane usher protein           1.016962381     
fimbrial protein       1.147297         
fimbrial protein FimD fimD   1.252401           
fimbrial protein Type 1, A chain fimA   2.151372           
fimbrial yfcV yfcV 1.21276 1.02406     1.827668275     
FKBP-type peptidyl-prolyl cis-trans isomerase fkpA -1.00537             
flagella synthesis chaperone protein FlgN flgN     -1.06725       -1.22551 
flagellar assembly protein H fliH -1.42356   -1.47985   -1.464887285   -1.62078 
flagellar basal body L-ring protein flgH -1.00094   -1.15809   -1.09647634   -1.44769 
flagellar basal body rod modification protein FlgD flgD -2.07152   -2.99159   -2.421987203   -2.78106 
flagellar basal body rod protein FlgB flgB -1.35681       -1.124573106   -1.30909 
flagellar basal body rod protein FlgC flgC -2.35356   -3.83487   -2.641818714   -2.31754 
flagellar basal body rod protein FlgG flgG -1.25593   -1.24453       -1.67164 
flagellar basal-body rod protein FlgF flgF -1.08496             
flagellar biosynthesis protein FlhA flhA -1.25666   -1.01842       -1.07308 
flagellar biosynthesis protein FlhB flhB     -1.389   -1.558100008   -1.19904 
flagellar biosynthesis protein FliO fliO -1.53125   -1.92901       -1.47052 
flagellar biosynthesis protein FliR fliR     1.070856         
flagellar biosynthetic protein FliP fliP -1.09792   -1.70571   -1.588900631   -1.20238 
flagellar brake protein YcgR ycgR     -1.86587   -1.738706246   -1.69259 
flagellar capping protein fliD     -3.24274   -2.75086122   -3.16955 
flagellar export chaperone FliS fliS     -2.79478   -1.553995241   -2.32108 
flagellar hook protein FlgE flgE -1.29363   -1.56139   -1.792255711   -1.70643 
flagellar hook-associated protein 3 flgL     -1.87658   -1.179462861   -1.74504 
flagellar hook-associated protein FlgK flgK     -3.19052   -2.017976073   -2.65516 
  
 
flagellar hook-length control protein FliK fliK -1.78451   -2.49466   -2.432154514   -2.46499 
flagellar motor protein MotA motA     -2.97271   -2.246027311   -3.09566 
flagellar motor switch protein FliG fliG -1.12248   -1.67689   -1.23526912   -1.58122 
flagellar motor switch protein FliM fliM -1.6174   -2.08467   -1.997080898   -1.74744 
flagellar motor switch protein FliN fliN -2.11177   -2.9028   -2.281867819   -2.11771 
flagellar M-ring protein FliF fliF -2.54583   -2.40843   -1.964029496   -1.51139 
flagellar P-ring protein flgI -1.15992   -1.5013   -1.093739287   -1.2037 
flagellar protein fliJ fliJ -1.61916   -3.0546   -2.344725922   -2.56522 
flagellar protein fliL fliL -1.91266   -2.19794   -1.987716366   -1.90897 
flagellar protein FliT fliT     -1.39665   -1.683921962   -1.5181 
flagellar regulatory protein FliZ fliZ     -1.88889   -1.493573615   -1.75954 
flagellin fliC     -6.48211   -2.28560547   -4.75505 
flagellum-specific ATP synthase fliI -1.29987   -1.30719       -1.58307 
flavohemoprotein hmp 1.451416       1.198232011 1.168902229   
Fml fimbriae subunit fmlA -1.41202   -1.30109 -1.220985034   -1.089303994   
FMN-binding protein MioC mioC     1.225233         
formate acetyltransferase pflB   -1.4879   -1.288073411       
formate dehydrogenase-N subunit alpha fdnG -1.07216   -1.05222 -1.054218764 -1.548641123     
fructose 1,6-bisphosphatase   -1.01867     -1.029124298 1.647247854     
fructose-bisphosphate aldolase   1.560542 1.023154   1.265661466 -1.857051453     
fructose-bisphosphate aldolase gatY         2.606781815   -1.46132 
fructuronate reductase uxuB   1.146524           
fuculose phosphate aldolase fucA         1.146592349     
fumarate hydratase fumC 1.180062 -1.34245   1.478118839 -1.403356758     
fumarate hydratase 
 
-1.77265     -2.869453902       
fumarate reductase flavoprotein subunit frdA -1.27133     -1.918520696       
fumarate reductase iron-sulfur subunit frdB -1.09306     -1.675131255       
  
 
fumarate reductase subunit C frdC -1.0103     -1.524198093       
fumarate reductase subunit D frdD -1.13539     -1.381625913       
GABA permease gabP 2.2354     2.769278781       
galactonate oxidoreductase lgoD 1.451892 1.326875   1.379041012       
galactonate transporter   -2.61609   1.73194 -2.562229226 -1.780845992     
galactose ABC transporter substrate-binding protein mglB       1.70243694       
galactose/methyl galactoside import ATP-binding protein 
MglA mglA 1.309831     1.584908819 1.631405468     
galactose-proton symporter galP   1.067409           
galactoside ABC transporter permease MglC mglC       1.07073029 1.186792869     
GalU regulator GalF galF         -1.218276615     
gamma-glutamyltransferase ggt         -2.395410552   -1.55164 
geranyltranstransferase ispA         -1.093936892     
GlcNAc-PI de-N-acetylase     2.563262           
glucans biosynthesis protein C opgC; mdoC             1.088962 
glucarate dehydratase gudD -2.61433   -1.24798 -2.442871659 -2.005785742 -1.675264389   
glucarate dehydratase   -2.54197     -2.153823809 -1.481383449 -1.243312362   
glucarate transporter gudP -2.3014   1.139103 -1.800540053 -1.255322256     
glucitol operon activator protein gutM   -1.04084           
glucohydrolase   -3.98138 -1.48517   -4.813904768       
glucose-1-phosphate thymidylyltransferase 2 rffH     -1.382   -1.484963768     
glucuronide uptake porin UidC uidC   1.047674           
glutamate ABC transporter permease         1.206203888 1.182056801     
glutamate ABC transporter permease         1.236403263       
glutamate decarboxylase alpha gadA 2.062303   -2.15394 1.409579891 -1.616993947   -1.56334 
glutamate decarboxylase beta gadB 2.30645   -3.28715 1.749649747 -2.860443165   -2.32593 
glutamate--cysteine ligase gshA 1.274822       -1.692661684     
  
 
glutamate--tRNA ligase gltX         -1.214263668     
glutaminase 1 glsA1 2.074415   -1.834 1.69770846 -3.109992398 1.080811343 -2.21477 
glutamine ABC transporter permease glnP             1.272332 
glutamine amidotransferase     1.282822     -2.382913019     
glutamine amidotransferase               -1.39347 
glutamine synthetase glnA             1.219407 
glutamine--tRNA ligase glnS         -1.053463536     
glutamyl-tRNA amidotransferase   1.776669           1.032959 
glutathione ABC transporter permease       1.263066         
glutathione-dependent reductase   1.291179     1.071903695       
glutathione-regulated potassium-efflux system ancillary 
protein KefF kefF         -1.154056521     
glutathione-regulated potassium-efflux system ancillary 
protein KefG kefG         1.228491047     
glutathione-regulated potassium-efflux system protein 
KefC kefC             -1.08731 
glycerate kinase   -2.63081     -2.278301975       
glycerol-3-phosphate transporter permease glpT 1.843262     2.342955678   1.235007201   
glycerophosphoryl diester phosphodiesterase glpQ         1.3523036     
glycine cleavage system protein H gcvH         1.100117705     
glycine--tRNA ligase subunit alpha glyQ         -1.335470953     
glycogen synthase glgA 1.759589     1.223112427 2.611079807 1.066388737   
glycolate oxidase iron-sulfur subunit glcF 1.087464 1.323866   1.307560987 1.231130591     
glycolate oxidase subunit GlcE glcE 1.373988 1.163797   1.801281332 1.660825282     
glycolate permease GlcA glcA 1.710411 1.636938   2.242751762 2.22574605 1.121604711   
glycoporin           1.372531709     
glycosyl transferase       -1.1636         
glycosyl transferase family 2       -1.04157         
  
 
glycosyltransferase     1.046937           
glyoxylate carboligase gcl   4.931055 3.255242 1.486417226 2.020715432 3.623064643 1.90583 
GMP synthetase guaA     -1.01431   -1.320587245     
GTP cyclohydrolase II ribA -1.02904     -1.207414158       
GTPase ObgE/CgtA obgE     -1.30115   -1.160265437   -1.14212 
GTPase-activating protein           -1.391013536     
GTP-binding protein           -1.069911482 -1.109551908   
head protein     -1.01061 -1.37779   -1.265942152     
heat-inducible protein       1.095443         
heat-shock protein Hsp15 hslR         -1.640454223     
heat-shock protein IbpB ibpB             1.117633 
helix-turn-helix transcriptional regulator hqeH 1.957311 1.715264 -1.59326 1.551642582   1.222529616 -1.10969 
heme ABC exporter ATP-binding protein CcmA ccmA   -2.244           
heme ABC transporter ATP-binding protein       1.294371   1.095399982     
heme ABC transporter permease     -2.4106           
heme exporter protein CcmB ccmB   -2.2822           
heme exporter protein D ccmD   -2.52825           
hemolysin expression-modulating protein Hha hha     1.051953         
high-affinity branched-chain amino acid transport ATP-
binding protein  livF 1.078275             
histidine phosphatase family protein               1.212996 
histidine transport ATP-binding protein HisP hisP         1.003349021     
homoserine O-succinyltransferase metAS       1.240101386       
HslU--HslV peptidase ATPase subunit hslU     -1.16066   -2.090489844     
HslU--HslV peptidase proteolytic subunit hslV -1.17135       -2.18856508     
HTH-type transcriptional regulator cbl cbl 1.198536       1.777132238     
hydrogenase   -1.08931   -2.26266 -1.867476883 -1.964026057     
  
 
hydrogenase 1 b-type cytochrome subunit hyaC     -1.72006   -1.231905742     
hydrogenase 1 maturation protease hyaD     -1.32219         
hydrogenase 2 large subunit hybC     -1.67134   -1.579009334     
hydrogenase 2 small subunit hybO -1.38966     -2.107617561       
hydrogenase assembly protein HypC hypC -1.01461     -1.456426411       
hydrogenase formation protein HypD hypD       -1.001217229       
hydrogenase isoenzymes nickel incorporation protein 
HypB hypB -1.21494     -1.683166123       
hydrogenase-1 operon protein HyaE hyaE     -1.2412         
hydrogenase-1 operon protein HyaF hyaF     -1.35607   -1.010380502     
hydrogenase-2 large chain     -1.12095           
hydrolase   1.816713     1.26201084 -3.069928832   -1.49237 
hydroxyethylthiazole kinase thiM 1.340028             
hydroxyglutarate oxidase   1.84152 1.583003   2.121406606 -1.419152255   -1.30871 
hydroxylamine reductase hcp 1.048176       1.07455264 1.44500107   
hydroxymethylpyrimidine/phosphomethylpyrimidine 
kinase thiD 1.425156             
hydroxypyruvate isomerase hyi 1.893045 5.482994 3.759037 2.085082273 3.720873885 4.49907396 2.476193 
IlvB leader peptide ivbL -1.07917 -1.5763       -1.379438518   
IlvGMEDA operon leader peptide     -1.29563   -1.510469714       
imidazole glycerol phosphate synthase subunit HisH hisH     -1.39534         
IMP dehydrogenase guaB         -1.227369456     
inhibitor of glucose transporter           1.164742522     
inner membrane protein YhjD yhjD         -1.917781763     
inner membrane transport permease YhhJ yhhJ 1.438155         1.07112344   
inositol monophosphatase suhB         -1.025098258   1.279002 
iron-siderophore ABC transporter permease           -1.065671994     
  
 
isochorismate synthase EntC entC         1.418858109     
isocitrate lyase aceA 2.161842 1.638174   3.461174061   1.170482645   
isomerase           1.069898224     
ketodeoxygluconokinase   -1.25728             
KHG/KDPG aldolase eda -1.21502 -1.205 -1.20684         
knotted carbamoyltransferase YgeW ygeW   -1.06374   -1.305628328       
L+-tartrate dehydratase subunit beta ttdB -1.258 -1.95835 -1.62162 -2.233886878   -1.066621202   
lactose permease lacY         1.376150841     
L-arabinose isomerase araA     1.031682   1.187055744     
L-arabinose transport system permease protein AraH araH         1.468387143     
L-asparaginase 2 ansB   -1.08919     1.118277667     
leu operon leader peptide leuL -1.01231 -1.12579   -1.887961074   -1.047786262   
LexA-regulated protein, CopB family ybfE     1.058498       1.064692 
L-fucose mutarotase fucU 1.1157       1.02441738     
L-fuculokinase fucK 1.078496             
L-fuculose-phosphate aldolase fucA         1.118791418     
L-galactonate-5-dehydrogenase lgoD     1.073072   1.271221682     
ligand-gated channel protein           1.282359797     
lipid A biosynthesis palmitoleoyl acyltransferase lpxP     1.223499         
lipid kinase YegS yegS         -2.165688885   -1.05206 
lipoprotein     -1.18405   -1.382550002 1.0615249     
L-lactate dehydrogenase lldD -1.21068         -1.241692461   
L-lactate permease       2.528416         
LPS O-antigen length regulator               1.073316 
L-ribulose-5-phosphate 4-epimerase araD     1.160669   1.214129005 1.108658385   
L-serine ammonia-lyase         1.029333842       
L-serine dehydratase     -1.41126   -1.064661055       
  
 
lysine decarboxylase CadA cadA         -1.116363421     
lysine--tRNA ligase heat inducible lysS       -1.039761021       
lysogenic protein           1.432100092     
lysozyme inhibitor     1.399339 1.657795         
LysR family transcriptional regulator   1.146253   1.154994   1.240848912     
LysR family transcriptional regulator   1.094233   1.405305   1.344589365     
lytic transglycosylase F       1.013336         
magnesium transporter ATPase mgtA 1.50589   -3.26288   -2.329508518   -1.79006 
major curlin subunit csgA         1.148072191     
major pilus subunit operon regulatory protein papI 1.115487       1.773977687 1.035428005   
malate dehydrogenase mdh         1.287524343     
malate synthase A aceB 1.421364 1.504013   2.344922927       
malate synthase G glcB   1.026546           
malonyl CoA-ACP transacylase fabD     -1.04462         
maltodextrin phosphorylase malP -1.75764 -1.6447   -2.346055504       
maltoporin lamB -1.84977 -1.85237   -1.995522823       
maltose ABC transporter substrate-binding protein MalE malE -2.71742 -2.05282   -2.989503128       
maltose operon protein MalM malM -3.65351     -3.910585532       
maltose transporter membrane protein malF -3.65994 -1.5958   -3.895893802       
maltose/maltodextrin import ATP-binding protein MalK malK -2.34439 -1.49114   -2.588821827       
maltose/maltodextrin transport system permease protein  malG -2.8487 -1.70804   -3.007863584       
manganese efflux pump MntP mntP     1.55864       1.369305 
mannose permease IID component   -1.2462 -1.25046           
mannosyl-3-phosphoglycerate phosphatase yedP       1.17642063 -1.631005238 1.270392517   
MBL fold metallo-hydrolase     1.100794     1.188051395     
MDR efflux pump AcrAB transcriptional activator MarA marA         1.500353974     
membrane protein insertion efficiency factor YidD yidD         -1.590634901     
  
 
metal-binding protein ZinT zinT 1.408427       2.045431579 1.187961699   
methyl-accepting chemotaxis protein tsr     -2.22331   -1.421798759   -2.27934 
methyl-accepting chemotaxis protein II tar     -4.48519   -2.395715707   -3.80001 
methylglyoxal synthase mgsA         1.581130436     
methylisocitrate lyase prpB   -1.83938 -1.2346   -2.20777103   -2.51048 
methyltransferase           -1.24702984     
MexE family multidrug efflux RND transporter 
periplasmic adaptor subunit           -5.743801507     
MFS transporter   -1.19122     -1.210640826       
microcompartment protein EutL eutL     -1.09646         
minor capsid protein E     -1.29158 -1.03609     -1.341038577   
molecular chaperone DnaK dnaK -1.08156       -2.347897757     
molecular chaperone FimC fimC   2.20865           
molecular chaperone GroEL groEL         -2.027025467     
molecular chaperone HscC hscC         1.071986831     
molecular chaperone Hsp31 and glyoxalase 3   1.34866             
molecular chaperone Hsp33 hslO         -1.939414913     
molecular chaperone HtpG htpG         -1.388566311     
molecular chaperone TorD torD 1.073508             
molybdopterin biosynthesis protein MoeB moeB 2.105819     1.478168031       
mononuclear molybdenum enzyme YedY yedY         -1.201176485     
monooxygenase           1.393186557     
motility protein B motB     -3.38021 1.068528485 -2.036618344   -2.6389 
multidrug ABC transporter permease/ATP-binding 
protein mdlA       1.152629045 1.002891525     
multidrug efflux RND transporter permease subunit   1.586454   -1.60512   -4.585115772   -1.31656 
multidrug efflux RND transporter permease subunit           -1.872861133     
  
 
multidrug export protein EmrA emrA         -1.073751655     
multidrug resistance protein MdtE mdtE 1.720385   -1.89824   -2.728744088   -1.39371 
multidrug resistance protein MdtH mdtH   -1.05956           
multidrug resistance protein MdtN mdtN         1.873964488     
multidrug transporter subunit MdtL mdtL     1.411614         
multiphosphoryl transfer protein   -1.04389 -1.20911   -1.106079174       
murein DD-endopeptidase MepS/Murein LD-
carboxypeptidase spr; yeiV             1.065486 
murein transglycosylase mltA -1.19502 -1.21739   -1.837771345   -2.209907403   
murein transglycosylase B mltB         -1.02412571     
N5-carboxyaminoimidazole ribonucleotide mutase purE   1.363896 2.155122 1.337089327   1.305578705   
N-acetyl-D-glucosamine kinase nagK         -1.191096066     
N-acetylgalactosamine permease IIC component 1 agaC 1.144704 -1.45181 -1.20715 1.400427811 1.066671478     
N-acetylgalactosamine-specific phosphotransferase 
enzyme IIB component 1 agaB 1.305456 -2.51578 -1.69656 1.60074701 1.220144309     
N-acetylglucosamine-6-phosphate deacetylase nagA   -1.88499 -1.51774   1.416986245     
N-acetylmannosamine kinase nanK         1.113070821     
N-acetylmannosamine-6-P epimerase             1.202138269   
N-acetylneuraminate epimerase nanM     -1.12113         
N-acetyltransferase     -1.26774           
NAD(P) transhydrogenase subunit alpha pntA   -1.26693 -1.40155         
NAD(P)-dependent oxidoreductase   -1.24731     -1.28162501       
NAD(P)H dehydrogenase (quinone) wrbA     -1.61166   -1.332632619   -1.3569 
NAD-dependent deacylase cobB         -1.166391742     
NAD-dependent succinate-semialdehyde dehydrogenase gabD 1.65585 1.381397 -1.21345 1.921715629 -1.760195736   -1.72651 
NADH dehydrogenase ndh   -1.25625 -1.00062         
NADH:flavorubredoxin oxidoreductase           1.151502144     
  
 
NADH-dependent flavin oxidoreductase           2.082674585     
NADH-quinone oxidoreductase subunit F nuoF     -1.19389         
negative regulator of flagellin synthesis flgM     -1.08619   -1.290015867   -1.44226 
Ni/Fe-hydrogenase b-type cytochrome subunit         -1.158416567       
nickel ABC transporter, nickel/metallophore periplasmic 
binding protein         -1.210945538       
nitrate reductase     -2.56281 2.604453     1.293311756   
nitrate reductase A subunit beta narH   2.171319     -1.782916547     
nitrate reductase catalytic subunit     -3.29377 1.248517     1.106665526   
nitrate reductase molybdenum cofactor assembly 
chaperone NarJ narJ 1.005426 1.9279 -1.5409 1.165775294 -1.780213285   -1.71218 
nitrate reductase molybdenum cofactor assembly 
chaperone NarJ narJ         -2.757549449     
nitrate reductase subunit alpha narZ   2.408206 -2.30304 1.005817494 -1.573224801   -1.70311 
nitrate reductase subunit alpha narZ         -2.856319514     
nitrate reductase subunit beta narH     -2.34683   -2.901841624   -1.88093 
nitrate/nitrite transporter NarK narK -1.53228 1.140004 1.045364 -1.37036816 -1.549252635     
nitrite extrusion protein 2 narU 1.051608   -2.44289 1.104326426 -3.281023732   -1.42838 
nitrite reductase (cytochrome; ammonia-forming) c552 
subunit nrfA         1.05355534 1.035252102   
nitrite reductase large subunit nirB -1.15432   1.034864 -1.045286514   1.085822959   
nitrite reductase small subunit nirD     1.134389     1.298247425   
nitrite transporter NirC nirC     1.925257     1.917414204 1.342738 
nitrogen regulatory protein P-II 2 glnK 1.446277   2.043794 1.459188481 2.672575924 1.606476419 1.09413 
non-canonical purine NTP pyrophosphatase           -1.219535786     
non-heme ferritin ftnA 1.30668 -1.16197     2.224089817     
NrdH-redoxin   1.638894     1.682646781   1.62925904   
N-succinylglutamate 5-semialdehyde dehydrogenase astD 2.102714 1.542596 1.442752 2.044775709 1.161774224 1.119555249   
  
 
nucleoid-associated protein     2.482541 -1.07064   -1.653685137     
nucleoside permease       1.023637   1.327281891 1.623917825   
nucleoside permease           1.965854532     
nucleoside recognition pore and gate family inner 
membrane transporter yjiH         1.661124133     
nucleoside triphosphatase nudI     1.083008   1.004656813     
nucleotide exchange factor GrpE grpE -1.26098             
NUDIX hydrolase           -1.057512269     
octanoyltransferase lipB   -1.03101           
oligopeptide ABC transporter substrate-binding protein 
OppA oppA   1.005154     1.083752678     
ornithine decarboxylase speC/F   -1.03564           
osmoprotectant uptake system permease         1.145863758 -1.636571895     
osmoprotectant uptake system substrate-binding protein       -1.06936   -2.769750871   -1.16128 
osmotically-inducible lipoprotein B osmB   2.526407 2.514519         
osmotically-inducible protein Y osmY 1.688076 1.742297 -1.24166 1.512569469 -3.044958711   -1.67963 
o-succinylbenzoate synthase menC     -1.42715     -1.196857424   
outer membrane integrity lipoprotein           -1.034178973     
outer membrane integrity lipoprotein               -1.12233 
outer membrane protein assembly factor BamB bamB           -1.005831077   
outer membrane protein slp slp 1.794826   -1.75972       -1.33313 
outer membrane protein W ompW   -1.18392           
oxidoreductase   1.0758 -1.56693 -1.39018 1.018312413       
oxidoreductase FeS-binding subunit   -1.09558     -1.304173575       
oxidoreductase FixC fixC         1.06112056     
PAS domain-containing sensor histidine kinase phoR 1.086235       1.101716247     
peptidase     1.223884   -1.214760946 1.210830663     
  
 
peptidase E pepE -1.47052 -1.00789   -1.61658609       
peptidase M37           -1.112179745     
peptide ABC transporter ATP-binding protein dppD 2.752686 3.339171 1.530426 2.585338291   1.902923284   
peptide ABC transporter permease   2.771301 3.102961 1.937968 3.102405113   2.164611771   
peptide ABC transporter permease   2.80573 3.413521 2.761191 3.380545132   2.789842286   
peptide chain release factor 2 prfB         -1.008969609     
peptidoglycan hydrolase FlgJ flgJ     -1.86839   -1.281698054   -1.8209 
peptidoglycan-binding protein LysM lysM 1.212193       -1.150404662   -1.26425 
periplasmic dipeptide transporter dppA 1.817551 3.502534 1.19989 1.787953476   2.09251152   
periplasmic nitrate reductase, electron transfer subunit napB   -4.26939           
periplasmic protein CpxP cpxP     1.338223         
periplasmic trehalase treA     -1.03856   -2.677415903     
periplasmic trehalase treA             -1.57981 
permease   1.09385 1.722223 2.691906 2.105746044 2.196843252 2.81638144   
permease   3.166126     1.008138888       
peroxiredoxin OsmC osmC 1.141894       -1.409689976   -1.01386 
phage antitermination protein     -1.41915       -1.454177035   
phage encoded cell division inhibitor protein       -2.42178   1.584977656     
phage major tail tube protein         -1.016622941       
phage protein     1.037037           
phage recombination protein Bet bet     -1.31088         
phage Tail Collar domain protein       1.428296         
phage tail protein           1.212611354     
phage-shock protein pspG     1.121886   1.09326646     
phenylalanine--tRNA ligase subunit beta pheT     -1.09626         
pheromone autoinducer 2 transporter               -1.11547 
phosphate acetyltransferase pta         -1.038210631     
  
 
phosphate acetyltransferase pta         1.370883926     
phosphate starvation-inducible protein PsiE psiE   1.116247           
phosphate starvation-inducible protein PsiF psiF 1.224139             
phosphoadenosine phosphosulfate reductase cysH 1.449919 3.597341 1.670915   1.868481043     
phosphoadenosine phosphosulfate reductase cysH   1.3325           
phosphoanhydride phosphorylase appA         -1.015018536     
phosphogluconate dehydratase edd -1.22081   -1.3335 -1.372350884 -1.004607413   -1.2474 
phosphogluconate dehydrogenase (NADP(+)-dependent, 
decarboxylating)     -1.26884           
phosphoglycolate phosphatase gph     -1.11185   -1.114957383     
phosphomethylpyrimidine synthase ThiC thiC 2.658962     1.353916389       
phosphonate metabolism protein PhnP phnP   1.051612           
phosphoporin protein E   1.594362     1.704085691       
phosphoribosylamine--glycine ligase purD       1.157156024       
phosphoribosylaminoimidazolesuccinocarboxamide 
synthase purC       1.349215882   1.094066791   
phosphoribosylformylglycinamidine cyclo-ligase purM     1.112934 2.14080823   1.238333929   
phosphoribosylformylglycinamidine synthase purL   1.117734 1.125461 1.398915693   1.221188626   
phosphoribosylglycinamide formyltransferase purN     1.139568 1.104443106       
phosphoribosylglycinamide formyltransferase 2 purT     1.843347 2.196907365   1.728999603   
phosphotriesterase           1.242095981     
plasmid partition protein parA           -1.258236521   
poly(A) polymerase pcnB         -1.04158127     
polyamine ABC transporter ATP-binding protein   1.767649     1.691155213 -2.458348947 1.41340634 -1.12539 
poly-beta-1,6-N-acetyl-D-glucosamine biosynthesis 
protein PgaD pgaD         1.084102326     
Poly-beta-1,6-N-acetyl-D-glucosamine N-deacetylase pgaB     -1.0074         
polysaccharide production threonine-rich protein       1.514398   1.367270386     
  
 
polysialic acid capsule synthesis protein KpsS kpsS         1.385160218     
polysialic acid transport ATP-binding protein KpsT kpsT 1.096318       1.161547794     
polysialic acid transporter kpsD     -1.05567   -1.024628604     
polysialic acid transporter KpsM kpsM 1.496602     1.163389028 1.966510022 1.356072468   
porin   1.281174       1.254394078 1.215796299   
porin           1.070898024     
primosomal protein 1 dnaT         -1.180608891     
primosomal replication protein N priB     -1.33689   -1.524813897 -1.272629592   
PrkA family serine protein kinase   1.523657     1.150160015 -2.534518243 1.206781412 -1.54322 
probable cadaverine/lysine antiporter cadB     1.76682       1.506767 
proline/betaine transporter proP         -1.579176691     
propionate catabolism operon regulatory protein PrpR prpR 1.680333 1.218814   1.796650523       
propionate/acetate kinase     -1.07613   -1.039404012 1.080578567     
protease         -1.198916883       
protease 7   1.431444   1.510351   1.294853378 1.697419786   
protease modulator HflK hflK         -1.184968488     
protein AaeX aaeX             1.023228 
protein AfaD afaD   -2.57638   -1.338895434 1.11970708   2.021172 
protein BolA bolA 1.238158             
protein ElaB elaB         -2.42307918   -1.22945 
protein GlcG glcG   1.049112   1.051962552 1.048494083     
protein GnsA gnsA     1.274167         
protein HypA hypA -1.02667     -2.202763432       
protein MtfA mtfA         1.145887734     
protein NrdI nrdI       2.067069127       
protein PhnO phnO         -1.33920729     
protein phosphatase CheZ cheZ -1.22369   -3.99691   -2.614266398   -2.89054 
  
 
protein SufA sufA 1.167004       -1.804852172   -1.3133 
protein Syd syd -1.03618       -1.013757497     
protein translocase subunit SecF secF   -1.0187       -1.207155053   
protein translocase subunit SecY secY     -1.1407     -1.40410035   
protein transporter HofC hofC 1.036451 1.026246           
protein TsgA tsgA   1.257335 1.148054       1.270565 
protein TusB tusB         -1.186904657     
protein UmuD umuD         1.06598021     
protein-export membrane protein SecG secG     1.006063       1.166305 
protoheme IX farnesyltransferase cyoE       1.069578098       
pseudouridine kinase psuK     1.193383   1.451442634     
pseudouridine-5'-phosphate glycosidase psuG         1.427061224     
PTS fructose transporter subunit EIIBC fruA         1.040476913     
PTS fructose transporter subunit IIC   1.560703       1.755047435     
PTS galactitol transporter subunit IIC gatC 1.540763   1.119385 1.088015824 1.847141952 1.09718785   
PTS glucose EIICB component ptsG -1.18447       -1.229689862     
PTS mannose transporter subunit EIIAB manX -1.10577 -1.11641   -1.039656313       
PTS mannose/fructose/sorbose transporter subunit IIC sorA -1.1922 -1.40269           
PTS N-acetylgalactosamine transporter subunit IIA     -2.77395 -2.21776 1.154729775 1.388000589     
PTS N-acetylgalactosamine transporter subunit IIB     -2.76798 -1.57568   1.19999167     
PTS N-acetylgalactosamine transporter subunit IIC   1.248252 -2.23891 -1.35454   1.536529368 1.037708752   
PTS N-acetylgalactosamine transporter subunit IID     -2.1401 -1.61204 1.151985262 1.349950671     
PTS N-acetylglucosamine transporter subunit IIABC           1.352720754     
PTS sorbitol transporter subunit IIA     -2.28129 -1.30809         
PTS sugar transporter subunit IIA   1.00079       1.521447255     
PTS sugar transporter subunit IIB glvC         1.045812819     
PTS sugar transporter subunit IIB glvC         1.221192195     
  
 
PTS system glucitol/sorbitol-specific EIIB component srlE   -2.07868 -1.13222         
PTS system glucitol/sorbitol-specific EIIC component srlA   -2.02715           
PTS trehalose transporter subunit IIBC treB -4.93242 -2.24455   -5.428954376   -1.015039719   
PulS_OutS family protein       1.137398         
purine-nucleoside phosphorylase       1.393126   1.923018426     
putative cation transport regulator ChaB chaB         -1.646149657     
putrescine transport ATP-binding protein PotG potG       1.023333358       
putrescine-ornithine antiporter potE   -1.66241 -1.19387         
pyrBI operon leader peptide     -1.11102       -1.222739725   
pyridine nucleotide-disulfide oxidoreductase   1.071955   -1.22884   -1.327052095   -1.59003 
pyrimidine utilization protein A       1.158778   1.248184642     
pyruvate dehydrogenase       -1.15848   -3.621986746   -1.64227 
pyruvate dehydrogenase E1 component aceE -1.31552 -1.3458 -1.95774 -1.686989034 -1.368089345 -1.38919925   
racemase               -1.22815 
reactive intermediate/imine deaminase     -2.22273 -1.41699 -1.432581401       
recombination protein RecR recR -1.16536       -1.617314055     
regulator of sigma D rsd       1.082992114       
regulatory protein AriR ariR 1.288055     1.20520338 1.237259558     
respiratory nitrate reductase subunit gamma narI   1.241906     -1.918836457     
restriction endonuclease         -1.019561566       
Rha family transcriptional regulator rha         1.018604304     
ribokinase rbsK 1.165683   1.136679   1.206359262 1.324412867   
ribokinase rbsK         1.178143107     
ribokinase RbsK rbsK 1.241417       1.787017265 1.367908326   
ribonuclease HII rnhB         -1.174549119     
ribonuclease P protein component rnpA         -1.396474658     
ribonuclease PH rph         -1.356906552     
  
 
ribonuclease T rnt             1.023681 
ribonucleoside hydrolase RihC rihC         1.04716315     
ribonucleotide-diphosphate reductase subunit beta nrdB 1.207312     1.18857136   1.259252253   
ribose ABC transporter permease rbsC 1.223409             
ribosomal-protein-alanine N-acetyltransferase RimI rimI         -1.299786334     
ribosome modulation factor rmf   -1.60422 -1.1141   1.109433124   -1.08613 
ribosome-associated inhibitor A raiA         1.507080953     
ribosome-binding factor A rbfA     -1.53691     -1.221477238   
RNA chaperone ProQ proQ         -1.443494525     
RNA polymerase sigma factor FliA fliA     -3.40407   -1.929735414   -3.14584 
RNA polymerase sigma factor RpoD rpoD     -1.08857   -1.171647218     
RNA-binding protein           1.270682942     
RNase II stability modulator yciR     -1.10388   -2.139629733   -1.06317 
RpoE-regulated lipoprotein yfeY -1.29099             
S-adenosyl-L-methionine (SAM)-dependent 
methyltransferase PhcB phcB     1.146464         
SCP-2 sterol transfer family protein     -1.09193 -1.00647         
SDR family oxidoreductase       -1.79511         
secretion pathway protein       1.277401         
SecY/SecA suppressor protein       -1.17834   -1.975221225   -1.35109 
serine endoprotease   -1.27053   -1.18272     -1.116152455   
serine hydroxymethyltransferase glyA     1.083968 1.317505732       
serine/threonine dehydratase     -1.15339     1.522328363 1.145186056   
serine/threonine protein phosphatase pphA   1.022703   1.052530705       
serine/threonine transporter       1.139312         
serine/threonine transporter SstT sstT   2.056471 1.260339 1.026735346 1.274056578     
short-chain dehydrogenase       -1.89887         
  
 
short-chain fatty acids transporter atoE         1.197922033     
sialic acid transporter nanT         1.120019011     
sigma-54-dependent Fis family transcriptional regulator   1.52722   1.030652   1.042785686 1.311285249   
sigma-54-dependent Fis family transcriptional regulator           1.503121588     
sn-glycerol 3-phosphate ABC transporter permease   1.696391 1.088209   2.007354756       
sn-glycerol-3-phosphate ABC transporter substrate-
binding protein   1.286202     1.474165048 -1.063357423   -1.26576 
sn-glycerol-3-phosphate dehydrogenase subunit A glpA -2.77367 -1.49989 -1.01124 -1.855418535   -1.124941685   
sodium:proline symporter putP       1.312446753       
sodium:solute symporter           1.116090939     
soluble cytochrome b562 cybC 1.033565             
sorbitol 6-phosphate dehydrogenase srlD   -2.11007 -1.24914         
SoxR reducing system protein RseC rseC         -1.384306919     
spermidine/putrescine ABC transporter permease potB 1.422584     1.422311622 -1.261390927     
spermidine/putrescine ABC transporter substrate-binding 
protein potA 1.149556   -1.20279 1.354995255 -3.002350209   -1.86918 
spermidine/putrescine ABC transporter substrate-binding 
protein PotF potF       1.36839352       
spermidine/putrescine-binding periplasmic protein potD     -1.08759         
SpoVR family protein   1.552021       -2.49132886   -1.6394 
SprT family protein sprT     1.05379         
stationary phase inducible protein CsiE csiE     -1.25634   -1.664742545   -1.28276 
succinate dehydrogenase cytochrome b556 subunit sdhC       1.264012289       
succinate dehydrogenase flavoprotein subunit sdhA 1.241619     1.587673202       
succinate dehydrogenase hydrophobic membrane anchor 
subunit sdhD       1.600173297       
succinate dehydrogenase iron-sulfur subunit sdhB 1.19216     1.705804283 1.153837927     
succinate-semialdehyde dehydrogenase gabD         1.081105388     
  
 
succinylarginine dihydrolase astB 1.76255 1.55444 1.173933 2.124027725 1.044097995     
succinyl-CoA ligase subunit alpha sucD 1.049996 1.333022 1.12211 1.303270696       
succinyl-CoA ligase subunit beta sucC   1.142977   1.341142867       
succinyl-CoA--3-ketoacid-CoA transferase             1.634668879   
succinylglutamate desuccinylase astE 1.875302 1.136489 1.086593 2.200411475 1.128240147     
sucrose porin scrY   -1.17137         1.113427 
sugar ABC transporter   1.005131       4.021609596 1.240311984   
sugar ABC transporter           1.468575294     
sugar ABC transporter ATP-binding protein   1.810212   -2.01984 1.296119177   1.038866003   
sugar ABC transporter permease   1.468875     1.340025819 2.72349871     
sugar ABC transporter permease   1.464831     1.342687446       
sugar ABC transporter substrate-binding protein           1.290030748     
sugar fermentation stimulation protein SfsA sfsA         1.132352518     
sugar kinase       -1.12567   2.22564744     
sugar phosphatase SupH supH     -1.13073         
sulfatase   1.436516       1.885457585 1.130344923   
sulfate ABC transporter permease cysW 1.575508 1.434139 1.013468 1.010861954 2.255189892 1.037395993   
sulfate ABC transporter substrate-binding protein cysP -1.24083     -1.1499416 -1.565417532     
sulfate adenylyltransferase cysN 1.646004 1.416276 1.196107   2.212346795 1.406671551   
sulfate adenylyltransferase subunit 2 cysD 2.061822 1.423871     2.447675979   -1.06805 
sulfate transporter subunit       1.350803   2.354229735 1.116350239   
sulfate/thiosulfate import ATP-binding protein CysA cysA 1.94393 2.016911 1.486323 1.380738952 2.540173541 1.298600392   
sulfate/thiosulfate transporter subunit   1.581931 1.240398   1.044046491 2.489202019 1.031759974   
sulfite reductase subunit alpha cysJ 1.113527 1.460377     1.44540612     
sulfite reductase subunit beta cysI 1.35802 1.750679     1.713668188 1.019341732   
superoxide dismutase sodA/B         1.366447244     
symporter YdjN ydjN         1.339002184     
  
 
tagatose-1,6-bisphosphate aldolase kbaY; agaY 1.225515 -2.36568 -1.81058 1.233612272       
tagatose-bisphosphate aldolase 
 
  -2.17514 -1.55282         
tail fiber assembly protein   1.059036             
tartrate dehydratase subunit alpha ttdA -1.09246 -1.64391 -1.20276 -2.27500166       
taurine ABC transporter substrate-binding protein tauA         1.311560616     
taurine dioxygenase tauD         1.029793969     
TDP-4-oxo-6-deoxy-D-glucose aminotransferase           -1.155776826     
TDP-fucosamine acetyltransferase wecD         -1.154585877     
terminase       -1.4742         
thiamine biosynthesis lipoprotein ApbE apbE         -1.277418744     
thiamine biosynthesis protein ThiH thiH 2.517461     1.803326034       
thiamine biosynthesis protein ThiS thiS 2.123782     1.353771869       
thiamine phosphate synthase thiE 1.822024     1.234644112       
thiamine transporter substrate binding subunit tbpA 1.032237             
thiamine-monophosphate kinase thiL         -1.082308196     
thiazole synthase thiG 2.157706     1.436401473       
thiol:disulfide interchange protein   -1.21559 -2.68829 -1.36587         
thiosulfate reductase cytochrome B ydhU         1.545303622     
thiosulfate sulfurtransferase PspE pspE         1.126928275     
thiosulfate transporter subunit   2.122218 1.115237     2.524452331     
threonine/serine transporter TdcC tdcC   -1.73728     1.167515658     
thymidine phosphorylase deoA           1.143402383   
thymidylate kinase tmk         -1.039181099     
toxin B               -1.37667 
toxin YhaV yhaV       -1.111996589       
trans-aconitate 2-methyltransferase tam 1.257216       -2.449996195 1.007995726 -1.22777 
transaldolase A talA 1.015437       -1.463223301   -1.12286 
  
 
transcriptional activator TtdR ttdR   -1.63853   -1.481315885       
transcriptional activatory protein CaiF caiF   -1.0887   -1.608327234 1.299025615     
transcriptional regulator       1.442941     1.327073377 -1.02569 
transcriptional regulator             2.505910105 -1.21307 
transcriptional regulator               -1.52499 
transcriptional regulator GadE gadE 2.03063   -2.21011   -1.970638408 1.186404037 -1.2399 
transcriptional regulatory protein RcsA rcsA   1.88301 1.14251         
transferase     1.436867           
transketolase       -2.92578   -1.357423802   -1.29002 
transketolase       -2.5855   -1.396903992   -1.02589 
transketolase       -1.16743   -1.514085749   -1.42455 
translation initiation factor IF-2 infB     -1.85332     -1.392507584 -1.20562 
translation initiation factor Sui1 sui1       -1.006639983       
transpeptidase       1.096626   -1.22227393     
transporter         1.297115721 1.245747431   -1.03291 
trehalose-phosphatase     1.20642     -2.723223004   -1.56329 
tRNA (cytosine(34)-2'-O)-methyltransferase TrmL trmL         -1.251788627     
tRNA (guanine-N(1)-)-methyltransferase trmD           -1.049077397   
tRNA methyltransferase           -1.199916424     
tRNA pseudouridine synthase TruC truC         -1.183873782     
tRNA pseudouridine(55) synthase TruB truB     -1.26451     -1.127574733   
tRNA threonylcarbamoyladenosine biosynthesis protein 
TsaB tsaB         -1.123028424     
tRNA(5-methylaminomethyl-2-thiouridine)- 
methyltransferase mnmA         -1.307125876     
tRNA-dihydrouridine synthase A dusA         -1.107138313     
tryptophan permease   1.235346   1.710155   2.432953266 1.592353488 1.429317 
  
 
tryptophanase leader peptide tnaL         1.266236825     
two-component sensor histidine kinase   1.069499       1.34145907     
two-component system response regulator       -3.10894   -2.215299104   -2.91895 
two-component system sensor histidine kinase EvgS evgS         1.511039324     
type I glyceraldehyde-3-phosphate dehydrogenase   1.812072     1.027235574 -1.573207257 1.135309891 -1.06349 
type II secretion system protein GspC gspC   1.459332     1.341070361     
type II secretion system protein GspH gspH         -1.105624339     
U32 family peptidase   -1.18468     -1.018926049       
UDP-N-acetylglucosamine 1-carboxyvinyltransferase murA         -1.103828495     
undecaprenyl-phosphate 4-deoxy-4-formamido-L-
arabinose transferase arnC     -1.01791         
universal stress protein A uspA         1.510536466     
universal stress protein B uspB             -1.13852 
universal stress protein C uspC   -1.14602     1.084658836     
universal stress protein D uspD     -1.03338         
universal stress protein F uspF         1.343585569     
universal stress protein G uspG         1.079043682     
uracil phosphoribosyltransferase upp         -1.311194658     
uracil/xanthine transporter ybbY -1.54153 -1.44752 -1.62589 -1.533717503 -1.300243417 -1.812818122   
uronate isomerase uxaC           1.147731464   
xanthine permease XanP xanP 1.586574 1.994395 3.575241 3.127456164 1.838939164 2.432877787 1.58842 
xylose ABC transporter substrate-binding protein xylF 1.088153       1.827009653     
xylose isomerase xylA         1.057099522     
xylulokinase xylB     1.163497   1.128319359     
YggU family protein           -1.087659942     
YggW family oxidoreductase           -1.076099647     
zinc resistance-associated protein zraP         1.038744457     
  
 
 
Table 9.2 Significantly differentiated genes identified from RNA sequencing of seven exposed isolates of EC958 compared with control isolate. 
Genes discussed in Chapter 5 are highlighted in bold. 
 
zinc-binding dehydrogenase       -1.01453   -1.861249039   -1.53388 
zinc-dependent alcohol dehydrogenase adhP; adhA   1.213187 -1.63077   -2.88922666   -1.52167 
Zn-dependent oxidoreductase rspB             -1.38513 
